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Chronic kidney disease and end-stage renal disease
In human physiology, the kidneys serve an important task as illustrated by their capacity to regulate 
volume status, plasma osmolality, blood purifi cation, vitamin D metabolism, and hematopoiesis. 
Thus, when the kidneys fail, a cascade of  pathological consequences is initiated. Kidney failure 
can occur in an acute setting, being then referred to as acute kidney injury, or in a more lingering, 
chronic form, which is known as chronic kidney disease.1 Chronic kidney disease encompasses a 
broad spectrum of  renal dysfunction syndromes in which 5 severity stages are recognized. On one 
side of  the spectrum is stage 1, which corresponds to the presence of  renal disease without any 
loss in renal function. On the other extreme end is stage 5 chronic kidney disease and end-stage 
renal disease (ESRD), in which the estimated glomerular fi ltration rate (eGFR) has fallen below 15 
mL/min/1.73m2.1
Throughout the different stages of  chronic kidney disease, increasingly intensive treatment 
is necessitated to prevent decompensation of  the various physiological systems. In end-stage 
renal disease, and despite optimal pharmacological treatment, the kidneys are no longer able to 
maintain homeostasis and renal replacement therapy is necessary. This can be done by either renal 
transplantation or dialysis, the latter option crudely coming in two forms: 1) hemodialysis and 2) 
peritoneal dialysis. In hemodialysis, blood is fl ushed through an extracorporeal device and purifi ed 
by a semipermeable membrane. In peritoneal dialysis, the endogenous peritoneal membrane assists 
in the removal of  uremic toxins and fl uids. Both forms of  dialysis generally yield an improvement 
in prognosis and reduction in symptoms.
Cardiovascular risk in end-stage renal disease
Despite dialysis treatment, mortality rates are approximately eight times higher in patients with end-
stage renal disease than in age- and sex- matched individuals without renal disease.2 Approximately 
50 and 10 percent of  all patients with end-stage renal disease survive 5 and 10 years after initiation 
of  dialysis, respectively.2 Although mortality hazard for both cardiovascular and non-cardiovascular 
causes are an eight fold higher than in age and sex matched individuals,2 the majority of  deaths 
in ESRD is attributable to cardiovascular causes.3 Congruently, the incidence of  coronary artery 
disease, left ventricular hypertrophy, and congestive heart failure is also substantially elevated in 
end-stage renal disease.4,5 This increased cardiovascular risk cannot be explained by an increased 
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Figure 1. The hypothalamic-pituitaric-thyroidal (HPT)-axis. TRH: Thyroid Releasing Hormone, TSH: Thyroid 
stimulating hormone, T4: thyroxine, T3, triiodothyronine, TR: thyroid hormone receptor. D1: Deiodinase type 1 (D2: 
type 2, D3: type 3), TR: thyroid hormone receptor. * The largest part of  the blood pool is bound to thyroxine binding 
globuline (TBG), transthyretin and albumin. 
During the last decade, we have come to realize that when renal function declines, a wave of  so 
called nontraditional cardiovascular risk factors overshadows the importance of  traditional ones.7 
So far, several non-traditional cardiovascular risk factors have been described including an increased 
sympathetic nerve activity, hemodynamic overload, endothelial dysfunction, oxidative stress, an 
increased grade of  infl ammation, and hormonal alterations, all of  which havng profound effects 
on the cardiovascular system.7 For many of  these disturbances, however, uncertainty remains on 
whether they represent causal risk factors or merely epiphenomena of  other processes. This thesis 
aimed at studying the states of  sustained infl ammation and low thyroid hormones as plausible 




Infl ammation and non-thyroidal illness in end-stage renal disease
1. An elevated infl ammatory state in end-stage renal disease
In end-stage renal disease, an increased infl ammatory state, as expressed by elevations in serum 
infl ammatory markers, is encountered in the majority of  patients.8 As will be reviewed in Chapter 
2, a variety of  stimuli, such as infections, comorbidities, accumulation of  toxins and fl uid overload, 
contribute to its genesis. Partly dependent on the type of  stimulus, the infl ammatory cascade is 
initiated with the recruitment of  polymorphonuclear cells and monocytes and activation of  the 
acute phase response. Whereas some parts of  this infl ammatory cascade are different, depending 
on the type of  stimulus, a rather non-specifi c and common feature is that of  the acute phase 
response belonging to the innate immune system.9  
The acute phase response is hallmarked by elevations in serum positive acute phase reactants 
(e.g. C-reactive protein (CRP)), and decreases in negative acute phase reactants (e.g. albumin and 
transferrin). The function of  the acute phase response has not been fully elucidated but is believed 
to serve several purposes including; 1) the opsonization and entrapment of  pathogens, 2) activation 
of  complement pathways, 3) modulating immune response differentiation, and 4) assistance in 
tissue repair.10 Apart from these immune modulatory functions, the acute phase response seems 
responsible for other provisionary adaptations, meant to prevail in the face of  illness. These 
adaptations include adjustments in the central thermostat causing an increase in body temperature 
(fever), stimulating protein degradation, and the initiation of  a hibernating modus by a central 
and peripheral downregulation of  the Hypothyroidal-Pituitaric-Thyroidal (HPT)-axis.11 Although 
functional to certain pathogens, this response seems dysfunctional in the face of  chronic kidney 
disease and end-stage renal disease. 
2. Nonthyroidal illness in end-stage renal disease
The regulation of  serum thyroid hormone levels is a complex process in which multiple endocrine 
organs are involved. As illustrated in Figure 1, under direct infl uence of  pituitaric Thyroid 
Stimulating Hormone (TSH), which is again produced in response to hypothalamic Thyroid 
Releasing Hormone (TRH), the thyroid gland synthesizes free Thyroxine (fT4) and, to a lesser 
extent, the biologically more active free triiodothyronine (fT3). After being released into the blood 
stream, a great portion of  fT4 and fT3 binds to binding proteins such as Thyroxine-Binding 
Globulin (TBG), transthyretin (TTR), and albumin. The complex of  protein bound thyroid 
hormones is measured as total levels (TT3 and TT4 for total triiodothyronine and total thyroxine, 
correspondingly) in the blood. At a tissue level, different subtypes of  deiodinase enzymes regulate 
local fT3 levels by activating and inactivating fT4 and fT3, respectively. Serum fT4 and fT3 levels 
provide a direct feedback to hypothalamic TRH production, and pituitaric TSH production thereby 
yielding a tight control of  serum levels. 
11
Alterations in thyroid hormone levels are found in a large proportion of  all patients with ESRD.12-15 
These alterations constitute part of  a so called “Nonthyroidal illness syndrome”. This syndrome 
is defi ned as the presence of  thyroid hormone alterations in the absence of  primary disease in the 
HPT-axis.11 Throughout its spectrum, a wide variety of  thyroid hormone derangements occur. The 
origin of  these alterations is thought to be offset by successive changes at all levels of  the HPT-
axis. Factors responsible for these changes specifi cally associated to end-stage renal disease pertain 
to an increased infl ammatory state, protein-energy wasting, comorbidities, accumulation of  iodine 
and medication usage (as will be extensively reviewed in Chapter 5). Although nonthyroidal illness 
can be viewed upon as an adaptive state serving to survive in times of  scarcity and disease, several 
adverse cardiovascular consequences could make it inappropriate in the setting of  end-stage renal 
disease.
Fluctuations of  serum infl ammatory markers and thyroid hormones over time
Because the majority of  triggers for the genesis of  an infl ammatory response and nonthyroidal illness 
fl uctuate over time, also the presence and severity of  these both risk factors show a large temporal 
oscillation. When interpreting the impact of  the infl ammatory response and nonthyroidail illnes on 
cardiovascular outcome, it seems essential to take into account this temporal variation for a number 
of  reasons. Firstly, a dose response association between different variability patterns and outcome 
would strengthen the belief  in causality. Secondly, it could provide insight in underlying triggers for 
both risk factors. Thirdly, it could assist in discovering pathways intermediating both risk factors 
and cardiovascular death which could in turn contribute to the identifi cation of  potential treatment 
targets. Finally, from a predictive point of  view, knowledge of  factors’ temporal variability may 
improve identifi cation of  patients at highest risk and those who may benefi t from treatment. 
Main study questions
This thesis aimed at increasing our understanding on two plausible risk factors for cardiovascular 
disease in patients with end-stage renal disease. The following two main questions were addressed:
1. Is there an association between an increased infl ammatory state and (cardiovascular) mortality 
in patients in end-stage renal disease and which mechanisms could contribute to such link?
2. Is there an association between thyroid hormone alterations and (cardiovascular) morbidity 
and mortality in patients with end-stage renal disease and which mechanisms could contribute 





The studies included in this thesis were performed in cohorts from the Netherlands and Sweden. 
Below follows a short description of  the patient populations included:
Dutch cohorts:
• For the Netherlands Cooperative Study on the Adequacy of  Dialysis (NECOSAD) study, incident 
dialysis patients from 38 dialysis centers in the Netherlands were recruited and collected between 
1997 and 2002. Out of  the total cohort, serum C-reactive protein levels were assessed at 3 and 
6 months after start of  HD therapy in 472 patients. After inclusion, patients were followed over 
time during which events of  death and censoring due to other reasons were recorded.
• The Leiden 85 Plus Study is a population-based cohort of  85-year old individuals. Between 1997 
and 1999, all residents of  Leiden, the Netherlands, celebrating their 85th birthday (belonging 
to the 1912-1914 birth cohort) were asked to participate. Out of  the 705 individuals who 
were found eligible, 14 died before the recruitment phase, 92 refused participation and 37 
participants refused blood sampling, leaving 562 participants to be included in the current 
study. During follow-up, participants were visited annually until reaching the age of  90 years 
or death.
Swedish cohorts:
• The Mapping of  Infl ammatory Markers in Chronic Kidney Disease I (MIMICK-I) cohort comprises 
prevalent patients with end-stage renal disease undergoing maintenance hemodialysis therapy 
at the Karolinska University Hospital and its satellite dialysis units throughout the city of  
Stockholm. From October 2003 through September 2004, 254 patients were invited to 
participate. Six declined and one subject was not included because of  an active HIV infection. 
247 patients were followed for 12 weeks during which clinical characteristics were gathered and 
blood was withdrawn on a weekly basis. After 12 weeks, 23 patients had insuffi cient data and 
were excluded. Eventually, a total of  224 patients were included for the current analyses.
• The Mapping of  Infl ammatory Markers in Chronic Kidney Disease II (MIMICK-II) cohort was 
designed to study infl ammatory marker variability in patients on peritoneal dialysis (PD) 
and follows the same design as MIMICK-I. In this case, included patients were individuals 
undergoing maintenance PD in the city of  Stockholm. Recruitment lasted from March 2008 to 
April 2011. All patients on maintenance PD therapy in the region of  Stockholm (n =164) were 
invited to participate. Out of  these 164 individuals, 80 were excluded because of  unwillingness 
to participate (n=55), imminent transplantation (n=6), death (n=2), a switch to hemodialysis 
(n=8), or because of  medical or mental disorders that precluded their entry into the study 
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Monitoring of  inflammation in patients 
on dialysis: forewarned is forearmed
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Current evidence about the effects of  infl ammation on the outcomes of  patients with advanced 
chronic kidney disease (CKD) generally originates from single measurements of  infl ammatory 
biomarkers. Patients with CKD, however, are exposed to persistent low-grade infl ammation and 
levels of  serum infl ammatory markers are subjected to a substantial variability over time, being 
infl uenced by multiple processes, such as transient infections, comorbidities, and the intermittent 
stimulus of  dialysis. Understanding and evaluating infl ammation in the context of  its time-dependent 
oscillations in renal disease fl uctuation is therefore important. Nevertheless, the relationship 
between longitudinal infl ammatory variation and risk prediction has so far been addressed in only a 
few studies, not all of  which have been suffi ciently powered. Consequently, uncertainty exists about 
how to interpret the fi ndings of  these studies in the clinical setting. The purpose of  this Review 
is to explore the reasons and implications of  variability in levels of  infl ammatory biomarkers in 
patients with uremia, specifi cally focusing on C-reactive protein (CRP) measurements. We also 
discuss the value of  repeated versus single measurements of  infl ammation in the clinical setting 
and provide solutions to reduce both sample size and intraindividual variability in hypothetical, 
randomized controlled trials aimed at reducing CRP levels in patients undergoing hemodialysis. 
Keypoints: 
• In patients with end-stage renal disease, infl ammatory markers are subject to substantial 
variability over time, and are infl uenced by transient infections, comorbidities, and the 
intermittent stimulus of  dialysis.
• Insuffi cient evidence exists about the implications of  regular CRP screening in patients 
undergoing dialysis; multiple measures of  CRP seem to offer predictive advantages with single 
determinations.
• Regular CRP screening could identify short-term variation in levels of  infl ammatory markers 
associated with mortality, which could facilitate risk stratifi cation of  patients with chronic 
kidney disease.
• Regular CRP screening for individual patients could enable extensive exploration of  underlying 
causes of  infl ammation and the assignment of  appropriate treatment.
• When designing a randomized controlled trial to lower CRP level in patients on hemodialysis, 
sample size and intrapatient variability can be reduced by estimating infl ammation at each time 
point with averaged measurements for each individual.




The high mortality risk of  patients with chronic kidney disease (CKD)1–3 has been partly attributed 
to the infl ammatory state,4,5 a condition encountered in the vast majority of  patients with CKD, 
and especially in those with end-stage renal disease (ESRD). In patients with renal failure, the 
systemic concentrations of  both pro-infl ammatory and anti-infl ammatory cytokines are several-
fold higher than concentrations in healthy individuals,6  as a result of  both decreased renal clearance 
and increased production of  cytokines. Indeed, several dialysis-related factors (such as membrane 
bioincompatibility, dialyzate backfl ow, and endotoxemia) and factors not related to dialysis (such as 
infections, comorbidities, intercurrent clinical events [including sepsis, exacerbation of  pulmonary 
diseases, heart failure, gastrointestinal diseases] genetic factors, and diet) might contribute to 
increased cytokine production and, therefore, a persistent state of  infl ammation.7–11 
The robust evidence available concerning single measurements of  various infl ammatory biomarkers 
as independent predictors of  infectious complications and mortality in patients with CKD12–15 has 
justifi ed the use of  such measurements for identifying patients at increased risk of  infl ammation. 
C-reactive protein (CRP) is the prototype marker currently used for infl ammatory monitoring in 
clinical units.16 In the uremic milieu, patients are exposed to a low-grade, persistent infl ammation 
that is subject to a substantial intraindividual and interindividual variability.7,17,18 The coexistence of  
CKD with background infl ammation and fl uctuation of  cytokines emphasizes the importance of  
understanding and evaluating infl ammation in the context of  its time-dependent oscillations as the 
process of  renal disease fl uctuates. In this Review, we explore the reasons for, and the implications 
and clinical importance of  infl ammatory biomarker variability in the setting of  uremia with a focus 
on CRP measurements given their extended use in the clinical setting. The advantages of  regular 
monitoring of  infl ammation in patients undergoing dialysis as a means of  risk stratifi cation within 
patient groups is also discussed. 
The dynamic infl ammatory response 
In response to tissue damage, bacterial particles, tissue necrosis, or other provoking stimuli, 
polymorphonuclear cells and monocytes are triggered and recruited to the affected area. These 
cells initiate the infl ammatory cascade by producing a diverse range of  proinfl ammatory and anti-
infl ammatory cytokines, which are involved in autocrine, paracrine, and endocrine communication.19 
Cytokines expand the infl ammatory response to a systemic level via the endocrine pathway by 
initiating production of  acute-phase proteins, including CRP, in the liver.19 Systemic manifestation 
of  this orchestrated system is soon apparent. Levels of  proinfl ammatory mediators synthesized 
locally at the area of  damage and/or infection, such as interleukin (IL)-6 or pentraxin 3 (PTX-3), 
are the fi rst to increase systemically, typically 1.5–3.0 hours following tissue injury.20–22 CRP levels, 
however, increase slightly later, about 6–8 hours following injury,20,21 and peak after >24 hours from 




Of  all the acute-phase proteins and plasma markers of  vascular infl ammation, CRP has been 
studied the most extensively in patients with CKD. Depending on the severity of  the infl ammatory 
stimulus, CRP levels can increase by up to 500 times the normal level. CRP has a half-life of  19 
hours,24 this prolonged half-life makes it easy to detect CRP in the blood. Established methods 
for measuring CRP serum levels seem reliable, with relatively low coeffi cients of  variation.25 CRP 
is currently thought to be a ‘bystander’ marker of  vascular infl ammation, rather than a ‘culprit’ 
and risk factor for vascular disease.11,26,27 Biological intraindividual and inter individual variability 
in CRP level exists, however, even among healthy individuals in whom CRP levels are low or 
undetectable.28–30 This biological variability could be related to the refl ective nature of  CRP, and 
gradually increases in infl ammatory and atherosclerotic conditions.31 In early population studies, 
the 4-year reproducibility of  CRP measurements was equivalent to those for cholesterol and blood 
pressure measurements.30 Interindividual variability results from differences in both demographic 
factors and comorbidities between patients.30,32–37 Intraindividual variability, on the other hand, 
is associated with the presence and infl uence of  transient intercurrent events and the dynamic 
response of  the immune system.30 In 1,800 healthy Japanese patients who were tested twice during 
a 1-year period, increasing age was associated with larger intraindividual CRP variation in men than 
in women;38 this difference could affect the risk assessment of  CRP values, and, therefore, the sex of  
the patient needs to be taken into account when CRP is used to assess risk in age-related diseases.39 
Proinfl ammatory cytokines are also subject to a considerable day-to-day variation; intraindividual 
IL-6 variability was reported in healthy adults, with a mean age of  59 years, during six consecutive 
daily fasting measurements,40 describing an index of  individuality of  0.20 and a standard error of  
the mean (SEM) of  0.32 pg/ml. Such an SEM indicates that observed differences of  ≤0.32 pg/ml 
in a trial should be understood as part of  the normal daily fl uctuation of  IL-6 levels.
In patients undergoing dialysis, the intraindividual and interindividual variability of  serum 
CRP levels might be even greater than the variability in the general population. However, this 
variability has been investigated considerably less in the dialysis population. The main cause of  
CRP variability in the setting of  renal dialysis are intercurrent clinical events.41–43 However, other 
factors could also contribute to variability, as intraindividual CRP variation in patients undergoing 
hemodialysis who are free from intercurrent clinical events is very high.44 Additional interindividual 
variation might result from decreased renal function and the uremic environment, comorbidities, 
and protein-energy wasting.18,45,46 Intraindividual variation, however, could be enhanced by 
membrane bioincompatibility, dialyzate backfl ow, endotoxemia and the intermittent nature of  
hemodialysis.7,10,41,47–49 In addition, residual renal function can further contribute to variation in 
CRP levels among patients undergoing dialysis.50 
Quantifying the magnitude of  variability specifi cally attributable to dialysis-related and nondialysis-
related factors is diffi cult in the clinical setting. However, as demonstrated by Kaysen et al.,42 the 
intermittent activation of  the acute-phase response often spans multiple dialysis sessions, thereby 
suggesting that the causative value of  the dialysis session per se is of  less importance in inducing 
and maintaining the infl ammatory response. Finally, genetic determinants might infl uence the 
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intraindividual variability of  the infl ammatory response, as suggested for both CRP variance in 
relation to cardiovascular disease risk51 and IL-6 response following vaccination in the general 
population.52 In patients undergoing hemodialysis, Girndt et al. observed that a polymorphism in 
the gene encoding IL-10 associated with reduced production of  IL-10 was associated with reduced 































Figure 1. Course of  CRP levels in three selected pa-
tients. Intraindividual CRP variability could, in part, 
be genetically determined. The fi gure depicts CRP 
values of  15 patients a) an IL-10 ‘high-producer’ 
genotype or b) an IL-10 ‘low-producer’ genotype. 
CRP measurements were taken during the fi rst week 
of  each month before dialysis, regardless of  wheth-
er or not the patient had complications. The IL-10 
‘low-producer’ genotype seemed to be associated 
with more frequent elevations in CRP than the ‘high-
producer’ genotype. The mean CRP measurement 
in the ‘low-producer’ group was 173.3 nmol/l (18.2 
mg/l) ± 15.2 nmol/l (1.6 mg/l), and in the ‘high-
producer’ group the mean CRP measurement was 
80 nmol/l (8.4 mg/l) ± 16.2 nmol/l (1.7 mg/l) (P 
= 0.002,Mann–Whitney test). To convert values to 
mg/l, divide by 9.524. Abbreviation: CRP, C-reactive 
protein. Permission obtained from Nature Publish-
ing Group © Girndt. M. et al. Kidney Int. 62, 949–
955 (2002).
Single measurement assessment 
In the general population, strong links exist between elevated levels of  systemic infl ammatory 
markers during a single assessment and an increased risk of  cardiovascular morbidity and mortality.5,32 
Such links are also observed for the majority of  cytokines and acute-phase reactants in various 
subpopulations of  patients with CKD, including individuals in the early stages of  this disease,5,54 
patients with ESRD awaiting their fi rst dialysis session,55 individuals undergoing hemodialysis12,14,56–63 
and patients on peritoneal dialysis.64–67  In addition, single CRP measurements have been positively 
associated with left ventricular hypertrophy (LVH),67 myocardial infarction,66 and hospitalization68 
in patients undergoing dialysis. Despite the fact that many comparative studies suggest that IL-6 
might be the best outcome predictor in early and advanced CKD,56,64,69,70 CRP measurement is still 
the prototypic marker of  uremic infl ammation, owing to the widespread availability of  this method.




Although several, arguably, arbitrary CRP cut-off  values have been suggested for patients with 
CKD.12,54,67,74 At present, no consensual defi nition of  ‘uremic infl ammation’ exists in terms of  
levels of  CRP and other infl ammatory markers. Furthermore, safe target CRP values for patients 
with CKD are still undefi ned. Follow-up periods for studies in which single measurements of  
infl ammatory biomarkers were used typically range from 2 years to 10 years.5,12,14,54–67 From a 
clinical point of  view, and misinterpreting traditional Cox models, it would be incorrect to assume 
that a single CRP measurement would predict the probability of  death within 10 years. Indeed, 
conditional or time-stratifi ed analyses show that CRP is an excellent predictor of  risk in the short 
term (1 year of  follow-up).75 Over an extended period (2–3 years of  follow-up) however, the 
association between CRP and mortality diminishes as other comorbidities and conditions take part 
in the patient’s prognosis.76 Using periodical CRP monitoring for short-term risk prediction only 
therefore seems pertinent.
Biological variance associated with single measurements of  CRP could have been incorrectly 
misinterpreted as a negative aspect of  using this biomarker as a clinical tool. Increased variation in 
CRP levels would, however, have imposed a reduction in point estimates towards the null hypothesis 
in all of  the aforementioned studies that included a single baseline CRP measurement.5,12,14,54–67 As 
such, the observed relative risk associated with infl ammation might be underestimated compared 
with the true relative risk.77 Platz et al. reassessed mortality risk ratios attributed to single CRP 
measurements by correcting for intraindividual and interindividual variances (calculated from three 
determinations 2 years apart) in 50 healthy men aged >55 years (mean age at baseline 64.9 years).78 
The investigators reported an intraclass correlation coeffi cient of  0.66 for CRP levels measured at 
three time points over a 4-year period, which we consider to indicate good consistency over time. 
This observation indicates the following: if  the CRP level is measured once, and, assuming no other 
errors exist, if  the observed relative risk for an elevated CRP level is 2.06, then the true relative 
risk equals 3.0. Thus, although a single CRP measurement probably underestimates the true risk, 
it could be considered a valid estimate. A single measurement, however, prevents clinicians from 
gaining important information on the variability of  the infl ammatory response and the underlying 
processes behind this variation. Figure 2 demonstrates that a single measurement of  CRP level is 
probably insuffi cient for medical decision-making in day-to-day clinical practice. 
Longitudinal CRP changes
To the best of  our knowledge (details on the literature search are specifi ed in Appendix 1), as 
many as 10 small-to medium studies, all but one examining patients undergoing hemodialysis, have 
addressed the consequences of  fl uctuating levels of  CRP, IL-6, or tumor necrosis factor (TNF) 
on mortality or cardiovascular disease (Table 1). with respect to study design and methods of  
analysis, these studies can be grouped into three different categories: 1) ‘ summary measures’, 2) 
‘long-term fl uctuation’ and 3) ‘intradialytic fl uctuation’. In the fi rst category, Snaedal et al. assessed 
whether summary measures of  repeated measurements (average, median or upper/lower values 
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within a given time period) offer a predictive gain as compared with a single assessment.18 In this 
report, CRP levels were measured every week over a 3-month period in 224 patients who were 
undergoing hemodialysis.18 As shown in Figure 3, an elevation of  10 nmol/l (1 mg/l) in median 
or mean CRP levels contributes a statistically signifi cant 1.2–1.3% increase to the all-cause mortal-
ity hazard ratio.18 As an example, a patient with a mean CRP value of  143 nmol/l (15 mg/l) has a 
15% increased risk of  death during follow-up compared with a patient with a mean CRP value <48 
nmol/l (<5 mg/l). As such, the results from this study indicate that multiple measurements might 
offer improved mortality prediction. 
Figure 2. Weekly CRP variability in three selected hemodialysis patients at Karolinska University Hospital, Stockholm, 
Sweden. Three different hypothetical patients illustrate the usefulness of  regular monitoring of  the infl ammatory 
response in patients undergoing dialysis. In patient 1, CRP levels remained low during the entire follow-up period 
apart from during a cold at week 3. In patient 2, CRP levels were, on average, within the ‘smoldering’ range (mostly 
remaining within the range 48–476 nmol/l (5–50 mg/l)). However, acute increases in weeks 2 and 9 denoted infec-
tions that were appropriately treated. In patient 3, CRP levels were high, indicating acute infl ammatory processes that 
should have alerted the clinician about appropriate treatment and prognosis. Although a single measurement would 
have suffi ced for patient 1, it would have provided misleading information in the other two cases. Regular monitoring 
in these cases could help to detect systemic CRP elevations warranting a work-up for the source of  infl ammation and 
























A second category of  studies assessed the temporal variation of  infl ammatory biomarkers during 
several consecutive measurements over a longer time period that spanned multiple dialysis ses-
sions. In these reports, the analysis included three different categorization strategies: 1) persistently 
low CRP levels, 2) persistently high CRP levels, or 3) CRP elevations and/or decreases. Study 
periods varied from 3 months to 6 months.74,76,79 These studies consistently showed that patients 
with persistently elevated CRP levels exhibited the worst prognosis (that is, all-cause mortality) as 
compared with the other groups, followed by patients that presented a rise or a fall in CRP during 
the observation period 74,76,79 (Figure 4). Such observations also seem to be valid for patients un-
dergoing peritoneal dialysis 80 and are further reinforced by the results reported by Kim et al. who 
demonstrated that LVH was more prevalent among patients on hemodialysis who had persistently 
elevated CRP levels.81 We could also demonstrate that this pattern of  mortality linked to CRP vari-
ation is identical to that seen with variation in IL-6 and TNF.79 An unexpected fi nding, however, 
was that the correlation between changes in these infl ammatory markers was not very strong, lead-
ing to the hypothesis that various infl ammatory pathways contribute in parallel to the pathogenesis 
of  CKD.79 In a more complex analysis, Rao et al. used a time-dependent Cox model to analyze, 
on a yearly basis, the infl uence of  IL-6 levels on mortality in 206 stable patients undergoing he-
modialysis.82 In comparison with baseline values, hazard ratios were higher when IL-6 levels were 
incorporated as a time-dependent covariate.82 These study results are similar to results from studies 
on the variability of  parathyroid hormone83 or hemoglobin,84 which suggests that fl uctuation in risk 
biomarkers in patients undergoing dialysis might affect both clinical decision-making and patient 
outcome. 
A third category of  studies examines the association between intradialytic changes in serum CRP 
levels and death and/or development of  cardiac disease. The investigators of  these studies base 
their hypotheses on the putative intermittent proinfl ammatory stimuli of  the dialysis procedure. 
Although some studies reported elevated CRP levels following a single dialysis session,85–87 the 
effect of  hemoconcentration during the hemodialysis session was taken into consideration. The 
observation of  Park et al., that a proinfl ammatory response to a single hemodialysis session was 
associated with  LVH, could be a consequence of  this lack of  correction.58 The only study that, 
despite postdialytic CRP correction, showed an association between intradialytic CRP elevations 
and mortality7 is, in our opinion, diffi cult to interpret in light of  the biological plausibility of  a rise 
in CRP within 6–8 h following tissue injury.88 Indeed, similar analyses looking at intradialytic CRP 
changes from our group, including two independent cohorts of  European patients undergoing 
hemodialysis, could not replicate these fi ndings.89 Moreover, as evidenced by statistically 
nonsignifi cant Pearson correlation coeffi cients, the congruency between CRP changes amidst 
consecutive dialysis sessions was poor.89
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Monitoring infl ammatory markers
In determining how infl ammatory markers should be measured, the key points to consider are 
the reasons why CRP needs to be measured and the likelihood that diagnostic and therapeutic 
strategies not currently being used might change on the basis of  these test results. A substantial 
amount of  evidence included in the 2003 scientifi c statement by the American Heart Association 
(AHA) and Centers for Disease Control and Prevention (CDC)90 is still applicable to patients 
undergoing dialysis. However, despite 10 years of  extensive research on the causes and effects 
of  uremic infl ammation,91 no randomized trials with testing of  infl ammatory markers as the 
primary intervention have been performed, nor have cost-effectiveness analyses been completed 
to assess additional costs or cost savings through the use of  such tests. Consequently, the following 
suggestions about the routine monitoring of  infl ammatory markers are not evidence-based and 
refl ect the authors’ opinion only. Although lacking a precise defi nition, according to the literature 
from western countries, CRP levels in patients with uremia are usually higher than the >29 nmol/l 
(3 mg/l) level that indicates a high mortality risk in the general population.92,93 A pragmatic cut-off  
value for serum CRP concentrations, which are typically observed in western patients with ESRD, 
would be 48 nmol/l (5 mg/l).94 Individuals with CRP values <48 nmol/l (<5 mg/l), however, might 
still be at increased mortality risk. On the basis of  published data from pooled European cohorts, a 
cut-off  point of  95 nmol/l (10 mg/l) has been proposed for uremia-related infl ammation95 and is 
often used in research studies for the prediction of  mortality. However, this cut-off  value has not 
been approved for use in clinical practice. Notably, a substantially increased risk of  mortality was 
already associated with a CRP concentration of  29 nmol/l (3 mg/l) in a large cohort of  Japanese 
patients undergoing dialysis (adjusted HR 1.64, P = 0.04).96 However, because ethnic differences 




























Figure 3. Prediction of  all-cause mortality with 
single and averaged measurements in prevalent 
patients undergoing hemodialysis. Ratios indi-
cate the increase in risk per 10 mg/L in CRP. 
Abbreviation: CRP, C-reactive protein. Permis-
sion obtained from Elsevier © Snaedal, S. et al. 




Table 1. Studies addressing the effect of  multiple measurements of  infl ammatory marker levels on mortality or on 
a cardiovascular end point
Study Number 
of  patients, 



















224, HD 28 (14–57)** hs-CRP 3 months, 12 29.0 (11)# Mortality Average CRP 





to et al.70 
180, HD 59 (36)# CRP 6 months, 12 21 Mortality Persistent high 






3 CRP 3 months, 2 27.2 (0.0-78.5)‡‡ Mortality Persistent high 
> solitary high > 
persistent low3
Kim et al.77 52, HD 41.8 (33.7)# hs-CRP 3 weeks, 2 Cross-sectional LVH Persistent high > 
persistent low3
Ates et al.76 98, CAPD >3 CRP 20 months, 5 33.9# Mortality Persistent high 















Mortality Persistent high 
> increase > 
decrease > per-
sistent low
Rao et al.78 198, HD1 44.4 (52.8)# IL-6 4 years, 1–5 31.2 (20.2)# Mortality Time dependent 





115, HD 9 (5)# CRP 1 HD ses-
sion, 2
22.5 (17.4)# Mortality Intradialytic CRP 
increase predicts 
mortality3
Park et al.54 118, HD 23 (2–225)§§ CRP 1 HD ses-
sion, 2



















Hemodialysis (HD), peritoneal dialysis (PD), continuous ambulatory peritoneal dialysis (CAPD). 1A sample from 
the Hemodialysis (HEMO) study. During the 5 years of  follow-up, 10 out of  198 patients could fulfi ll all 5 measure-
ments. The dialysis vintage was retrieved from Cheung et al.116 2 In this study, two cohorts were included in which 
separate analyses were performed. 3 Period during which measurements took place and number of  measurements. 
Total include baseline measurements. 3Highest mortality in groups in order. Characteristics of  LVH in most preva-
lent in groups are displayed in the following order:#Mean (standard deviation), **Median (IQR), ‡‡Mean (range), 
§§Median (range). When summaries were given for separate groups in a study, a pooled estimate for the total popu-
lation was calculated. Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; CRP, C-reactive protein; 
hs-CRP, high sensitivity CRP (nmol/l), HD, hemodialysis; interleukin-6 (pg/ml), LVH, left ventricular hypertrophy; 
PD, peritoneal dialysis; TNF, tumor necrosis factor (pg/ml). 



































Figure 4. Kaplan–Meier survival curves according to trimestral variation patterns. a) CRP and b) IL-6 variations. 
Variation groups were created according to the tertile distribution at each time point. Survival curves in four different 
variability patterns are highlighted: a ‘decrease’ group, which contained individuals having a decrease in CRP levels 
from the upper tertile to the middle or lower tertile or from the middle tertile to the lower tertile; an ‘increase’ group 
which contained patients in whom CRP levels increased from the lower tertile to the middle or upper tertile, or from 
the middle tertile to the upper tertile; a ‘stable high’ group containing patients in whom levels remained in the highest 
tertiles; and a ‘stable low’ group containing patients who had both values in the lower or middle tertile. Abbreviation: 
CRP, C-reactive protein. 
Why should we assess CRP?
In dialysis units, monthly CRP estimation could help to monitor the presence of  contaminated 
water or dialysis fl uid, audit vascular access status, and ensure optimization of  dialysis protocols 
and dialysis. From a preventive point of  view, however, CRP screening should not be used as an 
alternative to screening for major risk factors in determining patient risk, but should complement 
clinical judgment. Additional reasons for performing CRP measurements could be to motivate 
individuals with persistently elevated CRP levels to improve their lifestyles (by smoking cessation, 
dietary modifi cation, exercise, and/or weight loss) or to comply with drug therapies. 
To date, no solid evidence exists demonstrating the advantage of  regular CRP monitoring in 
dialysis units. However, in an analysis from the ecological Dialysis outcomes and Practice Patterns 
Study,16 Kawaguchi et al. reported that cardiovascular mortality was lower in renal facilities that 
measured CRP levels in ≥50% of  patients. These data suggest that regular CRP monitoring 
could aid physicians’ judgment and decision making, positively affecting overall patient survival. 
However, the design of  ecological studies calls for caution in their interpretation owing to their 
susceptibility to the ecological fallacy. In this case, it is possible that units with a higher occurrence 
of  CRP testing exhibited systematic differences in the use of  materials affecting vascular access, 
dialysis fi lters, dialysis regimes or medicines. These factors could confound the observed inverse 




When should we assess CRP? 
At the patient level, regular CRP screening 
could lead to further investigations into 
the underlying causes of  infl ammation and 
the assignment of  appropriate treatment. 
During short-term monitoring, the most 
clinically interesting patients are those 
presenting a ‘smoldering’, chronically 
elevated CRP level in the range of  48–476 
nmol/l (5–50 mg/l) (Box 1). Possible 
causes of  these smoldering elevations 
include graft-related or catheter-related 
infections, peripheral arterial disease, silent 
coronary ischemia, ulcers, infl ammatory 
bowel disease, malignancies, periodontitis, 
or hepatitis. According to the AHA/
CDC recommendations, a second CRP 
measurement taken 2 weeks after the fi rst 
might be useful in identifying transient 
processes while reducing biological 
variation in usual clinical practice.90 
Patients with elevated CRP levels within 
this smoldering range should undergo 
an extensive clinical work-up, whether 
or not they exert clinical symptoms. 
This scenario, in our view, is the most 
important and justifi ed use for CRP 
screening at present. What has not been 
established, however, is how a clinical 
work-up should be performed in patients 
undergoing hemodialysis who have 
elevated CRP levels but no clinical signs 
of  infl ammation. In patients with rapidly 
rising CRP levels or levels consistently 
>476 nmol/l (>50 mg/l), the clinician 
should undertake all measures to detect 
overt infection, as well as other conditions 
associated with elevated CRP levels, such 
Box 1. Possible causes of  infl ammation according to CRP ranges 
in patients undergoing dialysis*
CRP 47.6–476 nmol/L (smoldering or chronically raised) 
• Failed kidney transplant in situ 
• Biofi lm (grafts, catheters, hemodialysis machine) 
• Silent (encapsulated) infection of  AV or arterial grafts 
• Chronic obstructive uropathies
• Calciphylaxis 
• Cholesterol emboli 
• Peripheral arterial disease 
• Silent cardiac ischaemia (myocardial ischaemia, stroke) 
• Congestive heart failure 
• Ischaemic ulcers, neuropathic and venous ulcers 
• Chronic obstructive pulmonary disease 
• Infl ammatory bowel disease 
• Periodontal infl ammation 
• Arthritis 
• Hepatitis 
• Major surgery 
 CRP >476 nmol/l (acute infection) 
• Underlying renal diagnosis (infected cysts in autosomal dom-
inant polycystic kidney disease) 
• Vasculitis relapse, sinusitis, otitis 
• Discitis, osteomyelitis, endocarditis 
• Urinary tract infection/urosepsis, biliary sepsis 
• Septicaemia, any cause (foreign material) 
• Malignancy, de-novo and recurrent 
* Normal CRP <47.6 nmol/l. Abbreviation: CRP, C-reactive 
protein. Adapted with permission from Oxford University Press 
© Wanner, C. et al. Nephrol. Dial. Transplant. 22 (Suppl 3), iii7–
iii12 (2007).
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as malignancy or relapse of  vasculitis.94 These diagnoses clearly show dynamic changes in the 
individual CRP distribution curve over time.94 The studies addressing longitudinal changes in 
infl ammatory status discussed above could assist clinicians in their interpretation of  the outcomes 
of  monitoring the infl ammatory status. Clearly, persistent CRP elevations or increasing trends in 
CRP levels indicate patients at high risk of  dying, and efforts should be made to address the causes 
of  such elevations. 
CRP measurements for mortality prediction
The evidence for a correlation between elevated CRP levels and an increased mortality risk among 
patients undergoing dialysis (even with multivariate adjustment for traditional risk factors) is 
abundant.76,97 However, whether CRP measurements add prognostic value beyond traditional risk 
factor algorithms (such as the Framingham risk factor score) is not clear. Mallamaci et al. studied 
the predictive value of  a composite of  CRP and brain natriuretic peptide (BNP) levels in 246 
patients undergoing dialysis.98 The investigators observed that, by adding these two biomarkers to 
a basic score that was estimated using factors such as age, sex, smoking status, presence of  diabetes 
mellitus and cardiovascular disease, and level of  albumin, the explained variance increased by 9.9% 
for all-cause mortality and by 10.5% for cardiovascular mortality.98 To our knowledge, no study has 
assessed the predictive gain that CRP measurements alone offer in addition to risk stratifi cation by 
traditional risk factors in patients undergoing dialysis. 
The study by Danesh et al. addressed the question of  whether CRP level adds prognostic gain to 
traditional risk factors in patients with cardiovascular disease.32 The investigators compared 2,459 
patients who had a nonfatal myocardial infarction, or died as a result of  coronary heart disease, 
with 3,989 healthy controls, all of  whom were followed for 12 years. Danesh et al. reported that 
CRP measurements provided limited predictive value for mortality over and above established 
risk factors such as hypertension, cholesterol, and smoking. This study was acknowledged by the 
AHA/CDC as being indicative that insuffi cient evidence existed to support the use of  CRP as a 
clinical tool in the prediction of  cardiovascular events.90 Modern epidemiological approaches have, 
however, helped us to gain further insight into the potential of  such a clinical tool through the 
discrimination of  deceased patients and the reclassifi cation of  risk by introducing novel biomarkers 
into a model based on traditional risk factors.99,100 The study by Blankenberg et al., published in 2010, 
added CRP, n-terminal pro-BNP, and troponin I to a conventional risk model in three independent 
cohorts.101 Adding any single biomarker separately to the established risk model did not improve 
risk estimation. By contrast, incorporation of  all three biomarkers effectively reclassifi ed the true 
mortality risk in 11% of  the patients.101 Such a risk model could have important implications in 
common risk algorithms for the general population; however, whether and how such a model 




Managing increased CRP levels
No clinical trials targeting a decrease in infl ammation as a means of  improving outcome in 
patients undergoing dialysis have been performed. Therefore, current recommendations for 
treating infl ammation in patients with CKD are patient-specifi c and mainly include identifying 
and treating the cause of  the infl ammatory response. The fi rst step in dealing with increased 
CRP levels in this patient group is the treatment of  intercurrent events and comorbidities that 
might cause infl ammation. The next step would be to evaluate and, if  possible, handle potential 
dialysis-related causes of  infl ammation. Various nonpharmacological anti-infl ammatory treatment 
strategies, such as physical training and nutritional interventions,91 could be considered at this stage. 
Another consideration is that infl ammation does not occur alone and clearly impinges upon many 
other metabolic manifestations of  uremia, perhaps acting as a catalyst and magnifying the risk of  
other concurrent risk factors.102 For instance, higher doses of  erythropoietin-stimulating agents are 
needed to maintain target hemoglobin levels in patients experiencing infl ammation.103,104 Thus, the 
best treatment for patients undergoing hemodialysis who have elevated biomarkers of  infl ammation 
would probably be multifaceted. Interventional studies reported since 2008 have suggested 
that a variety of  drugs, such as cholecalciferol,105 sevelamer,106 angiotensin- convertingenzyme 
inhibitors,107 pentoxifylline108 and statins109 have anti-infl ammatory effects. Finally, on the basis of  
the observation that chemokine receptor type 5 (CCR5) polymorphisms infl uence the outcome 
of  patients undergoing dialysis who are experiencing infl ammation,110 blockade of  CCR5 could 
provide a novel therapeutic approach in some individuals.111 Randomized, placebo controlled trials 
that specifi cally target infl ammation in patients with CKD are eagerly awaited.
Anticytokine therapies are gaining importance in treating diseases with an elevated infl ammatory 
component, such as rheumatoid arthritis.112 However, some concerns have been raised about 
the use of  such therapies, as they are usually mediated through the blockade of  cellular and/or 
molecular functions that presumably have an important role in host defense. For instance, because 
TNF, IL-1 and IL-6 are key factors in both the innate and adaptive host defense system, increased 
rates of  infections with the use of  these therapies have been reported.113 Additionally, since TNF 
plays an important role in granuloma formation and the defense against intracellular pathogens, 
reactivation of  tuberculosis has been observed with TNF inhibitors in patients with diseases other 
than CKD.113 In patients undergoing dialysis, the safety of  TNF blockers (specifi cally etanercept) 
has been assessed in two small, but important, reports. Don et al. initially designed a 3-month 
intervention trial with subcutaneous etanercept (25 mg twice weekly) in six patients undergoing 
hemodialysis who had normal albumin (>42.0 g/l) or CRP levels (<48 nmol/l [<5 mg/l]).114 
The investigators reported no adverse effects during the treatment phase or subsequent 6-month 
follow-up. The pharmacokinetics of  etanercept in patients undergoing hemodialysis were similar 
to those in individuals with normal renal function and, therefore, administration of  etanercept to 
patients on hemodialysis was deemed feasible without dose adjustment. Following on from this 
research, in 2010 the same group reported the results of  an intervention trial where 10 patients 
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undergoing hemodialysis were randomly assigned to receive etanercept or placebo over a 44-
week period.115 Risk of  infection was a major exclusion criterion, and patients were allowed to 
participate if  both hypoalbuminemia (>38.0 g/l) and infl ammation (CRP >48 nmol/l [>5 mg/l]) 
were present. Unfortunately, <6% of  the screened patients met the inclusion criteria and the study 
was therefore not suffi ciently powered to detect potential changes in the primary outcome (an 
increase in albumin and prealbumin levels).115 However, an important message from this report 
is that, again, administration of  etanercept for more than 7 months seems to be safe and is not 
associated with the occurrence of  adverse events. 
Sample size in a hypothetical trials
At present, we await adequately powered, randomized controlled trials targeting infl ammation 
as a treatment strategy in patients undergoing hemodialysis. However, on the basis of  reported 
variability of  the infl ammatory response in patients with CKD, one would expect such studies to 
include, a priori, a large sample size. Intraindividual variability can be the result of  measurement 
error and/or variability in the biomarker of  interest (in this case CRP) or of  patient-specifi c factors. 
In both cases, a practical solution to overcome the effects of  such variability involves averaging 
consecutive measurements in each individual patient. To reduce variability due to measurement 
error, one solution would be to use the average of  duplicate CRP measurements at each time point. 
However, given the reliable existing methodology for measuring CRP levels, variability caused by 
measurement error is not a major issue.25 Intrapatient variability caused by patient-specifi c factors 
should be taken into account when a relatively longer period (for instance, weeks) is considered 
between successive measurements.
In practical terms, the primary outcome of  a hypothetical study design can be defi ned as the 
average of  two or more consecutive CRP levels measured some time apart. The following example 
illustrates that, by using the average of  two or more consecutive CRP measurements taken 1 week 
apart, the minimum number of  individuals needed in a hypothetical randomized controlled trial 
examining the CRP-lowering ability of  a drug can be reduced. In this example, we use a cohort 
of  167 prevalent patients undergoing hemodialysis from the Stockholm region,18 in whom CRP 
levels were measured weekly for 12 consecutive weeks. All CRP measurements were logarithmically 
transformed, because of  non-normalcy in their distribution. Changes in the CRP levels, along 
with their standard deviations, were calculated over a 6-week period (during which a theoretical 
intervention could have taken place) on the basis of  three different scenarios. In the fi rst scenario, 
preintervention and postintervention values of  CRP were both based on single measurements. In 
the second scenario, preintervention and postintervention values of  CRP were both based on the 
average of  two weekly measurements (two consecutive measurements 1 week apart). In the third 
scenario, preintervention and postintervention values of  CRP were both based on the average of  




Table 2. Theoretical reduction in the sample size per arm of  a hypothetical randomized controlled trial based on 
the use of  average weekly CRP measurements to defi ne end points1 
Δ CRP2 SD3 Reduction (%)4
End points based on single measurements - 0.005 0.523 100
End points based on the average of  two weekly measurements 0.016 0.442 71
End points based on the average of  three weekly measurements 0.017 0.416 63
1The table illustrates a simulation of  a hypothetical randomized controlled trial in which an increasing number of  
measurements causes a decrease in the standard deviation. This, in turn, effectively reduces the minimal number of  
subjects needed per arm. 2Δ CRP; Changes in serum C-reactive protein levels over a 6-week period. Because of  non-
normality, CRP levels at both time points were logarithmically transformed. 3SD, Standard deviation of  the change in 
log-serum CRP levels. 4Reduction in the minimum numbers of  patients needed for a hypothetical trial. The squared 
ratios were multiplied by a hundred to obtain percentages. The scenario based on single measurements served as the 
reference category (100%).
From the logarithmic changes in CRP levels and their standard deviations, the reduction in the 
number of  patients needed was calculated. This reduction equals the squared ratio of  the standard 
deviation based on a single preobservation and postobservation, and on the standard deviation 
based on multiple measurements. As shown in Table 2, when the number of  measurements is 
increased, the standard deviation of  the change decreases gradually. Consequently, the minimum 
numbers of  patients needed also decreases. This solution to high numbers of  participants required 
would offer certain complexity in the accomplishment of  the trial, but would provide a considerable 
reduction in the minimum numbers of  individuals needed.
Conclusions
Infl ammation is a prominent characteristic of  patients undergoing dialysis. Although CRP is 
considered to be the prototypic infl ammatory biomarker, its levels fl uctuate substantially over time. 
Regular monitoring of  CRP levels could provide us with important information on the existence of  
the processes behind this variability. Identifying and treating underlying proinfl ammatory processes 
is currently the only demonstrated way to tackle infl ammation in this patient population. A number 
of  studies in the dialysis setting pinpoint CRP levels as a powerful predictor of  outcomes. Whether 
measurement of  CRP levels adds predictive power beyond traditional risk factors is currently 
unclear. The available evidence suggests that regular monitoring of  the infl ammatory status could 
be an informative clinical tool for assessing disease progression and predicting outcomes. Finally, 
intraindividual CRP variability could be used to our advantage to reduce the number of  patients 
necessary to adequately power future randomized controlled trials.
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Background: The impact of  intra-individual changes of  infl ammatory markers (other than C-reactive 
protein; CRP) on mortality in hemodialysis patients is unknown. We therefore studied survival in 
relation to trimestral variation of  CRP, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).
Methods: In 201 prevalent hemodialysis patients from the Mapping of  Infl ammatory Markers in 
Chronic Kidney Disease (MIMICK) cohort, serum CRP, IL-6 and TNF-α were measured 3 months 
apart and survival was assessed during follow-up. Based on fl uctuations along tertiles of  distribution, 
four patterns were defi ned  for each infl ammatory marker: stable-low, decrease, increase and stable-
high. Hazard ratios were calculated by the Cox proportional hazard model and Pearson’s test was 
used to correlate changes. CRP analyses were replicated in 472 incident hemodialysis patients from 
the Netherlands Cooperative Study on the Adequacy of  Dialysis (NECOSAD). 
Results: Patients with persistently elevated CRP values had the worst mortality in crude (HR: 2.98 
[95% CI: 1.71-5.20]) and adjusted (2.79 [1.58-4.94]) Cox models, together with those who increased 
in their CRP levels (crude 3.27 [1.91-5.60]; adjusted 3.13 [1.79-5.45]). Similar survival patterns 
were observed for IL-6 and TNF-α variation categories. Correlations among these changes were, 
however, not strong. In the replication cohort, individuals with persistently elevated CRP values 
also showed the highest mortality risk (crude 3.38 [2.31-4.94]; adjusted 2.33 [1.58-3.45]). 
Conclusions: Trimestral variation patterns of  TNF-α, IL-6, and CRP are similarly associated with 
survival in hemodialysis patients. The concordance between changes of  these biomarkers was low, 
suggesting that different pathways may trigger each of  these markers.




Patients with advanced chronic kidney disease (CKD) are at an increased mortality risk.1 Understanding 
the pathophysiology of  this excess mortality may contribute to adequate risk profi ling and encourage 
clinical interventions. Recent attention has focused on the role of  increased infl ammation among 
advanced CKD patients in promoting progression of  underlying comorbid illnesses and acting as 
a catalyst for other risk factors, as a consequence leading to increased mortality.2 
The robust evidence concerning single-measurements of  various infl ammatory biomarkers as 
independent predictors of  comorbidities and mortality in CKD patients has justifi ed there use 
for identifi cation of  patients at increased risk.3-5 However, few studies have until now addressed 
the relationship between longitudinal infl ammatory variation and mortality risk.6-9 Clinically, this 
translates into an uncertainty regarding how to interpret the impact of  intra-individual variability 
of  the infl ammatory response on mortality. Moreover, the few studies available on this topic have 
only focused on C-reactive protein (CRP) variation. Hence, we aimed at studying the association 
between the pattern of  changes over a 3-month period of  CRP, interleukin-6 (IL-6) and tumor 




This study comprises individuals from two independent patient cohorts. The fi rst one corresponds to 
the Mapping of  Infl ammatory Markers in Chronic Kidney Disease (MIMICK) cohort, the protocol 
of  which has been described elsewhere in more detail.10 This cohort includes prevalent patients 
(n=228) on maintenance HD therapy recruited during the period of  October 2003 to September 
2004 in six dialysis units in the Stockholm-Uppsala (Sweden) region. Patients were observed for 
a period of  3 months and infl ammatory biomarkers were measured at the beginning and after 3 
months, with subsequent follow-up for survival analyses. During the 3 months observational period, 
3 patients died, 24 additional individuals had at least one missing value in one of  the infl ammatory 
markers studied. Therefore, 201 patients with complete data for all infl ammatory markers at both 
time-points were included. From inclusion on forward, events of  death were recorded, with no loss 
to follow-up. The Ethics Committee of  Karolinska Institutet (Stockholm, Sweden) approved the 
protocol and informed consent was obtained from each patient. To replicate fi ndings, a sample from 
the Netherlands Cooperative Study on the Adequacy of  Dialysis (NECOSAD) study was included.11 
Briefl y, NECOSAD is a prospective follow-up study including all incident dialysis patients from 38 
dialysis centers in the Netherlands between 1997 and 2002. This study includes 472 patients with 
serum CRP assessed at 3 and 6 months after start of  HD therapy. The NECOSAD protocol was 
approved by the Ethics committees of  all participating centers and while being informed, all patients 




scale which was later on simplifi ed into 3 risk categories (low, medium and high comorbidity risk). 
Nutritional status was quantifi ed by means of  the subjective global assessment which, for reasons 
of  simplicity, was trans-calculated to a 3 point scale.13 Body mass index (BMI) was calculated as the 
body weight (kg) divided by the squared height (m2).
Biochemical Methods
In both cohorts, venous blood was obtained before the dialysis session at each time point. Plasma 
was separated, and samples were kept frozen at -80 °C if  not analyzed immediately. CRP in the 
NECOSAD was analyzed with an immunoturbidimetric assay with a detection limit of  3 mg/L. 
In the MIMICK cohort, high-sensitivity CRP levels were measured by an immunometric assay 
(detection limit 0.1 mg/L) on an Immulite Analyzer (Immulite, DPC, Siemens, California) similarly 
to plasma IL-6 and TNF- α levels (Immulite DPC, Siemens, California). Serum albumin levels were 
measured with bromecresol purple in the MIMICK cohort, whereas immunonephelometry was 
used in the NECOSAD. 
Statistical Methods
At each time point, patients were grouped according to each biomarker’s tertiles of  distribution (low, 
middle, high). The change in infl ammatory marker was categorized according to the fl uctuation 
between the tertiles of  the studied biomarker at both time points (Figure 1). From the nine possible 
combinations, four groups were created by clustering patients with changes in the same direction: 
a) Individuals who showed a change to lower tertiles were classifi ed as the “decrease” group; b) 
Individuals showing an increase to upper tertiles were assigned to the “increase” group; c) Individuals 
with both values within the highest tertile of  distribution were labeled as “stable high” group; d) 
Individuals with both values within the lower or the middle tertile were labeled as “stable low” group. 
The same procedure was applied for each infl ammatory mediator and for each cohort separately. 
Additionally, an extra categorization was performed for CRP values using the internationally accepted 
CRP thresholds (the CDC/AHA) of  >3 mg/L and >10 mg/L.14
To test differences between the four groups, Kruskal Wallis, one-way ANOVA, and Chi square 
tests were applied for normally, non-normally distributed and categorical data, respectively. In the 
analysis of  survival, Kaplan Meier curves were created and Cox proportional hazards model were 
used to calculate hazard ratios (HR). Since age, sex, comorbidities and nutritional status are known to 
interact with infl ammation and infl uence mortality, they were included as confounders in multivariate 
Cox models. To take into account the potential confounding effect of  baseline infl ammatory levels, 
the logarithmic transformed value was included in crude as well as in multivariate analyses. Since 
NECOSAD is composed of  incident patients with identical preceding time on dialysis, dialysis 
vintage was not included as covariate in the Cox models for this cohort. All variables satisfi ed the 
proportional hazards assumption. As sensitivity analyses, different cut-off  values (p40 and p80) were 
used to form the different groupings. Also, in both cohorts, hazard ratios were recalculated using 
one cut-off  value for CRP (10 mg/L) on both time points to defi ne the different groupings.
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To assess the correspondence between changes of  the different infl ammatory markers we used 
Pearson correlation tests. For all statistical tests, SPSS version 16.0 (SPSS Inc., Chicago, USA) was 
used. For all hazard ratios, a 95% confi dence intervals (95%CI) not including 1 and for all other tests, 
a p-value smaller than 0.05, were considered to be statistically signifi cant. Kaplan Meier fi gures were 
created using Prism 5.02 (Graphpad, 1992). 
Low tertile 
















Figure 1. Classifi cation of  trimestral variation patterns for each infl ammatory marker
Results
In the MIMICK cohort, the 33rd and 66th percentiles of CRP distribution were 3.6 and 14 mg/L 
for the fi rst measurement and 3.6 and 12 mg/L for the second measurement, respectively. In the 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Crude and adjusted mortality risk for each variation category according to tertile categorization





CRP Stable low 1.00 1.00
Decrease 1.43 (0.77 to 2.65) 1.38 (0.73 to 2.60)
Increase 3.27 (1.91 to 5.60) 3.13 (1.79 to 5.45)
Stable high 2.98 (1.71 to 5.20) 2.79 (1.58 to 4.94)
IL-6 Stable low 1.00 1.00
Decrease 1.94 (1.02 to 3.68) 1.76 (0.92 to 3.38)
Increase 3.38 (1.86 to 6.14) 3.62 (1.96 to 6.69)
Stable high 5.73 (3.30 to 9.97) 3.80 (2.10 to 6.87)
TNF-α Stable low 1.00 1.00
Decrease 1.27 (0.70 to 2.29) 1.43 (0.79 to 2.60)
Increase 1.89 (1.09 to 3.25) 1.81 (1.04 to 3.14)
Stable high 2.46 (1.49 to 4.07) 1.59 (0.92 to 2.74)
 NECOSAD cohort
CRP Stable low 1.00 1.00
Decrease 1.68 (1.15 to 2.46) 1.45 (0.98 to 2.16)
Increase 1.27 (0.83 to 1.94) 1.39 (0.91 to 2.15)
Stable high 3.38 (2.31 to 4.94) 2.33 (1.58 to 3.45)
1. The stable-low group (see methods) served as the reference category.
2. After adjustment for age, sex, Davies Comorbidity score, protein-energy wasting (SGA>1), and 
log (vintage on dialysis). 
Tables 1 and 2 depict the baseline characteristics of  the patients included in this study according 
to the four CRP variation categories for the MIMICK and NECOSAD cohorts, respectively. Also, 
characteristics of  follow-up are presented. In the MIMICK cohort, no difference was observed 
among the groups except for the severity of  comorbidities and dialysis vintage: patients with 
increasing CRP levels having more frequently a comorbidity ≥ 2 (high comorbidity risk) and a lower 
dialysis vintage. In addition, baseline values and changes of  IL-6 and TNF-α were also signifi cantly 
different between all groups. In the NECOSAD cohort however, signifi cant differences existed 
with regard to age, BMI, comorbidities and malnutrition across the four CRP variation groups: 
patients with elevated CRP levels on both time points were older, more often malnourished, had a 
higher BMI and more comorbidities. 
In the MIMICK cohort, survival was assessed for each infl ammatory biomarker after a median 
(IQR) follow-up of  38.4 (17.4-45.1) months, during which 97 (48.3%) individuals died. As shown 
in Figure 1a-c, a similar mortality pattern was observed for fl uctuation categories of  CRP, IL-6 
and TNF-α. Crude and adjusted HRs are presented in Table 3. As compared with patients from the 
stable low group (reference), individuals who increased or had persistently elevated concentration 
of  infl ammatory biomarkers experienced an increased mortality risk, both crude and adjusted. 
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The magnitude of  the HRs for these two categories was, from a clinical perspective, similar. For 
the case of  IL-6, a decrease during the observational period was also associated with an increased 
mortality risk in the crude analysis (HR 1.94 [95% CI: 1.02-3.68]). Although adjustments made 
signifi cance disappear, the magnitude of  the HR was still substantial (1.76 [0.92-3.38]).
Table 4 illustrates a correlation matrix among the changes in infl ammatory markers (deltas, as 
continuous variables) over the 3 months period. The correlation between ΔCRP and ΔIL-6 was 
substantial. On the other hand, correlations between ΔIL-6 and ΔTNF-α and between ΔCRP 
and ΔTNF-α, were relatively weak. In crude (3.38 [2.31-4.94]) and adjusted (2.33 [1.58-3.45]) Cox 
analysis (Table 3), patients within the stable high group exhibited the highest mortality hazard.
Patients who showed decreases in CRP concentrations also presented an increased mortality risk 
in crude analysis (1.68 [1.15-2.46]), being barely lost after adjustment for confounders (1.45 [0.98-
2.16]), and reaching a similar magnitude as the increase group.
As sensitivity analyses we used in both cohorts different cut-off  values based on quartiles; however, 
results did not change (data not shown). Finally, Table 5 repeats the analysis using the established 
CRP thresholds of  3 and 10 mg/L. Results confi rm the same trend, namely that stable high levels 
associated with the highest mortality risk, followed by the increase group in the MIMICK cohort.




Correlations were calculated by means of  Pearson correlation tests; *p=0.05; ** p<0.001.
Discussion
The present study is the fi rst to concurrently analyze the implications of  CRP, IL-6 and TNF-α 
trimestral variation on outcome in HD patients. Our results show a similar survival pattern for 
all three biomarkers. Both an increase as well as a persistent elevation in all these biomarkers was 
linked to a poor prognosis during the follow-up period. The concordance between the changes of  
these biomarkers was low, especially between ΔCRP and ΔIL-6 with ΔTNF-α. 
Our fi nding of  an increased mortality risk amongst individuals with persistently elevated serum 
CRP levels is in agreement with previous studies in HD patients, which substantially differed re-
garding lengths and frequency of  CRP measurement.6,7,15 Also, our observations accord with fi nd-
ings from a cross-sectional study in which measures of  cardiac hypertrophy were more prevalent 
amongst HD patients with persistently elevated CRP levels.16 A novel fi nding in our study is that 
increasing levels of  CRP over the 3 months period in prevalent patients are also associated with a 
higher mortality risk in both uni- and multi-variate analysis, agreeing with a small report in patients 




 Table 5. Crude and adjusted mortality risk for each variation category according to the established CRP thresholds 






CRP Stable low 1.00 1.00
Decrease 1.30 (0.67 to 2.52) 1.33 (0.67 to 2.62)
Increase 3.25 (1.84 to 5.73) 2.77 (1.55 to 4.93)
Stable high 2.92 (1.69 to 5.07) 2.36 (1.34 to 4.16)
NECOSAD cohort
CRP Stable low 1.00 1.00
Decrease 1.39 (0.92 to 2.11) 1.16 (0.76 to 1.79)
Increase 1.35 (0.89 to 2.05) 1.28 (0.84 to 1.96)
Stable high 2.62 (1.81 to 3.81) 1.86 (1.27 to 2.72)
1. The stable-low group (see methods) served as the reference category. 
2. Adjusted for age, sex, Davies score, protein-energy wasting (SGA>1), and log (vintage on dialysis). 
Figure 2. Kaplan-Meier survival curves in MIMICK patients according to CRP (Panel A), IL-6 (Panel B) and TNF-α 
(Panel C) variation groups.
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Results were partially replicated in a second cohort of  incident patients, in whom both increases 
and decreases of  CRP were similar in magnitude in adjusted analyses. The inclusion of  incident 
or prevalent patients in each of  these cohorts, together with different baseline characteristics, may 
have infl uenced at this level. 
Our analysis also longitudinally assesses the implications of  IL-6 or TNF-α variation on HD out-
come. We found a similar relation between mortality and variation patterns for all three biomarkers, 
thereby complementing the reported associations between single measurements of  these markers 
and mortality.3,17 In this context, it must also be noted that the association between infl ammatory 
marker variability and mortality was the strongest for IL-6. A fi nding which is in line with previous 
observations with single measurements.3,18 While the cross-sectional correlations between single 
measurements of  TNF-α, CRP and IL-6 are consistently reported to be strong.19,20 and a congruent 
pattern of  altered cytokine profi ling is observed cross-sectionally in HD patients,21 we anticipated 
a better correlation between the three month variation patterns of  these infl ammatory markers.  
Several differences should be acknowledged as limitations. Firstly, the cohorts share different in-
cident (NECOSAD) and prevalent (MIMICK) designs. Secondly, while in the MIMICK CRP was 
measured with a high-sensitivity assay, a non-high-sensitivity assay with a detection limit of  3 mg/L 
was used in the NECOSAD. Nonetheless, sensitivity analyses using other cut-offs did not alter our 
fi ndings, and we could recently demonstrate an excellent agreement between high-sensitivity and 
non high-sensitivity CRP measurements on mortality prediction in this same patient material.25 A 
fi nal drawback is that this study was performed in patients treated with HD, who may be different 
from patients treated with other dialysis modalities. This would limit the generalizability of  our 
fi ndings to other populations.
Altogether, our study indicates that persistent elevation and increases of  CRP, IL-6, and TNF-α 
over a short period of  time associate with a worse outcome. Since the correlation between these 
changes was not strong, it is likely that different infl ammatory pathways are in parallel infl uencing 
the CKD patient´s risk. Whilst our fi ndings may be of  help to physicians when interpreting the 
evolution of  the infl ammatory response in HD patients, the question whether reduction of  infl am-
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Variations in C-reactive protein during 
a single hemodialysis session do not 
associate with mortality
Chapter 4






Background: An increase in C-reactive protein (CRP) levels during a single hemodialysis (HD) session 
has been associated with mortality. These associations, however, are diffi cult to understand from 
the current understanding of  CRP metabolism.
Methods: In 190 Swedish HD patients from the Mapping of  Infl ammatory Markers in Chronic 
Kidney Disease (MIMICK) cohort, CRP was measured before and after a HD session. During 
follow up, events of  death and censoring were recorded and hazard ratios were calculated and 
analyzed as a function of  CRP variation. Results were replicated in 94 Dutch HD patients from 
the Netherlands Cooperative Study on the Adequacy of  Dialysis (NECOSAD). In this cohort, 
also correlation and kappa statistics were calculated to assess concordance in CRP changes amidst 
multiple dialysis sessions from the same individuals. 
Results: In both cohorts, mean CRP values did not increase during a single HD session. In the 
MIMICK, median (IQR) dialysis vintage was 29.0 (14.8-57.0) months. In both crude (HR [95% 
CI]: 1.008 [0.971 to 1.047]) and multivariate Cox models (0.996 [0.949 to 1.046]), no association 
was observed with mortality. In the NECOSAD, individuals endured 6.0 (6.0 to 12.0) months on 
dialysis. No association was found with mortality neither in a crude (0.961 [0.908 to 1.018]) nor in 
an adjusted analyses (0.978 [0.923 to 1.037]). Finally, the concordance between changes in different 
sessions was poor. 
Conclusions: CRP changes during a single HD session do not associate with mortality, thereby adding 
to the biological uncertainty concerning the ability of  CRP to rise in such short period.




Patients with chronic kidney disease (CKD), and especially those with end stage renal disease 
(ESRD), are at considerable increased risk of  premature death.1 Since the surplus in CKD mortality 
is strongly associated with a state of  persistent infl ammation and chronic activation of  the acute 
phase response, the identifi cation of  factors involved in the pathogenesis of  the infl ammatory 
response is of  considerable therapeutic interest.2-5 
In addition to CKD related factors, such as decreasing renal function, comorbidities, infections or 
the uremic environment per se,6 the hemodialysis (HD) procedure has been suggested to play a 
pivotal role in the development of  infl ammation. Indeed, several studies have shown that intradialytic 
activation is associated with increased fractional synthesis rates of  albumin and fi brinogen as well 
as of  pro-infl ammatory cytokines, leading to a state of  increased muscle-protein catabolism.7-10 
While the long-term consequences of  intradialytic activation (that is, increased infl ammation) on 
the muscle may, indeed increase the mortality risk,11,12 it is uncertain whether these infl ammatory 
fl uctuations are as such valid prognosticators of  the patient’s outcome. A previous study based 
on the NECOSAD cohort reported that an increase in C-reactive protein (CRP) during a single 
HD session was positively related to subsequent mortality.13 However, while CRP is predominantly 
produced in the liver as induced by Interleukin-6 (IL-6) and typically raises after 6-8 hours from a 
major tissue damage,14 this somewhat surprising fi nding is diffi cult to understand from the current 
biological perspective. Since external validation of  observational fi ndings in unrelated populations 
is a fundamental step in the assessment of  purported risk factors, the predictive power for death 
of  intradialytic CRP changes has still to be confi rmed in other cohorts of  dialysis patients. This 
confi rmation is of  particular relevance because CRP levels appear highly variable across different 
studies in ESRD patient.15-17 With this background in mind, we used available data from two 
historical cohorts of  dialysis patients to investigate and further clarify the association between 
changes of  plasma CRP levels during a single HD session and subsequent outcome. 
Subjects and methods
Subjects
This study comprises individuals from two independent patient cohorts. The fi rst one corresponds to 
the Mapping of  Infl ammatory Markers in Chronic Kidney Disease (MIMICK) cohort, the protocol 
of  which has been described elsewhere in more detail.18 This cohort includes adult patients (n=224) 
on maintenance HD therapy recruited during the period of  October 2003 to September 2004 in 
six dialysis units in the Stockholm-Uppsala (Sweden) region. Out of  these individuals, 190 patients 
had CRP and body weight measurements performed both before and after the index session. A 
comparison between the included individuals and the overall cohort revealed no differences in 
general characteristics (data not shown). The study Ethics Committee of  Karolinska Institutet, 




patient. From inclusion on forward, events of  death were recorded, with no loss to follow up.
The second cohort is a selection from the Netherlands Cooperative Study on the Adequacy of  
Dialysis (NECOSAD) study, described in more detail elsewhere.19 This is a prospective follow up 
study in which all new ESRD patients from 38 dialysis centers in the Netherlands were asked to 
participate between 1997 and 2002. Patients were re-assessed every six months. During follow up, 
events of  death and censoring, due to renal transplantation, leaving the study or the end of  follow 
up, were prospectively recorded. For the current analysis, individuals were selected conditionally 
on having completed at least a second HD session six months after an initial observation with 
an identical protocol. Ninety-six patients met these criteria and again, no major differences were 
observed with regards to general baseline characteristics when compared with the overall cohort 
(data not shown). Of  these ninety-six individuals, an overlap of  eleven patients existed with the 
sample reported on by Korevaar et al..13 The Medical Ethics Committees of  all participating Dutch 
centers approved the protocol and informed consent was obtained from every individual. 
For the MIMICK cohort, plasma CRP levels were measured before and after a single dialysis 
session (index session). The same measurements were recorded in the NECOSAD individuals, 
which additionally collected data on one or two additional consecutive dialysis sessions (six months 
apart as per protocol). Co-morbidity was classifi ed according to Davies et al.,20 on a seven point 
scale which was later on simplifi ed into three risk categories (low, medium and high co-morbidity 
risk). Nutritional status was measured by means of  the subjective global assessment which was 
trans-calculated to a three-point scale.21 Weight was recorded before and after each dialysis and 
rounded up to the nearest decimal. Body Mass Index (BMI) was calculated as the body weight (kg) 
divided by the squared height (m).
Biochemical Methods
In both cohorts, venous blood was obtained immediately before and after the dialysis session. In 
the MIMICK cohort, samples were stored at -80°C for a period ranging between 2 to 14 months 
before high-sensitivity CRP measurements were performed. High-sensitivity CRP concentration 
was measured by commercial immunometric assays (LKCRP, DPC, Siemens, California) on an 
Immulite Analyzer (Immulite, DPC, Siemens, California), which had a detection limit 0.1 mg/L. 
Coeffi cient of  variation for a 20-fold repetitive measurement of  a single sample is reported of  
7.5%.  In the NECOSAD cohort, samples were stored at -80 °C degrees for a period ranging from 
4 to 8 years before high-sensitivity CRP measurements were performed. We recently reported that 
this different storage time did not affect the measurements.22 Measurements were done by means 
of  particle-enhanced immunonephelometry using a standard CardioPhase high-sensitivity CRP 
for BNII (Dade Behring Holding GmbH, Liederbach, Germany) which had a detection limit 0.1 
mg/L. Coeffi cient of  variation for a 20-fold repetitive measurement of  a single sample is reported 
of  7%.22 While in the MIMICK cohort serum albumin levels were measured with bromecresol 
purple, immunonephelometry was used in the NECOSAD.




For both the MIMICK as well as the NECOSAD cohort, a change in serum CRP levels over a HD 
session was calculated as the levels after- minus before- dialysis in which an increase is refl ected 
by a positive value. Body weight change was calculated as the weight before- minus the weight 
after- dialysis. In addition, relative body weight change (Relative Δ body weight) was calculated 
by dividing the change during dialysis by the weight before dialysis and multiplying this value by 
100 to obtain percentages. To take into account potential volume shifts during the index session 
(hemoconcentration), CRP levels after dialysis were adjusted by means of  the formula proposed 
by Bergström & Welhe23 based on bodyweight change. As a sensitivity analysis in the NECOSAD, 
correction for hemoconcentration was also done using the albumin ratio during HD (described in 
more detail by Korevaar et al.13). Because this approach did not yield any differences in fi ndings, 
results are not presented. To assess whether the mean change of  serum CRP levels (both unadjusted 
and adjusted for hemoconcentration) deviated from zero (no change), one sample t-test statistics 
were calculated.
In each cohort, individuals demonstrating an increase in serum CRP levels during the HD session 
(>0 mg/L) were grouped as “increase” group, while individuals showing either no-change in CRP 
or a decrease (≤0 mg/L) were classifi ed as “no-increase” group. In the comparison of  baseline 
characteristics between both groups in each cohort, data is presented as means plus standard 
deviations (SD) and medians plus interquartile ranges (IQR), depending on the variable distribution 
and parametric and non-parametric tests were applied as appropriate. In the analyses of  survival in 
MIMICK subjects, the Cox proportional hazards model was used to calculate hazard ratios for a 
change in CRP over the index session. Since age, gender, comorbidity, nutritional status, and dialysis 
vintage are known to infl uence CRP levels and mortality, they were included as confounders in a 
multivariate Cox model. Moreover, to take into account the potential confounding effect of  CRP 
levels before dialysis, the logarithmic transformed value was included in the crude as well as in 
the multivariate analysis, together with the relative body weight change. The proportional hazards 
assumption was tested by calculating the correlation between the Schoenfeld residuals of  each 
covariate and the survival rank for each patient. For all variables, this test was non-signifi cant, 
indicating no violation of  the proportional hazards assumption. 
To assess the concordance in changes of  CRP between subsequent hemodialysis sessions in 
NECOSAD individuals, Spearman correlation coeffi cients and Cohens Kappas were calculated. 
Identical statistical methods were used for the survival analyses in NECOSAD patients. Since 
individuals in the NECOSAD sample were selected on having fulfi lled measurements during at 
least two dialysis sessions, follow up started from the second session onwards. For the same reason, 
characteristics at the time of  the second session were included as confounders in the multivariate 
Cox model. For all the statistical tests, SPSS version 17.0 (SPSS Inc., Chicago. IL. USA) was used. 
Furthermore, a 95% confi dence interval (95%CI) not including 1 for all hazard ratios and a p-value 
< 0.05 for all other tests was considered to be statistically signifi cant. Kaplan Meier curves were 









by body weight 2
MIMICK, n=190
Δ CRP, mg/L # 1.99 (5.23) * - -0.76 (4.49)
Relative Δbody weight,  % # -3.5 (1.9) *
NECOSAD, n=94
Δ CRP 1st HD session, mg/L#  1.03 (8.75) -0.79 ( 7.78)  -1.83 (7.73) *
Relative Δbody weight 1st HD, % # -2.5 (1.6) *
Δ CRP 2nd HD session, mg/L #  1.17 ( 6.60)  0.41 ( 5.38)  -0.90 ( 5.57)
Relative Δbody weight 2nd HD, % # -2.7 (1.6) *
1. Corrected by means of  the albumin ratio. In 9/94 individuals, albumin was not measured.
2. Corrected by means of  the formula suggested by Bergstrom and Welhe21 based on body weight change.
# Means plus SD. Deviations from zero were tested with a one sample t-test, with a * denoting p<0.05.
Results
In a crude analysis, mean CRP levels were signifi cantly increased after the HD session in the 
MIMICK cohort (Table 1), but not in the two NECOSAD recorded sessions. Correction of  CRP 
levels after the HD session for hemoconcentration made these differences disappear. 
In the MIMICK cohort, mean age (SD) was 62.6 (14.0) years and median (IQR) vintage on dialysis 
29.0 (14.8-57.0) months. Furthermore, of  all individuals, 56.3% were men and 26.3% had diabetes 
mellitus. As shown in Table 2, no substantial differences were observed between patients who 
increased or did not increase in their CRP levels during a HD session with regards to age, sex, 
dialysis vintage, time on dialysis per week, relative body weight change, co-morbidities and type of  
dialyzer used. However, BMI and body weights before- and after- dialysis were higher in the CRP 
increase group.  
During a median follow up of  41.3 (IQR: 22.2 to 48.5) months, 87 out of  190 patients died, of  
which 58/125 (46.4%) and 29/65 (44.6%) in the no-increase and increase groups, respectively. As 
shown in the Kaplan Meier survival curve (Figure 1), no difference in survival was noted between 
the two groups. When a change of  CRP during the index session was analyzed as a continuous 
variable in a univariate Cox proportional hazards model, no association was found with mortality 
neither in the crude analyses, (HR [95%CI]: 1.008 [0.971 to 1.047]), nor after adjustment for CRP 
levels before dialysis, age, sex, malnutrition (SGA score), Davies co-morbidity score, relative body 
weight change and dialysis vintage (0.996 [0.949 to 1.046]). In the NECOSAD cohort, individuals 
were on average 65.2 (13.7) years of  age and endured a median (IQR) time of  6.0 (6.0 to 12.0) 
months on dialysis (Table 3). When the sample was restricted to changes during the fi rst session, 
no substantial differences with respect to age, gender, co-morbidity, type of  fi lter, BMI and relative 
body weight change were observed between the increase group and no-increase group. However, 
the increase in serum albumin levels was substantially higher in the increase group. 
CRP Variations during Haemodialysis
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Table 2. Baseline characteristics of  MIMICK patients according to the CRP change during a single HD session







Age, years # 62.3 (14.0) 63.2  (14.0) 0.6
Men, % ¶ 58.4 52.3 0.4
BMI, kg/m2 1,# 24.0  (5.4) 25.6  (5.0) 0.05
CRP before, mg/L * 6.3    (1.5 to 21.0) 7.6    (2.1 to 24.0) 0.7
CRP change,  mg/L 2,# -2.1   (4.2) 1.9    (3.8) -
Body weight before, kg # 72.5  (18.0) 77.4  (17.1) 0.07
Body weight change, kg 3,# -2.6    (1.3) -2.7    (2.0) 0.8
Relative body weight change, % 4,# -3.6 (1.7) -3.4 (2.3) 0.5
Dialysis vintage, months * 28.0    (12.5 to 57.0) 30.0    (15.0 to 57.0) 0.6
Time on dialysis per week, hours * 12.0    (12.0 to 13.5) 12.0    (12.0 to 13.5) 0.4
Type of  dialyzer, Synth/cell. based, % ¶                        95.2/4.8 93.8/6.2 0.7
Part with Diabetes Mellitus, % ¶ 24.0 30.8 0.3
Comorbidity, low/middle/high, 5,¶ 24.8/52.8/22.4 15.4/52.3/32.3 0.2
Malnourished, % 1,6,¶ 47.2 53.1 0.9
1. In a few subjects, not all characteristics were measured.
2. CRP changes were calculated as CRP after- minus before the index session, in which serum CRP concen-
trations after the index session were adjusted for volume shifts during dialysis by use of  the formula sug-
gested by Bergstrom and Welhe. 23.
3. Weight change was calculated as weight before dialysis minus weight after dialysis. 
4. Relative body weight change was calculated as body weight change divided by body weight before dialysis 
times hundred. 
5. Comorbidity was defi ned according to Davies (scale 1 to 3). 
6. Malnourishment was defi ned as a SGA score >2 on a scale of  1 to 3.
¶ Categorical variables were compared using a Chi square test.
*  Data are expressed as median (IQR) and differences were tested by means of  a Mann Whitney U test.
# Data are expressed as mean (SD) and difference were tested by means of  an independent sample t-test.
In the NECOSAD cohort, when comparing changes amidst different sessions, a low concordance 
and agreement existed between the changes in the index session and the second session (n=94), as 
expressed by non-signifi cant kappa and correlation statistics with a value close to zero (Table 4). 
Out of  the 94 patients, having fulfi lled measurements during the fi rst and second measurement, 
47 attended a third HD session in which CRP variation was assessed. Again, concordance and 
agreement between both sessions were very low (Table 5). During the median follow up of  18.4 
(IQR: 9.3-41.6) months, 52 patients died. However, no differences were observed between the 
patients that showed or did not show an increase in their CRP value during the HD session (Figure 
2). No association was observed between ΔCRP as a continuous variable with mortality in a crude 
Cox model (0.961 [0.908 to 1.018]) nor when adjusted for the abovementioned confounders (0.978 




 Table 3. Baseline characteristics of  NECOSAD patients according to the CRP change during a single HD session







Age, years# 64.4 (14.3) 66.6 (12.5) 0.4
Men, % ¶ 49.2 63.6 0.2
BMI, kg/m2 1,# 25.0 (4.8) 26.1 (3.3) 0.2
CRP before, mg/L* 11.4 (3.0 to 21.3) 8.6 (3.1 to 21.5) 0.5
CRP change, mg/L 2,# -3.6 (8.9) 1.5 (2.3) -
Albumin before, g/L # 38.7 (3.9) 39.0 (4.0) 0.7
Albumin change, g/L 3,# 2.4 (4.3) 5.1 (4.7) 0.006
Body weight before, kg # 74.5 (13.5) 76.4 (12.8) 0.5
Body weight change, kg 4,# -1.8 (1.2) -2.1 (1.0) 0.2
Relative body weight change, % 5,# -2.4 (1.7) -2.6 (1.3) 0.6
Dialysis vintage, months* 6.0 (6.0 to 12.0) 6.0 (6.0 to 12.0) 0.7
Time on dialysis per week, hours* 10.5 (8.0 to 12.0) 12.0 (9.0 to 12.0) 0.2
Type of  dialyzer, Synth/cell. based, % ¶                       86.0/14.0 92.7/6.3 0.5
Part with Diabetes Mellitus, % ¶ 9.8 6.1 0.1
Comorbidity, low/middle/high, % 6,¶                                              39.3/52.5/8.2 36.4/57.6/6.1 0.9
Malnourished, % 1,7,¶ 32.7 27.3 0.7
1. In a few subjects, not all characteristics were measured.
2. CRP changes were calculated as CRP after- minus before- the index session, in which serum CRP con-
centrations after the index session were adjusted for volume shifts during dialysis by use of  the formula 
suggested by Bergström and Welhe. 23
3. Albumin changes were calculated as Albumin after- minus before- the index session.
4. Weight change was calculated as weight before dialysis minus weight after dialysis.
5. Relative body weight change was calculated as body weight change divided by body weight before dialysis 
times hundred. 
6. Comorbidity was defi ned according to Davies (scale 1 to 3).
7. Malnourishment was defi ned as a SGA score ≥2 on a scale of  1 to 3.
¶ Categorical variables were compared using a Chi square test.
*  Data are expressed as median (IQR) and differences were tested by means of  a Mann Whitney U test.
# Data are expressed as mean (SD) and difference were tested by means of  an independent t-test.
In a sensitivity analysis in the MIMICK cohort, only individuals with a vintage on dialysis under 
15 months were included (n=44). Moreover, in additional analyses, cut-off  values were chosen 
differently, testing the median CRP change, the 75th percentiles, or even including a third stable 
group (-0.5 to 0.5mg/L change) to the increase (>0.5 mg/L) and decrease (<-0.5 mg/L change) 
Group. All these analyses did not yield any difference in fi ndings. Because the previous study13 was 
performed with a non high-sensitivity CRP assay, we further excluded in the survival analyses of  
both cohorts all patients with a CRP concentration before, and/or after dialysis under 3 mg/L. 
Finally, we also re-ran the survival analyses without correction for hemoconcentration. Also in 
these analyses, fi ndings did not change.  
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The current study demonstrated in two independent European cohorts that on average, CRP 
levels do not signifi cantly change during a single HD session. In addition, we demonstrated a 
lack of  association between these changes and mortality. Furthermore, it was observed that the 
concordance and correlation in CRP changes amidst different sessions was very poor. 
In both cohorts, corrected CRP levels did not increase during dialysis. These fi ndings are in 
disagreement with previous works in which serum CRP levels were found to be elevated after 
a HD session.8,24-26 In all these studies, however, CRP levels after dialysis were not adjusted for 
hemoconcentration, leading possibly to a misinterpretation of  the results. Indeed, the signifi cant 
crude CRP increase observed in the HD session of  MIMICK patients was explained by the effect 
of  hemoconcentration, as volume extraction (indicated by relative body weight change) was higher 
in this patient material. In a cross sectional study, Park et al.26 found characteristics of  left ventricle 
hypertrophy (LVH) to be more prevalent amongst individuals who showed an increase in CRP 
levels during dialysis (responders). However, as basal levels were substantially higher in responders 
and no correction for the effect of  hemoconcentration on CRP measurements took place, it could 
be argued that the observed rise in serum CRP levels is, at least partly, secondary to the effect of  
fl uid removal during dialysis. Moreover, ultrafi ltration was slightly higher in the response group, 
thereby aggravating this effect. In this perspective, the association between an increase in CRP 
during dialysis and LVH could be considered as an invalid consequence of  the known association 
between high CRP levels and LVH.27 
Table 5. Percentage of  individuals with concordant/discordant CRP changes during the second and third 
HD sessions in the NECOSAD sample
n=47 Change during 3rd session
Change during 2nd session Increase Decrease 
Increase, n(%) 5   (10.6) 11 (23.4)
Decrease, n(%) 10 (21.3) 21 (44.7)
κ = -0.01, p=0.9, Pearson correlation: 0.07 (p=0.6)
Table 4. Percentage of  individuals with concordant/discordant CRP changes during the fi rst and second 
HD sessions in the NECOSAD sample
n=94 Change during 2nd session
Change during 1st session Increase Decrease 
Increase, n (%) 15 (16.0) 18 (19.1)
Decrease, n (%) 23 (24.5) 38 (40.4)




Most importantly, the current study contradicts our previous fi nding in the NECOSAD cohort in 
which an increase of  1 mg/L in serum CRP levels during dialysis was associated with a statistically 
signifi cant 8 percent higher mortality risk during follow up.13 There are some important similarities 
and differences between these two studies, which are of  importance when analyzing the strengths 
and limitations of  the current analysis. Firstly, whereas Korevaar et al.13 studied HD patients with a 
median vintage of  6.0 months on dialysis, the MIMICK cohort is composed of  HD patients with 
a median vintage of  29.0 months on dialysis. Thus, it could be argued that a survival bias masked 
a potential association between a change in serum CRP levels and mortality in the MIMICK 
population. More specifi cally, when considering a pro-infl ammatory response to extracorporeal 
circulation to be a subject-specifi c characteristic, individuals with a more pronounced infl ammatory 
response to dialysis would have died before reaching 29 months on HD therapy. This reasoning 
is further supported by the fact that on average, age was lower and dialysis vintage approximately 
three fold higher in the MIMICK cohort as compared with the NECOSAD cohort. However, the 
theory of  a possible survival bias is contradicted by the absence of  an association between changes 
of  CRP during dialysis and mortality in the current NECOSAD sample and in the sensitivity 
analysis of  MIMICK patients, restricted to those being less than 15 months on dialysis. 


































Figure 1. MIMICK sample: Survival plots 
by change of  serum CRP during dialysis
Figure. 2. NECOSAD sample: Survival 
plots by change of  serum CRP during di-
alysis
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Secondly, it could be argued that while CRP levels in our previous observation13 were measured 
using an assay with a detection limit of  3 mg/L, our current analysis utilized high-sensitivity CRP 
assays. Nonetheless, sensitivity analyses excluding CRP values <3 mg/L in the present analyses also 
showed no differences in outcome prognostication in both cohorts. Additional limitations of  our 
study include the fact that the protocol was not specifi cally designed to evaluate changes during 
the HD session, and several factors that potentially could infl uence CRP generation or degradation 
during the dialysis session, such as fl uid status, were not taken into account. Finally, it would have 
been desirable to measure CRP repeatedly after the HD session over a longer time window to study 
whether CRP rose afterwards.
When putting these results in the context of  the current understanding of  CRP biology, more 
uncertainties add to the previously observed association between an intradialytic CRP change and 
mortality. When the dynamics of  the acute phase response was studied after the aggressive stimulus 
of  cutting the sternal bone during open heart surgery, CRP levels rose after approximately 7 
hours.14,28 Because a dialysis session typically lasts 4-5 hours, an increase of  CRP within this period is 
biologically less plausible. On the other hand, while extrahepatic CRP production has been reported 
in adipocytes29 and endothelial cells30 in experimental conditions, we cannot exclude the possibility 
that specifi c phenotypes, for example obese individuals, or certain genetic profi les may translate, 
under the exposure to the uremic milieu,31 in a faster CRP production from alternative tissues in 
response to the intermittent HD stimulus. However, this hypothesis has to date no substantiation 
and it is unknown if, and to what extent other tissues may contribute to systemic CRP levels in the 
context of  uremia. In the interpretation of  the current results, we have assumed the established 
statement that the vast majority of  circulating CRP comes from hepatic production.32 Also, as 
Kaysen et al.15 pointed out, the acute phase response generally spans multiple dialysis sessions, 
thereby suggesting the value of  intradialytic causes to be of  less importance. Moreover, intradialytic 
changes in infl ammatory markers seem to be very complex and infl uenced by many factors, such 
as adhesion of  molecules to the dialyzer membrane, shifts between extravascular and intravascular 
compartments, and activation of  the infl ammatory response by extracorporeal circulation.33,34 
As apparent by the lack of  consistency amidst the different HD sessions in our study, CRP is 
probably not a valid marker to monitor the intradialytic infl ammatory response. Focus should 
instead go out to more adequate markers. For example, in a study by Boehme et al.,35 blood leaving 
the dialyzer produced more Pentraxin 3 (PTX3) than blood withdrawn before the dialysis session. 
In another study by Friedrich et al.36 intracellular RNA levels in leucocytes encoding TNF-alpha, 
IL-1 beta and IL-8 increased signifi cantly during dialysis. Since the intracellular compartment does 
not seem to be affected by volume extraction during dialysis, no differences are encountered when 




Based on fi ndings in the current study and the diffi culty to explain an increase in CRP levels within 
the course of  a single HD session from a biological perspective, we conclude that CRP changes 
during dialysis do not associate with mortality. However, whether patients exhibiting a more pro-
nounced infl ammatory response to extracorporeal circulation, have an increased mortality risk, is 
still of  substantial interest. Therefore, future research should focus on understanding the conse-
quences of  activating other infl ammatory markers or interleukins during HD. 
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Nonthyroidal illness and the 
cardiorenal syndrome
Chapter 5






The cardiorenal syndrome represents a fi nal common pathway for renal and congestive heart 
failure and heralds a poor prognosis. Factors that link the failing heart and the failing kidneys, 
the so called cardiorenal connectors, are therefore of  clinical and therapeutic interest. Alterations 
in the levels and function of  thyroid hormones that fi t the spectrum of  nonthyroidal illnesses 
could be considered to be cardiorenal connectors as both renal failure and heart failure progress 
with the development of  nonthyroidal illness. In addition, circumstantial evidence suggests that 
nonthyroidal illness can induce deterioration in the function of  the heart and the kidneys via 
multiple pathways. As a consequence, these reciprocal associations could result in a vicious cycle of  
deterioration that likely contributes to increased mortality. In this Review, we describe the evidence 
for a pathophysiological role of  nonthyroidal illness in the cardiorenal syndrome. We also discuss 
the available data from studies that have investigated the effi cacy of  thyroid hormone replacement 
therapy in patients with renal failure and the rationale for interventional trials to examine the effects 
of  normalization of  the thyroid hormone profi le in patients with renal failure and congestive heart 
failure.
Key points
• Cardiac disease and renal disease are frequently accompanied by nonthyroidal illness (that is, 
alterations in thyroid hormones in the absence of  hypothalamic–pituitary–thyroidal disease).
• General factors (such as infl ammation and nutritional defi ciencies) and pathophysiological 
factors that are specifi c to cardiac and renal disease contribute to the development of  
nonthyroidal illness. The presence of  nonthyroidal illness is associated with an increased risk 
of  cardiovascular death in patients with cardiac and/or renal disease. 
• Nonthyroidal illness can result in deterioration of  cardiovascular and renal function via several 
pathways.
• The genesis of  nonthyroidal illness in cardiac and renal failure as well as its deleterious effects 
on both organ systems suggest that nonthyroidal illness acts as a cardiorenal connector in the 
cardiorenal syndrome.




Cardiac and renal function are closely connected in both physiological and pathological states.1 
Heart failure can lead to renal failure and vice versa, a condition commonly known as cardiorenal 
syndrome.1 As the presence of  this syndrome is associated with increased mortality,2 factors that 
explain the connection  between the failing heart and failing kidneys are of  clinical interest.3  Several 
of  these so-called cardiorenal connectors have been identifi ed and include infl ammation, oxidative 
stress, anaemia and increased sympathetic nerve activity.3 These factors, however, do not seem to 
fully explain the increased mortality of  patients with cardiorenal syndrome.
Many patients with congestive heart failure (CHF)4 and/or  chronic kidney disease (CKD)5  present 
with alterations in the levels of  thyroid  hormones in the absence of  an apparent underlying 
dysfunction in the hypothalamus–pituitary–thyroid (HPT) axis. This condition, known as 
nonthyroidal illness, was traditionally considered to be the result of  a physiological adaptation  to 
slow metabolism and save energy in the presence of  disease.6 In patients with CHF7,8 or CKD,9–11 
nonthyroidal illness is associated with an additional 2–3- fold increase in mortality. Direct effects 
of  a low thyroid hormone state on both cardiovascular and renal function may explain this risk 
association.
Both CHF and CKD drive the development of  non- thyroidal illness, which in turn could result 
in a deterioration in both renal and cardiac function (Figure 1). In this Review, we discuss the 
hypothesis that nonthyroidal illness is a cardiorenal connector in the genesis and maintenance 
of  the cardiorenal syndrome, and describe available data from interventional studies that have 
investigated the potential benefi cial effects of  thyroid hormone supplementation in CHF and CKD. 
Nonthyroidal illness
Thyroid hormone abnormalities that result from nonthyroidal illness are encountered in a 
variety of  diseases, including severe infections, liver disease, severe malnutrition and psychiatric 
morbidities.12 In mild-to-moderate disease states, levels of  free and total triiodothyronine decrease, 
reverse triiodothyronine accumulates in the serum and levels of  free thyroxine might increase 
slightly (Figure 2).12,13 Severe forms of  nonthyroidal illness (such as those observed in the majority 
of  patients in intensive care units), are typifi ed by a reduction in the levels of  thyroid-stimulating 
hormone (TSH; also known as thyrotropin) and free and total thyroxine.14 These alterations seem 
to be induced by functional changes that occur at all levels of  the HPT axis, including an impaired 
central feed- back mechanism,12  a reduction in the binding capacity of  thyroxine binding globulin,14 
alterations in iodothyronine deiodinase activity and in the transport  of  thyroid hormones across 
cell membranes,15 and differential expression and activity of  the nuclear thyroid hormone receptor 
subtypes α and β.16,17 Importantly, nonthyroidal illness occurs in patients who did not have overt 




Below, we describe the genesis and prevalence of  nonthyroidal illness in CKD and in CHF. Some 
important considerations  must, however, be taken into account. Firstly, nonthyroidal illness refl ects 
a heterogeneous spectrum of  abnormalities in thyroid hormone levels. As a consequence, various 
studies might differ in the thyroid hormones and cut-off  values used to defi ne nonthyroidal illness. 
The defi nition of  nonthyroidal illness is further complicated by the existence of  considerable 
inter-assay variability in measurements of  the levels of  free triiodothyronine and free thyroxine, 
particularly if  the older radioimmunoassay method is used.18 Secondly, as many of  the available 
studies excluded the sickest patients (for example those with unstable CHF) the prevalence of  
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Figure 1. Nonthyroidal illness as a cardiorenal connector. Various mechanisms could drive the genesis of  nonthyroidal 
illness in patients with chronic kidney disease and/or congestive heart failure and explain the potential negative conse-
quences of  nonthyroidal illness on cardiac and renal function.
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Thirdly, in nearly all of  the available studies of  nonthyroidal illness in cardiac and renal disease, 
serum levels of  thyroid hormones were assumed to refl ect the tissue levels of  these hormones.  The 
expression and activity of  the various iodothyronine deiodinase subtypes, co-activator complexes, 
and nuclear thyroid hormone receptor isoforms, however, seems to differ between tissues and 























Figure 2. Thyroid hormone levels in nonthyroidal illness. Worsening of  disease severity is associated with increasing 
abnormalities in thyroid hormone levels. The blue band indicates the normal range of  thyroid hormone levels. Permis-
sion obtained from Society of  Endocrinology © Warner, M.H. et al. J. Endocrinol. 205, 1–13 (2010).
Genesis of  nonthyroidal illness
In renal disease
The prevalence of  nonthyroidal illness gradually increases as renal function declines and recent 
studies have reported that clinically low serum concentrations of  free and/or total triiodothyronine 
are present in more than 75% of  individuals with end-stage renal disease (ESRD).11,19,20 Low serum 
levels of  free and total thyroxine have been reported in 10–50% of  patients with ESRD,21–24 and 
low levels of  TSH have been reported in up to 10% of  patients with ESRD.21 The bioactivities 
of  thyrotropin-releasing hormone (TRH; also known as prothyroliberin) and TSH may also be 
reduced in these patients.20,25 In contrast to classical nonthyroidal illness, however, total serum 
levels of  reverse triiodothyronine are not increased in patients with ESRD,20 possibly as a result of  
the increased transfer of  reverse triiodothyronine to extravascular tissues.20 In acute kidney injury 
(AKI), a reduction  in the levels of  total and/or free triiodothyronine in combination with low 
levels of  total and/ or free thyroxine and an increase in reverse triiodothyronine concentrations 
has been reported in up to 80% of  patients.26,27 As TSH levels infrequently exhibit a compensatory 
increase,20 low levels of  free thyroxine also seem to be part of  the nonthyroidal illness spectrum 




Both general factors and renal-specifi c factors may explain the high prevalence of  nonthyroidal 
illness in patients with ESRD.19,28 A persistent chronic state of  infl ammation is observed in the 
majority of  patients with ESRD29 and is strongly associated with the presence of  nonthyroidal 
illness in patients on dialysis.30,31 In rats, infusion of  interleukin-1 resulted in alterations in thyroid 
hormone  levels that were similar to those seen in nonthyroidal illness in humans.32 Nutritional  dis- 
orders that are associated with the development of  nonthyroidal illness12 are common in patients 
with ESRD,33 and hypoalbuminaemia (a proxy for nutritional status) was inversely correlated  with 
the presence of  nonthyroidal illness in these patients.10,31 In CKD, nutritional disorders often coexist 
with a systemic break down of  various muscle proteins and perturbations in the levels of  appetite 
controlling hormones (that is, protein–energy wasting).34 These abnormalities are also considered 
to be risk factors for nonthyroidal illness.12 
Together, infl ammation and protein–energy wasting may affect thyroid hormone physiology at all 
levels of  the HPT axis, by mechanisms including decreasing the activity of  type 1 iodothyronine 
deiodinase (which converts thyroxine into active triiodothyronine) and the thyroid-hormone- 
binding capacities of  various proteins.12,21 Finally, anaemia, which is common in patients with 
ESRD is associated with a decrease in triiodothyronine levels.35 To some extent, the development 
of  nonthyroidal illness also seems to be a direct consequence of  factors related to the loss of  
renal function. For example, iodide retention owing to renal dysfunction causes thyroidal iodide 
oversaturation, which inhibits thyroid hormone oxidation and release, eventually resulting in 
functional hypothyroidism (a mechanism known as the Wolff–Chaikoff  effect).36 Low levels of  
free triiodothyronine have also been reported in patients with metabolic acidosis.37 A further 
contribution to the development of  nonthyroidal illness is made by comorbid diseases that are 
associated with CKD (such as, diabetes mellitus, gout and intermittent infections) and the use of  
certain drugs commonly  used to treat patients with CKD, such as corticosteroids, amiodarone, 
propranolol and lithium.38,39 In addition, phosphate binders such as calcium carbonate may reduce 
the intestinal absorption of  L-thyroxine (a synthetic form of  thyroxine).40 In patients with pre- 
existing thyroidal disease receiving thyroxine therapy, this phenomenon may affect thyroxine 
dosages.
Researchers have suggested that loss of  thyroid hormone binding proteins during dialysis might 
account for defi ciencies in total levels of  thyroid hormones in patients receiving dialysis. However, 
levels of  total thyroxine and thyroxine-binding globulin correlate poorly in patients on dialysis, 
suggesting that the mechanism of  thyroid hormone defi ciencies in these patients is more complex 
than initially assumed.23 Finally, because iodothyronine deiodinase activity is selenium dependent, 
abnormalities in peripheral conversion that result in low levels of  total and free triiodothyronine 
have been partly attributed to selenium defi ciency, which is common in patients with ESRD.41 
Testosterone defi ciency is also a frequent fi nding in these patients42 and is associated with a decrease 
in the activity of  hepatic type I iodothyronine deiodinase in rats.43




CHF attributable to ischaemic and nonischaemic causes is often accompanied by low levels of  free 
and/ or total triiodothyronine and elevated levels of  reverse triiodothyronine.8 These derangements 
are reported to be prevalent in ≤58% of  patients with CHF7,44–48 and are observed even during the 
early stages of  the disease.49 A strong dose-relationship exists between a reduction in serum levels 
of  free and total triiodothyronine and the severity of  symptoms in patients with decompensated47,50 
and compensated CHF.51 In the settings of  acute myocardial infarction52,53 and cardiac arrest,52,54 
serum levels of  free triiodothyronine and free thyroxine sometimes decrease below detection limits.
In CHF, a reduction in the serum levels of  total and free triiodothyronine parallels worsening of  
disease48,55 and is induced by general and disease-specifi c factors. Firstly, infl ammation is induced 
by both atherosclerosis56 and CHF57 and is associated with the presence of  nonthyroidal illness 
in CHF.7 Malnutrition and anaemia also contribute to the development of  nonthyroidal illness by 
blunting pituitary responses to TRH and reducing the peripheral conversion of  free thyroxine into 
active free triiodothyronine.58,59 Certain drugs that are routinely prescribed by cardiologists also 
drive this process.47 For example, the potent type III anti-arrhythmia drug, amiodarone, affects 
the thyroid via its high iodine content, alteration of  triiodothyronine receptor binding affi nity 
and iodothyronine deiodinase activity and its metabolites, which act as weak antagonists of  free 
triiodothyronine.60 Propranolol treatment was shown to selectively lower total triiodothyronine 
levels without signifi cantly altering total thyroxine concentrations in hyperthyroid and hypothyroid 
patients, likely refl ecting an effect of  this drug on iodothyronine deiodinase activity.39 Lastly, high 
dosages of  furosemide (≤500 mg) have been associated with a reduction in the binding capacity 
of  thyroxine binding globulin.61
Risk factors for nonthyroidal illness that are specifi cally linked to cardiac disease include those that 
are induced by CHF and ischaemia. In rodent cardiomyocytes, the activity of  type 3 iodothyronine 
deiodinase (the major thyroid hormone inactivating enzyme) was selectively upregulated after 
induction of  cardiac ischaemia62 and right ventricular pressure overload.63  This upregulation was 
hypothesized to result in a systemic lowering of  triiodothyronine levels.1 A similar decrease in 
serum triiodothyronine levels after streptococcal infection was, however, observed in mice with 
knock-out of  deiodinase type 3 and in wild type controls, suggesting that deiodinase type 3 may not 
have an important role in the regulation of  systemic triiodothyronine levels.64
Interestingly, type 3 iodothyronine deiodinase knock-out mice subjected to adrenergic overdrive 
developed restrictive cardiomyopathy, whereas wild type mice developed left ventricular dilatation.65 
As the liver is one of  the major sites of  conversion of  free thyroxine to free triiodothyronine,66 
hepatic congestion in patients with right sided CHF might contribute to further inhibition of  




Nonthyroidal illness and organ dysfunction
Cardiac dysfunction in renal disease
Cardiovascular mortality is more than eight times higher in patients with ESRD than in the general 
population,67 and is further increased in patients with cardiorenal syndrome.2 In observational 
studies, this increase in cardiovascular death in patients with ESRD has been partly attributed to 
the presence of  nonthyroidal illness.9–11
The increased mortality that is associated with nonthyroidal illness can be explained by several 
biological mechanisms. At a cardiac level, low levels of  free triiodothyronine are associated with an 
increase in left ventricular mass and a reduction in left ventricular function in patients on dialysis.31 
This observation is consistent with the fi nding of  reduced left ventricular systolic dysfunction and 
impaired diastolic performance in Langendorff-prepared (that is, in vitro perfused) hearts of  mice 
with starvation-induced nonthyroidal illness compared with those from well-fed, euthyroid animals.68 
In these animals, both phases of  cardiac function improved after triiodothyronine substitution.68 As 
cardiomyocytes have hardly any deiodinase activity69 and are, therefore, largely dependent on free 
triiodothyronine in serum, the cardiac consequences of  nonthyroidal illness might be equivalent 
to those of  overt hypothyroidism.70,71 During overt hypothyroidism, structural alterations occur 
in the heart that are associated with a reduction in its inotropic and lusitropic properties.72 These 
alterations are the result of  direct effects of  thyroid hormones on the transcription of  genes 
encoding myosin-α (also known as myosin-6), sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
(SERCA),72–75 and β-1 adrenergic receptor proteins,76,77 via stimulation of  thyroid hormone response 
elements in the promoter regions of  these genes (Figure 3). Thyroid hormones also negatively 
regulate the synthesis of  myosin-β (also known as myosin-7) subtypes of  adenylyl cyclase,78 and 
phospholamban, an inhibitor of  SERCA activity.72 A low thyroid hormone  state will, therefore, 
result in a cardiac phenotype encompassing upregulation of  myosin-β, phospholamban and adenylyl 
cyclase, and a reduction in the activity of  myosin-α, the β-1 adrenergic receptor and SERCA.
As is apparent from thyrotoxic atrial fi brillation (that is, atrial fi brillation associated with 
hyperthyroidism), thyroid hormone physiology also affects cardiac electrophysiological properties. 
In a study of  patients with CHF, nonthyroidal illness was associated with an increased frequency 
of  non-sustained ventricular tachycardias.46 A poorer haemodynamic situation (that is, lower 
cardiac index and greater congestion) and higher levels of  noradrenaline could, however, migh 
have accounted for this difference. Nonetheless, in patients on haemodialysis, the presence of  
nonthyroidal illness is associated with an increase in the occurrence of  ventricular late potentials (as 
assessed on signal-averaged electrocardiograms) and in the risk of  ventricular tachyarrhythmias.79 
In patients with hypothyroidism, cases of  QT interval prolongation and torsades de pointes 
ventricular tachycardias have also been reported.80,81 These events might be the result of  a decrease 
in the activity of  voltage-gated potassium channels and in the expression of  Na+/K+ ATPase and 
the Na+/Ca2+ exchanger in response to low levels of  thyroid hormones.72,81
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At the vascular level, increased arterial calcifi cation in patients with ESRD82 could be partially 
explained by the presence of  nonthyroidal illness. This hypothesis is suggested by studies in which 
levels of  free triiodothyronine in patients with ESRD were inversely associated with coronary 
artery calcifi cation (CAC) scores,83,84 intima-media thickness84 and measures of  systemic arterial 
stiffness.83–85 Several potential mechanisms might underlie an association between nonthyroidal 
illness and arterial calcifi cation in patients with ESRD. Firstly, in ESRD a low thyroid hormone 
state is associated with endothelial dysfunction,86,87 which is generally considered to be a prodromal 
step in atherosclerosis.56 Secondly, a low thyroid hormone state exerts direct effects on vascular 
smooth muscle cells, promoting vasoconstriction and thereby increasing peripheral vascular 
resistance.88 Thirdly, ex-vivo studies have indicated that low levels of  free triiodothyronine induce 
downregulation of  the synthesis of  Klotho89 and matrix Gla protein,90 which are important 
inhibitors of  the calcifi cation process. Fourthly,  low levels of  free triiodothyronine were associated 

























Figure 3. Direct effects of  T3 on the cardiomyocyte. Binding of  T3 to thyroid hormone receptors in the nucleus 
of  the cardiomyocyte activates thyroid hormone response elements leading to the transcription of  genes encoding 
myosin-α, SERCA and β-R, increased expression of  voltage-gated K+ channels, Na+/K+  ATP-ase and the Na+/
Ca2+ exchanger, and downregulation of  myosin-β, AC and PLN. Abbreviations:  AC, adenylyl cyclase; β-R, adrenergic 
β-1 receptor; PLN, phospholamban; SERCA, sarcoplasmic/ endoplasmic reticulum Ca2+ ATPase; T , triiodothyro-




Renal dysfunction in cardiac disease
Renal dysfunction is common among patients with CHF and is associated with increased mortality 
in this population.2 Various researchers have attributed  this increased mortality to the presence of  
nonthyroidal illness.48,92 Circumstantial  evidence for this association comes from studies in patients 
with overt hypothyroidism. These patients often show reduced renal function that normalizes in 
response to restoration of  thyroid hormone levels.93,94 Recently, thyroid hormone replacement 
therapy in patients with subclinical hypothyroidism was shown to attenuate the slope of  renal 
function loss.95,96 Although thyroid hormone physiology directly affects the production of  serum 
creatinine and levels of  cystatin C,97 the association between thyroid and renal function may not 
solely refl ect a direct effect of  thyroid hormone levels on renal function. Systemic myopathy, 
which is common in patients with hypothyroidism, could cause an increase in serum creatinine 
levels and, therefore, result in a reduction in estimated glomerular fi ltration  rate (eGFR) that does 
not refl ect worsening of  renal function. However, hypothyroidism has also been associated with 
reduced renal function in studies that used gold-standard assessments of  renal function (such as 
clearance of  radio-iodinated hippuran, inulin or 51Cr-edetic acid),98–100 and  micropuncture studies 
have shown a reduction in single nephron fi ltration rate in rodents with experimentally-induced 
hypothyroidism.101
The putative effects of  nonthyroidal illness on kidney function can be subdivided into effects 
on the prerenal and renal compartments. In the pre-renal compartment, hypothyroidism may 
cause a decrease in renal plasma fl ow98,102 that can be explained by several mechanisms. Firstly, 
cardiac output decreases in low triiodothyronine states induced  by ESRD,31 thereby reducing renal 
perfusion. Secondly, the renal vasculature and the systemic circulation show a diminished sensitivity 
to adrenergic and vasodilatory stimulation, leading to a further decrease in renal blood fl ow.103,104 
Thirdly, systemic levels of  vasodilators, such as insulin-like growth factor-1, are reduced, shifting 
the balance to a relative vasoconstriction in the renal vessels.105 Lastly, hypothyroidism has been 
associated with a decrease in circulating plasma volume.98 
At the renal level, a low thyroid hormone state results in a reduction  in the weight of  the kidney 
cortex and medulla that seems to be reversed after restoration of  euthyroidism.106 There is a lack 
of  studies of  direct effects of  a low thyroid hormone state on the glomerulus itself. A small, 
uncontrolled pathological study, reported basement membrane thickening, glomerulosclerosis 
and alterations in the mesangial matrix in renal specimens obtained from deceased patients with 
hypothyroidism.107 Observations of  a reduction in intravascular volume and impairment of  urine 
concentration in patients with hypothyroidism have been attributed to hypothyroidism-induced 
tubular dysfunction.108 Namely, a decline in eGFR in a hypothyroid state causes a decrease in sodium 
and water delivery to the diluting segments of  the kidney, which in turn reduces reabsorption of  
sodium and water.108 Reabsorption of  salts in the setting of  hypothyroidism seems to be further 
hampered by downregulation of  the Na+/K+/CL2–exchanger and of  the activity of  Na+/
K+  ATPase.109,110 Another frequent phenomenon in hypothyroidism concerns hyponatraemia, 
which has been associated with inappropriate secretion of  anti-diuretic  hormone  (SIADH).110 
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Increased tubular toxicity due to a hypothyroid-myopathy-induced increase in the levels of  serum 
myoglobulin and creatinine phosphokinase could also affect renal function.111
Therapeutic options
Nonthyroidal illness in renal disease
In several studies, renal transplantation resulted in an increase in the serum levels of  free, 
total and reverse triiodothyronine,112,113 indicating a role of  kidney dysfunction per se in these 
derangements. However, thyroid hormone concentrations initially decreased in the fi rst few days 
after transplantation, likely refl ecting postoperative triggers for nonthyroidal illness (that is, delayed 
graft function and introduction of  immunosuppressive steroidal therapy).112 Nevertheless, a study 
in 20 patients with ESRD and hypothyroidism reported an average reduction of  55% in the required 
dose of  l-thyroxine 6 months  after renal transplantation.114
Targeting disease-specifi c risk factors for the development of  nonthyroidal illness also improves 
thyroid hormone derangements. Restriction of  dietary iodide,36 adoption  of  a low protein 
and phosphorus diet,115 erythropoietin therapy,35,116 correction of  metabolic acidosis37,117 and 
normalization of  selenium levels41 all resulted in increased levels of  triiodothyronine and/or 
normalization of  other thyroid hormone profi les in patients with renal disease and nonthyroidal 
illness.
Thyroid hormone supplementation accelerated renal recovery in rodents with renal insuffi ciency,118–120 
but evidence for a benefi cial effect of  such therapy in humans with kidney disease is limited. 
Several studies have investigated  the effects of  thyroid  hormone supplementation in these patients 
(Tables 1 and 2; details on our literature search are specifi ed in Appendix 2). A placebo-controlled 
randomized  clinical trial of  twice-daily thyroxine (150 μg delivered intravenously) versus placebo 
in 59 patients with AKI and nonthyroidal illness was terminated prematurely because of  increased 
mortality in the treatment group.121 It is plausible that because of  reduced iodothyronine deiodinase 
activity in these patients,14 the relatively high dosages of  thyroxine that were administered could have 
suppressed TSH production without providing a higher bioavailability of  free triiodothyronine.122 
Indeed, levels of  free triiodothyronine did not signifi cantly increase in the study participants during 
or after thyroxine supplementation.121 Similar observations were reported in rats with nonthyroidal 
illness owing to starvation.123 In addition, a combination of  L-triiodothyronine and L-thyroxine 
(but not L-thyroxine alone) normalized  tissue levels of  free triiodothyronine in all organs of  
thyroidectomized rats.124 On the basis of  these fi ndings, we speculate that l-triiodothyronine 
supplementation (with or without L-thyroxine) would be the preferred therapeutic approach in 
the context of  CKD-related nonthyroidal illness. Interestingly, in a study of  paediatric patients 
with AKI (n=8), diuresis commenced within 46 hours of  initiation of  L-thyroxine treatment in all 





Another uncontrolled, non-randomized clinical trial in 15 newborn infants with perinatal asphyxia 
reported a benefi cial effect of  L-triiodothyronine on renal recovery but not on respiratory recovery.126 
In two classic case series of  patients with CKD, near physiologic doses of  l-triiodothyronine 
resulted in a negative nitrogen balance, a fi nding that was considered to suggest that thyroid 
hormone supplementation should not be used in these patients.127,128 However, another case series 
and a single-blinded randomized controlled trial reported favourable effects of  thyroid hormone 
substitution  on lipid profi les in patients with ESRD.91,129 Finally, a randomized clinical trial of  
thyroid hormone replacement therapy in 38 patients with clinical or biochemical signs of  delayed 
graft function within 24 h after renal transplantation found no signifi cant differences in renal 
recovery or 1-year graft survival in the placebo and treatment groups.130 
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Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; IV, intravenous; -T4, Levo-thyroxine; NICU, neonatal 
intensive care unit; RCT, randomized controlled trial; TSH, thyroid-stimulating hormone.
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To date, no studies in patients with ESRD have examined the effects of  targeting nonthyroidal 
illness on cardiovascular endpoints. Below we discuss how this fi eld is evolving more rapidly in 
cardiac diseases.
Nonthyroidal illness in cardiac disease
In patients with mild-to-moderate heart failure and nonthyroidal illness, serum levels of  total 
triiodothyronine normalize rapidly after heart transplantation.46 Increases in triiodothyronine 
levels have also been observed in patients with CHF undergoing interventions that enhance 
haemodynamics, such as physical exercise programmes,45 cardiac synchronization therapy,131 and 
dobutamine  infusion.132 At least eight small studies have investigated the haemodynamic effects of  
thyroid hormone substitution using L-triiodothyronine,133–135 L-thyroxine,136–138 and the synthetic 
thyroid hormone analogue 3,5-iiodothyropropionic acid (DITPA)139,140 in these patients. In a phase 
II randomized  controlled trial that evaluated the safety of  DITPA versus placebo in patients with 
New York Heart Association (NYHA) class I–III CHF, cardiac index improved signifi cantly in 
the treatment versus the placebo group.139 The trial was terminated prematurely, however, because 
of  adverse effects and a trend towards increased mortality in the treatment group.139 A different 
bioactivity of  DITPA as compared with L-thyroxine, particularly in the high dosages administered, 
is thought to have accounted for these effects. In contrast to L-triiodothyronine and L-thyroxine, 
DIPTA  is also poorly tolerated by mice.141
The key therapeutic approach for the successful management of  nonthyroidal illness might be 
to restore thyroid hormone defi ciencies and maintain levels of  TSH, free thyroxine and free 
triiodothyronine within the normal ranges. Physiological doses of  L-triiodothyronine and 
L-thyroxine seem to be well tolerated and are not associated with adverse events.8 Although a 
substantial heterogeneity exists among the available data, supplementation with L-triiodothyronine 
and L-thyroxine was generally considered to be safe and resulted in improved haemodynamic 
status, characterized by increased exercise capacity, pressure development rate, and cardiac-
output index, together with a reduction in peripheral vascular resistance.8 Finally, in a placebo-
controlled  randomized trial that included 20 patients with CHF and nonthyroidal illness,3 days 
of  l-triiodothyronine therapy (20 μg/m2) maintained levels of  free triiodothyronine in the normal 
range and resulted in a substantial improvement in neuroendocrine profi les and ventricular 
performance.134 
In 1972, the only placebo-controlled randomized controlled trial of  thyroid hormone 
supplementation (D-thyroxine, 6 mg daily) in patients with acute myocardial infarction conducted to 
date was terminated because of  a higher occurrence of  arrhythmias and mortality in the treatment 
group than in the placebo group.142 Although the inactive D-thyroxine used in this study was likely 
contaminated with active L-thyroxine, resulting in a dose that was the equivalent of  many times 
the level of  endogenous thyroxine produced daily by the thyroid, this negative fi nding led to its use 
being terminated.143 
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Finally, a recent systematic review concluded that compared with placebo, triiodothyronine was 
associated with a statistically signifi cant increase in cardiac index without an increase in the risk of  
atrial fi brillation or death soon after cardiac surgery.144 In many of  the included studies, however, 
sample sizes were small and the duration of  follow-up was short so that fi rm conclusions cannot 
be drawn from these data. 
Arguments in favour
• ↑ Cardiac inotropy and lusitropy.8,144
• ↓ Peripheral vascular resistance.88
• Improves the neuroendocrine profi le.134
• ↓ Rate of  atherosclerosis.152
• ↑ Renal function.93,95
• Physiological doses of  l-thyroxine and l-triiodothy-
ronine seem to be well tolerated in patients with 
renal failure124,125,127 and in patients  with congestive 
heart failure.8
• Animal studies have shown benefi cial effects.68,119,120
• Indirect evidence exists of  restoration of  thyroid 
disorders without reported adverse effects through 
restriction of  dietary iodide,36 use of  a low protein 
and phosphorus diet,115 EPO therapy,35,116 correc-
tion of  metabolic acidosis37,117 or normalization of  
selenium levels.41
Arguments against
• ↑ Mortality in studies that used high dosages of  
DITPA,139 d-thyroxine,142  or l-thyroxine.121
• ↑ Cardiac oxygen consumption.70
• ↑ Occurrence of  atrial arrhythmias.146
• ↑ Protein catabolism.127,128
Abbreviations: DITPA, 3,5-diiodothyropropionic acid; EPO, 
erythropoietin; TH, thyroid hormone
Box 1. TH supplementation in nonthyroidal illness
Future studies
Additional studies are needed to improve 
our understanding of  the nature and 
consequences of  nonthyroidal illness in 
patients with cardiorenal syndrome. For 
example, in patients with nonthyroidal 
illness, thyroid hormone levels may 
differ substantially between the serum 
and tissues15 but tissue levels of  
these hormones have scarcely been 
investigated in the setting of  cardiorenal 
syndrome. Moreover, benefi cial effects 
of  thyroid hormone supplementation 
for the treatment of  nonthyroidal illness 
have been shown in animal models of  
ESRD119,120 and CHF68 but additional 
studies in models of  cardiorenal 
syndrome are required. Thyroid hormone 
replacement therapy in this setting is 
controversial (Box 1). Arguments in 
favour pertain to potential improvements 
in organ function and decreases in the 
rate of  atherosclerosis progression. 
Furthermore, the available data suggest 
that supplementation of  thyroxine and 
triiodothyronine in physiological dosages 
is well tolerated. As discussed above, 
treatment of  disease-specifi c risk factors 
for the development of  nonthyroidal 
illness also resulted in normalization of  





The main argument against thyroid hormone substitution originates from the two studies that 
showed an association between such therapy and increased mortality in patients with AKI and in 
patients with acute myocardial infarction.121,142 These studies, however, utilized thyroid hormone 
analogues or thyroxine in supra-physiological dosages. A more sensitive physiological approach 
would involve the restoration  of  thyroid hormone  levels to within the normal range. In addition, 
the possibility exists that thyroxine supplementation could increase myocardial contractility and 
heart rate,70 resulting in an increase in myocardial oxygen consumption that could theoretically 
result in cardiac ischaemia, particularly in the presence of  pre-existing coronary artery disease. 
Some studies have, however, suggested that thyroid hormone therapy might improve myocardial 
effi ciency, endothelial function and coronary fl ow reserve.70,145 In regards to the fear of  a possible 
increase in risk of  atrial fi brillation,146 thyroid hormone substitution in physiological dosages did 
not increase this risk in patients with nonthyroidal illness after cardiac surgery.144 
In two small studies that included patients with ESRD, protein catabolism increased in response 
to triiodothyronine supplementation.127,128 This fi nding may, however, simply refl ect the correction 
of  a hypothyroid state and could possibly be compensated by adequate protein intake. Last but not 
least, some similarities can be drawn between nonthyroidal illness and other cardiorenal connectors, 
such as infl ammation, sympathetic stress and anaemia, which could be interpreted as an adaptive 
response of  the human body to illness. In the case of  anaemia, although haemoglobin level is 
strongly associated with patient outcomes, and mechanisms that could explain the deleterious 
effect of  anaemia on patient outcomes have been documented, large intervention studies aimed at 
normalizing haemoglobin levels in patients with heart failure and in CKD have not shown a benefi t 
of  the therapy.147
If  randomized controlled trials exploring the hypothesis that thyroid hormone supplementation 
at physiological levels could improve outcomes in patients with cardiorenal syndrome are to be 
initiated,  triiodothyronine supplementation may be the preferred intervention. The development 
of  thyroid hormone analogues with specifi city for the various nuclear subtypes of  THR has 
evolved rapidly and these agents are also a potential therapeutic option.148 Other therapies targeted 
at thyroid hormone  metabolism are also in development. In a small cross-over trial that included 14 
patients with protracted critical illness, a combination  of  thyroid  releasing hormone  with growth 
hormone-releasing peptide (GHRP)-2 increased the serum levels of  TSH, total triiodothyronine 
and total thyroxine.149 Notably, these changes were accompanied by a reduction in markers of  
catabolism (that is, urea production and urinary excretion of  collagen cross-links) and an increase 
in markers of  anabolism (that is, levels of  serum osteocalcin and leptin).149
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If  interventions in the HPT-axis prove to be of  benefi t to patients with nonthyroidal illness 
attributable to renal failure and/or congestive heart failure, increased awareness among physicians, 
more extensive screening of  patients and a more universal defi nition of  nonthyroidal illness will be 
required.122,150 According to current screening recommendations, most patients with nonthyroidal 
illness (that is, those with selectively low levels of  total and/or free triiodothyronine) should be 
considered to be euthyroid.151 Conversely, patients with severe disease and low levels of  free 
thyroxine are not likely to suffer from primary hypothyroidism but rather from a more severe form 
of  nonthyroidal illness.150 However, in patients with nonthyroidal disease, low triiodothyronine 
levels typically precede low levels of  total and free thyroxine. If  interventions in the HTP-axis 
do prove to be of  benefi t to patients with cardiorenal syndrome, we suggest that levels of  TSH, 
free thyroxine and total and/or free triiodothyronine should be included in a screening tool for 
nonthyroidal illness.
Conclusions
The available evidence suggests that nonthyroidal illness develops in patients with either CHF or 
CKD and has adverse effects on the heart and on the kidneys. This fi nding leads us to describe 
nonthyroidal illness as a cardiorenal  connector  that is involved in the vicious cycle of  the cardiorenal 
syndrome. Existing studies of  the effects of  thyroid hormone supplementation in patients with 
nonthyroidal illness are limited by their design, small sample sizes and/or short durations of  follow-
up. As thyroid hormone replacement therapy in physiological dosages is generally well-tolerated, a 
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Background: Confl icting evidence exists with regards to the association of  thyroid hormone levels and 
mortality risk in patients with end-stage renal disease (ESRD). This study assesses the association 
between basal and trimestral variation of  thyroid stimulating hormone (TSH), triiodothyronine 
(T3) and thyroxine (T4) and cause-specifi c mortality in dialysis patients.
Methods: In 210 prevalent hemodialysis patients, serum T3, T4, TSH, and interleukin-6 (IL-6)were 
measured 3 months apart. Cardiovascular and non-cardiovascular deaths were registered during 
follow-up. Based on fluctuations along tertiles of  distribution, four trimestral patterns were 
defined for each thyroid hormone: persistently low, decrease, increase, and persistently high. The 
association of  baseline levels and trimestral variation with mortality was investigated with Kaplan–
Meier curves and Cox proportional hazard models.
Results: During follow-up, 103 deaths occurred. TSH levels did not associate  with mortality. Patients 
with relatively low basal T3 concentrations had higher hazards of  dying than patients with high 
levels. Longitudinally, patients with persistently low levels of  T3 during the 3-month period had 
higher mortality hazards than those having persistently high levels. These associations were mainly 
attributable to cardiovascular-related mortality. The association between T4 and mortality was not 
altered  after adjustment for T3 levels.
Conclusions: Hemodialysis patients with reduced T3 or T4 levels bear an increased mortality risk, 
especially  due to cardiovascular causes. This was true when  considering both baseline measurements 
and trimestral variation patterns. Our longitudinal design adds observational evidence supporting 
the hypothesis that the link may underlie a causal effect.




A reduction in kidney function encompasses a number of  alterations in thyroid hormone metabolism 
that renders a particular “Nonthyroidal illness” syndrome1 in patients with chronic kidney disease 
(CKD), where low levels of  both Total (T3) and free triiodothyroinine (fT3) are hallmark fi ndings. 
Recent reports suggest that as many as 70% of  patients with end-stage renal disease (ESRD) present 
with low T3 levels,2-5 and as many as 20-25% have subclinical hypothyroidism.6,7 The underlying 
pathophysiology of  these derangements is likely multifactorial, involving iodine retention, altered 
serum protein binding capacity, systemic infl ammation and peripheral deiodinase activity.8,9
These abnormalities have traditionally been considered as a physiological mechanism to save 
energy in response to uremic wasting.10 However, growing evidence suggests T3 to participate 
in the pathophysiology of  endothelial dysfunction,11 atherosclerosis12 and cardiac abnormalities13 
of  CKD patients. Some studies, with somewhat confl icting results, have also implicated thyroid 
alterations in the mortality risk of  CKD patients.14-16 Zoccali et al.14 were the fi rst to report a 
positive association between low fT3 levels and all-cause mortality in stable hemodialysis (HD) 
patients, with similar fi ndings in peritoneal dialysis (PD) patients.17 We could further confi rm 
and expand these observations in a cohort of  euthyroid incident HD patients, in which the 
variance of  all-cause and cardiovascular (CV) mortality was better explained by T3 than by fT3 
levels.16 In contrast, a study in 87 HD patients could not confi rm these fi ndings,15 and a more 
recent retrospective report found that the association between fT3 and all-cause mortality was 
confounded by the nutritional status of  the patients.5  Whereas existing evidence on the association 
between thyroid hormones and mortality is limited to studies considering single measurements of  
hormone levels, it is presently unknown whether thyroid hormone fl uctuation over time impacts 
on mortality hazards. In apparently healthy individuals, thyroid hormone concentrations show a 
narrow intra-individual variation,18 although certain circadian and seasonal (mainly due to seasonal 
differences in iodine intake) fl uctuations have been observed.19 In diseased individuals, however, 
thyroid hormone concentrations seem subjected to a higher fl uctuation as infl uenced among 
others by wasting syndromes, persistent infl ammation and cardiac comorbidities.19 No studies, to 
the best of  our knowledge, have assessed variation of  thyroid hormones in CKD patients and their 
association with mortality outcome. Against this background, the objective of  the present study 
was to evaluate the association between both basal levels and longitudinal (3-month) variation of  
T3, T4 and thyroid stimulating hormone (TSH), and all-cause and cause-specifi c mortality. We did 
so in a well-defi ned cohort of  maintenance HD patients.
Methods and patients
The Medical Ethics Committee at Karolinska University Hospital and Uppsala University approved 
the study protocol, and all patients consented to participate. This is a post-hoc analysis from the 




consisting of  prevalent HD patients in the Stockholm region. The protocol has been described 
elsewhere in more detail.20,21 The inclusion period ranged from October 2003 till September 2004. 
Laboratory measurements and patient characteristics were gathered at baseline and after 3 months. 
From inclusion onward, patients were followed for the occurrence of  fatal events. Out of  224 
patients originally included in this cohort, TSH, T3 and T4 were not measured in 6 individuals 
due to limited plasma volume. The patients were on angiotensin-converting enzyme inhibitors 
and⁄or angiotensin II receptor antagonists (n=72), betablockers (n=109), calcium-channel blockers 
(n=57), diuretics (n=104), statins (n=72), antiplatelet drugs (n=65), erythropoesis-stimulating 
agents (n=211), and iron substitution (n=144). Prescribed medication possibly infl uencing thyroid 
hormone levels was extracted from medical records: 16 patients were receiving levothyroxine 
and one of  these 16 patients additionally used amiodarone. No patients were receiving lithium 
medication or propranolol. Comorbidity was classifi ed according to Davies et al.22, on a seven point 
scale which was simplifi ed into a three risk category scale (low, medium and high comorbidity risk). 
Nutritional status was evaluated by means of  the subjective global assessment (SGA). 
Causes of  death were retrieved from death certifi cates and classifi ed as cardiovascular (CV) or 
non-CV. CV mortality was defi ned as death due to myocardial ischemia or infarction, cardiac arrest 
or unknown sudden death, acute as well as chronic heart failure, cerebrovascular accidents, cerebral 
hemorrhage, and ruptured aortic aneurysm. Non-CV death was defi ned as that not attributable to 
a cardiovascular origin. Individuals with unknown causes of  death (n=13) were grouped within the 
non-CV group.
Biochemical Methods
Venous blood samples were drawn with the patient in a supine position and stored at -70 °C 
if  not analyzed immediately. Concentrations of  high-sensitivity C-reactive protein (CRP) and 
serum albumin (bromcresol purple) were determined using routine methods at the Department 
of  Laboratory Medicine, Karolinska University Hospital, Huddinge, Sweden. Serum IL-6 
concentrations were quantifi ed in an automated immulite analyzer (Siemens Healthcare Diagnostics, 
Los Angeles, CA, USA). Thyroid hormones levels were also assessed on an Immulite system, using 
commercially available immunometric assays for T3 [analytical sensitivity (AS), 0.54 nmol/L; total 
coeffi cient of  variation (CVs), 13.2% and 5.4% at the levels of  0.95 and 6.02 nmol/L)], T4 [AS, 
5 nmol/L; total CVs, 8.4% and 6.3% at the levels of  49 and 167 nmol/L], and TSH [AS, 0.004 
mIU/L; total CVs, 12.5%, and 4.6% at the levels of  0.016 and 1.3 mIU L]. Results are expressed as 
the average of  two measurements. 
Statistical Methods
Because existing evidence suggests that up to 70% of  ESRD and dialysis patients present with 
low T3 levels,3,5 in our study, we chose to defi ne low T3 or T4 categories as those below the 66th 
percentile of  distribution (higher tertile as the reference group). For the analysis of  trimestral thyroid 
hormone variation (two time points: at study inclusion and after 3 months), we classifi ed patients 
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according to their shift along tertile distribution at each time point, a strategy described in more 
detail elsewhere23 and illustrated in Figure 1. From the nine possible combinations, four groups 
were created by clustering patients with changes in the same direction: (i) individuals who showed 
a change to lower tertiles were classifi ed as the ‘decrease’ group, (ii) individuals showing an increase 
to upper tertiles were assigned to the ‘increase’ group, (iii) individuals with both values within 
the highest tertile of  distribution were labeled as a ‘persistently high’ group and (iv) individuals 
with both values within the lower or the middle tertile were labelled as a ‘persistently low’ group. 
Differences between groups were tested by means of  parametric (independent sample t-test, one-
way ANOVA), non-parametric (Mann-Whitney U and Kruskal-Wallis test), and Chi-square tests as 
appropriate. Correlation was assessed by means of  Pearson or Spearman correlation coeffi cients, 
as appropriate. Intra-patient variability of  two measurements is depicted as a coeffi cient of  intra-
patient variation for each thyroid hormone. Survival during follow-up was analyzed by the Kaplan 
Meier method and hazard ratios (HR) were calculated with Cox-proportional hazard models with 
different degrees of  adjustment for potential confounders. Age, sex, comorbidity, protein-energy 
wasting (PEW), serum albumin levels, smoking history, levothyroxine prescription, dialysis vintage, 
and IL-6 were considered as possible confounders in the associations. In these models, T3, IL-6, 
and vintage on dialysis were logarithmically transformed because of  a non-normal distribution. In 
order to test whether the effect of  T4 levels at baseline and variation groupings on mortality was 
due to the effect of  T3 (in the causal pathway), we performed an additional adjustment for Log T3 
or delta T3, respectively.
Low tertile 
















Figure 1. Classifi cation of  trimestral variation patterns for each 
thyroid hormone based on shifts between tertiles of  distribution
As a sensitivity analysis, Cox analyses 
were repeated in biochemically 
euthyroid patients only, being defi ned as 
presenting with normal TSH (reference 
range 0.1-4.5 mIU/L) and T4 (reference 
range 57.9-169.9 nmol/L). Finally, Cox 
analyses were adjusted by CRP instead 
of  IL-6 as a surrogate of  infl ammation. 
HRs with 95% confi dence intervals 
(95% CI) not including one were 
considered to be statistically signifi cant. 
For all other tests, differences with 
p-values below 0.05 were considered to 
be statistically signifi cant. SPSS version 
17.0 (SPSS Inc., Chicago, USA) was 












































































































































































































































































































































































































































































































































































































































































Basal thyroid hormone levels and its association with mortality
In all 218 individuals, median (IQR) levels of  TSH, and T3 were 1.35 (0.84 – 2.52) uIU/mL, 
and 0.82 (0.67 – 1.03) nmol/L, respectively. Basal T4 levels were on average (SD) 70.44 (24.65) 
nmol/L and positively related to T3 levels (rho: 0.529, P<0.001). Thyroid hormone disorders on 
the basis of  circulating hormones were common: 146 patients were classifi ed as having a Low T3 
syndrome, 11 patients were classifi ed as having overt hypothyroidism, and additional 4 patients as 
having subclinical hypothyroidism. General and thyroid specifi c characteristics of  studied patients 
are presented in Table 1, according to low levels of  T3 (≤66th percentile; ≤0.94 nmol/L) and T4 
(≤ 66th percentile; ≤77.2 nmol/L). Patients with low T3 presented with a higher prevalence of  
comorbidities, increased IL-6 levels and lower T4 concentrations. Patients with low T4 were more 
often men, malnourished and presenting with lower T3 levels. In univariate analyses, IL-6 positively 
associated with TSH (Spearman’s rank test rho=0.16, P=0.01) and negatively with T3 (rho= -0.17, 
P=0.009). CRP levels positively associated with T4 (rho=0.19, P=0.003).
During a median (inter quartile range; IQR) follow-up period of  38.2 (17.6 – 45.1) months, 103 
deaths occurred (40 CV and 63 non-CV) of  which 77 occurred in the Low T3 group and 26 
in the High T3 group. As shown in Table 2, the crude and adjusted hazards of  dying (by all 
causes) were 1.8 and 1.6 times higher, respectively, in patients with low T3 levels than in those 
with high T3 levels. This was mainly due to CV deaths, where HRs were considerably higher in 
magnitude (crude HR [95%CI]: 2.8 [1.2 – 6.4]) and remained so after adjustment for confounders 
(adjusted HR: 2.7 [1.2 – 6.3]). A similar analysis was performed for T4. A statistically signifi cant 
association between low T4 levels and an increased all-cause and CV mortality was observed after 
adjustment for confounders (adjusted HR: 3.0 [1.3 – 6.8]). Further adjustment for log-T3 levels did 
not materially alter the strength of  these associations, although a 16% reduction in magnitude was 










Low T3, < 66th percentile (≤0.94 nmol/L)
All-cause mortality 1.8 (1.1 – 2.8) 1.5 (0.9 – 2.4) 1.6 (1.0 – 2.6) -
CV-mortality 2.8 (1.2 – 6.4) 2.5 (1.1 – 5.7) 2.6 (1.1 – 6.0) -
Low T4, < 66th percentile (≤77.2 nmol/L)
All-cause mortality 1.2 (0.8 – 1.9) 1.7 (1.1 – 2.8) 2.1 (1.3 – 3.5) 2.1 (1.1 – 4.0)
CV-mortality 1.8 (0.9 – 3.8) 2.6 (1.2 – 5.9) 3.1 (1.3 – 7.0) 2.6 (1.0 – 6.8)
1. Model 1: Adjusted for age, sex, Davies Comorbidity score, protein-energy wasting (SGA>1), smoking, log-
(vintage on dialysis) and serum albumin levels.
2. Model 2: Additionally adjusted for log-IL-6
3. Model 3: Variables included in Model 2 plus baseline log-T3 levels.




observed for CV mortality. Neither low T3, nor low T4 levels were signifi cantly associated with 
non-CV mortality. TSH levels did not associate with any outcome measure (data not shown).










Age, years 3 65.7 (12.1) 63.2 (15.6) 62.6 (15.3) 58.4 (14.8) 0.06
Men, % 4 52 61 61 54 0.68
Dialysis Vintage 5 24 (11–48) 26 (13–49) 34 (16–63) 44 (20–71) 0.05
Comorbidities, % 2,4 14/55/31 24/59/17 16/59/25 31/50/19 0.21
Smoking history, % 4 18 18 9 24 0.30
SGA>1, % 4 49 44 46 48 0.96
Albumin, g/L 3 35.0 (4.5) 35.1 (4.6) 33.7 (4.1) 35.7 (4.2) 0.16
IL-6 pg/mL 5 9.3 (5.8–16.6) 7.8 (4.2–14.8) 9.1 (5.5–11.4) 6.2 (4.3–10.1) 0.05
TSH, mIU/L5 1.51 (0.85–2.75) 1.66 (1.15–2.64) 1.20 (0.73–2.38) 1.12 (0.80–2.18) 0.20
T4, nmol/L3 59.38 (21.45) 78.18 (21.14) 66.48 (25.23) 85.46 (21.66) <0.0001
T3, nmol/L 4 0.67 (0.60–0.82) 0.96 (0.80–1.06) 0.72 (0.60–0.84) 1.19 (1.03–1.30) -
1. Groups defi ned according to basal and 3-month variation in tertile distribution (See Methods).
2. Davies score (see methods) showing the percentage of patients with low/medium/high comorbidity risk.
3. Means (SD). Differences were tested by one-way ANOVA.
4. Percentages. Differences were tested by Chi square test.
5. Medians (IQR). Differences were tested by Kruskal Wallis tests.
Trimestral thyroid hormone variation and its association with mortality
Thyroid hormones were assessed again after three months in 210 patients. Median (IQR) coeffi cients 
of  intra-patient variation were for T3: 7.8 (2.6 – 12.5)%, T4: 7.1 (4.0 – 12.0)%, and TSH: 14.0 (5.4 
– 24.8)%. In Table 3, general and thyroid specifi c characteristics are depicted across four different 
T3 variation groups (see Methods), not observing major differences among these groups. The same 
was true for T4 variation groups (data not shown). In univariate correlation analyses, delta TSH 
associated with delta IL-6 (rho= 0.17, P=0.01), while delta T3 associated with delta serum albumin 
(rho=0.22, P=0.01). Figure 2 shows the Kaplan Meier curves for T3 and T4 trimestral variation, 
both being clearly associated with patient outcome. Table 4 shows crude and adjusted Cox models. 
Patients with persistently low T3 levels presented the highest hazard for all-cause mortality (HR 2.7 
[1.5 –5.0)]) as compared with subjects having persistently high levels. This was particularly true for 
the association with CV mortality (HR 4.0 [1.3 – 11.7]), while no association between T3 variation 
and non-CV mortality was observed (data not shown). Adjustment for confounders did neither 
alter the magnitude of  the association nor the statistical signifi cance. Of  note, elevated HRs, albeit 
statistically non-signifi cant, were observed for patients showing increases or decreases of  T3 levels 
during the 3-month follow-up versus those having persistently high concentrations.
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 Table 4. Mortality hazard ratios (HR) and 95% confi dence intervals (95% CI) according to T3 (Panel A) and T4 








T3 Increase 1.4 (0.7 – 2.8) 1.1 (0.6 – 2.3) 1.3 (0.6 – 2.6) -
T3 Decrease 1.5 (0.7 – 3.0) 1.3 (0.6 – 2.7) 1.4 (0.7 – 2.9) -
Persistently low T3 2.7 (1.5 –5.0) 2.2 (1.2 – 4.1) 2.4 (1.3 – 4.5) -
CV-mortality
T3 Increase 2.4 (0.7 – 7.8) 2.1 (0.7 – 7.3) 2.3 (0.7 – 7.6) -
T3 Decrease 1.8 (0.5 – 6.5) 1.8 (0.5 – 6.5) 1.8 (0.5 – 6.7) -










T4 Increase 0.9 (0.4 – 1.7) 1.5 (0.7 – 3.3) 1.9 (0.9 – 3.4) 2.0 (0.9 – 4.4)
T4 Decrease 1.8 (0.9 – 3.4) 2.0 (1.0 – 3.9) 1.7 (0.9 – 3.6) 1.6 (0.8 – 3.1)
Persistently low T4 1.5 (0.8 – 2.7) 1.9 (1.0 – 3.6) 2.0 (1.1 – 3.8) 2.1 (1.1 – 4.0)
CV-mortality
T4 Increase 0.9 (0.3 – 3.5) 1.8 (0.5 – 7.1) 1.9  (0.5 – 7.5) 2.2 (0.5 – 8.8)
T4 Decrease 2.9 (1.0 – 8.4) 3.2 (1.0 – 10.0) 3.0 (0.9  – 9.3) 2.6 (0.8 – 8.0)
Persistently low T4 2.6 (1.0 – 7.2) 3.6 (1.2 – 10.6) 3.7 (1.3 – 10.8) 3.8 (1.3 – 11.2)
1. The group with persistently elevated levels served as the reference category in each analysis.
2. Model 1: Adjusted for age, sex, Davies Comorbidity score, protein-energy wasting (SGA>1), smoking history, 
log (vintage on dialysis), and serum albumin levels.
3. Model 2: Additionally adjusted for log-IL-6 levels.
4. Model 3: Variables included in Model 2 plus T3 changes (as a continuous variable).
Patients with persistently low T4 levels showed elevated hazards for all-cause mortality as compared 
with patients having persistently high T4 levels, an association that reached statistical signifi cance 
after adjustment for confounders. Higher hazards were observed for prediction of  CV-mortality 
(crude HR 2.6 [1.0 – 7.0]). In both cases, further adjustment for trimestral T3 variation (as a 
continuous variable) did not signifi cantly affect the results. Of  note, a decrease in T4 was also 
associated with elevated hazards for CV-mortality. No association was observed between T4 
variation patterns and non-CV mortality. Trimestral TSH variation patterns were not associated 
with outcome. In a sensitivity analysis, all baseline and longitudinal Cox analyses were repeated in 
biochemically euthyroid patients only (n=210 at baseline, n=202 with available data at both time 
points). Additionally, Cox adjustment was done with CRP instead of  IL-6. In both cases, results 





In this study, we show that both basal levels and trimestral variation of  T3 and T4 are associated 
with increased mortality, particularly due to cardiovascular causes. Adjusting in the causal pathway 
suggests that the mechanisms associating low T4 levels with an elevated mortality rate may be, at 
least in part, independent of  T3 levels. 
Our observation linking low basal 
T3 levels with increased all-cause 
mortality is in agreement with 
some,5;14;16;17 but not all preceding 
literature.15 While earlier studies5;14;17 
only studied the association between 
T3 and fT3 and all-cause mortality, 
our study also shows that mortality 
prediction is mainly attributable to 
CV causes of  death. The lack of  
mortality prediction observed by 
Fernandez-Reyes et al.15 could relate 
to the selection of  patients having 
survived at least 12 months, the low 
number of  events encountered and 
the strict inclusion criteria which 
excluded, among others, patients with 
abnormal fT3 and fT4 levels. In this 
sense, our analysis shows that patients 
with both baseline and longitudinal 
low T3 levels have a relatively shorter 
time to death, possibly suggesting a 
stronger impact of  thyroid hormones 
on short-term outcome. A recent 
study from Ozen et al.5 showed that 
adjustment for CRP and s-albumin 
abrogated the association between 
fT3 and all-cause mortality, and 
the authors concluded that poor 
nutritional status confounded the 
investigated association. The acute-
phase reactant nature of  s-albumin 
Figure 1. Kaplan–Meier curves for T3 and T4 trimestral vari-
ation. Kaplan–Meier survival curves for all-cause mortality ac-
cording to T3 (A) and T4 (B) trimestral variation in 210 prevalent 
hemodialysis patients.
  Thyroid Hormones and Mortality in Hemodialysis Patients
99
6
and its strong associations with the infl ammatory status however, make these results diffi cult 
to contextualize.24;25 In our own patient population, adjustment for infl ammation (IL-6) and 
malnutrition (SGA) did not affect this association. Furthermore, Zoccali et al.14 reported in their 
study that, since adjustment for fT3 abrogated the association between infl ammation and patient 
outcome, fT3 may be an intermediate pathological of  systemic infl ammation. In our data, as well as 
in the study conducted by Ozen et al.5, adjustment for infl ammation did not affect the link between 
T3 and mortality. Also, associations between trimestral thyroid hormone changes and variation 
of  infl ammatory markers were somewhat weak and inconsistent in our study. One limitation that 
makes our studies not fully comparable is, that while Zoccali et al.14 and Ozen et al.5 measured 
free fractions, we report on total T4 and T3 levels only. Although adjustment for s-albumin (one 
of  the main transporters of  T3 in plasma) did not modify the observed associations, we should 
acknowledge that fT3 is not tantamount of  T3. Several studies have, nevertheless, suggested anti-
atherosclerotic effects of  fT3 on the vascular bed via its effect on mitochondrial oxidative systems, 
induction of  vasodilatatory molecules, inhibition of  angiotensin II receptor expression and down-
stream signal transduction, mechanisms all of  which do not necessarily involve the infl ammatory 
cascade.26-28  
In support of  the association between T3 and the prediction of  cardiovascular death in our study, 
a previous report11 in patients with moderate to severe kidney disease reported that T3 levels 
inversely associated with fl ow mediated vasodilatation, and that this observation was dependent 
on multivariate adjustment for asymmetric dimethylarginine levels. At a cardiac level, low T3 levels 
in CKD patients are associated with reduced left ventricular function, increased left ventricular 
mass13 and elevated intima-media thickness12. Our study also adds novel evidence on the suggested 
impact of  trimestral T3 variation on all-cause and CV mortality in ESRD. Patients with persistently 
low T3 levels exhibited the highest hazards of  dying irrespective of  other concomitant risk factors. 
Interestingly, also an increased variation in T3 during the observation period (e.g. both increases 
and decreases in concentration) resulted in elevated hazards albeit statistically not signifi cant, 
leading us to hypothesize that also an increased T3 fl uctuation may link to an adverse outcome. 
This fi nding accords with a previous study in critically ill patients,29 in which a fast decline in T3 
and T4 (without a concomitant rise in TSH levels) was observed prior to death. Our longitudinal 
analysis, by including two observations 3 months apart in the same individual, represents a step 
forward from previous evidence by virtue of  observing the subject specifi c temporal order of  
events. Therefore, it is interesting to pinpoint that fl uctuation of  thyroid hormones over time exists 
in ESRD patients, and that this fl uctuation links to a worse outcome. What factors drive this, and 
whether uremic thyroid fl uctuation is higher than in other diseases remains, for now, unknown.
Another novelty in our analysis is the association between baseline and trimestral variation of  
T4 levels and (cardiovascular) mortality. Although this is the fi rst study to report so in a dialysis 
population, fi ndings are in line with previous evidence in non-renal patients with non-thyroidal 
illness.29;30 An interesting aspect in our analysis is that the strength of  the association between low 




that the effect of  T4 on outcome is, at least in part, not dependent on its metabolite and that both 
may participate in the increased CV risk. According to recent literature however, adjusting in the 
causal pathway may not be so straightforward as initially thought of,31 and caution is needed in 
the interpretation of  this fi nding which warrants confi rmation in further studies. Nevertheless, 
our previous report in incident dialysis patients also observed, by means of  receiving operator 
characteristics (ROC) analysis a signifi cant, albeit weak association between T4 levels and all-cause 
mortality.16 The recent study by Takamura et al.32 in euthyroid patients demonstrated that carotid 
intima-media thickness was inversely and independently associated with T4 and fT4, suggesting 
an increased cardiovascular risk in subjects with low T4 even within the normal reference range. 
Differential effects of  T4 and T3 on immune cells have also been reported: T4 stimulated while T3 
inhibited peripheral lymphocyte proliferation.33
In the interpretation of  our results, some additional limitations must be addressed: Causes of  death 
were extracted by death records and not confi rmed by autopsies, which could result in some degree 
of  misclassifi cation. As unknown causes of  death were denoted as non-CV, this could translate, 
in any case, into an underestimation of  the observed effect towards the null hypothesis, and the 
true hazards may possibly be bigger. The inclusion of  prevalent dialysis patients may infer into a 
survival bias, although preceding literature contemplates also prevalent patients in their designs. 
Finally, ours is an observational study and confounding by unmeasured factors cannot be ruled out.
To conclude, patients with reduced T3 and/or T4 levels bear an increased mortality risk, especially 
due to cardiovascular causes. This was true when considering both baseline measurements and 
trimestral variation patterns. Our longitudinal design adds important observational evidence 
-although non-decisive- that the link may underlie a causal effect. 
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Objectives: Low triiodothyronine levels, as part of  the non-thyroidal illness syndrome, are common 
in dialysis patients and have repeatedly been shown to be associated with increased (cardiovascular) 
mortality rates. We hypothesized that increased vascular calcifi cation may intermediate this 
relationship.
Methods: A total of  84 patients from the Stockholm region receiving maintenance peritoneal dialysis 
were included in the study. Serum concentrations of  free triiodothyronine (fT3), thyroxine and 
thyroid stimulating hormone were measured. Coronary artery calcium (CAC) scores were assessed 
by cardiac computed tomography scans. Surrogates of  arterial stiffness included aortic diastolic 
and systolic blood pressures, pulse pressure, augmentation pressure and Buckberg’s subendocardial 
viability ratio measured by pulse waveform analyses. Patients were subsequently followed and events 
of  death and censoring were recorded. Thyroid hormone concentrations were associated with 
CAC scores, measures of  arterial stiffness and all-cause mortality. The associations between CAC 
scores and arterial stiffness surrogates and mortality were also determined to evaluate a possible 
causal pathway.
Results: Both CAC scores and arterial stiffness surrogates were substantially higher in individuals with 
low fT3 levels. These associations persisted in multivariate logistic and linear regression analyses. 
During a median (interquartile range) follow-up of  32 (22–42) months, 24 patients died. Both fT3 
levels below the median value [HR crude 4.1, 95% confi dence interval (CI) 1.4 to 12.6] and CAC 
scores above the median value (HR crude 5.8, 95% CI 1.7 to 20.1) were strongly associated with 
mortality.
Conclusions: In patients undergoing peritoneal dialysis, fT3 levels were strongly associated with 
arterial stiffness, coronary artery calcifi cation and mortality. We speculate that the association 
between non-thyroidal illness and mortality may be partly mediated by acceleration of  vascular 
calcifi cation.
 




Coronary artery disease (CAD)1 and myocardial ischaemia2 frequently occur in patients with end-
stage renal disease (ESRD), and are directly associated with increased risk of  mortality.3,4 CAD 
in ESRD is characterized by media thickening (Mönckeberg media sclerosis) and heavily calcifi ed 
plaques.5 Furthermore, cardiac valve calcifi cation6 and systemic atherosclerosis7 are also common 
in patients with ESRD. Therefore it appears that uraemic risk factors, such as hyperphosphataemia, 
infl ammation and depletion of  vascular calcifi cation inhibitors [fetuin-A and matrix gla protein 
(MGP)] may promote the calcifi cation of  the vasculature on a systemic level.
Thyroid hormone alterations due to chronic disease are frequently observed in ESRD and are char-
acterized by low serum concentrations of  triiodothyroinine (T3) with normal thyroid-stimulating 
hormone (TSH) levels. This pattern is known as non-thyroidal illness,8 and its prevalence increases 
progressively with reduced renal function; it is found in approximately 70% of  individuals with 
ESRD.8,9 A low T3 level in patients with chronic kidney disease (CKD) has long been considered a 
benign compensatory response to malnutrition and wasting. However, recently, these abnormali-
ties have been associated with a two- to three-fold elevated mortality rate in patients undergoing 
haemodialysis (HD)10-12 or peritoneal dialysis (PD).13 This excess mortality risk seemed to be most 
specifi c for cardiovascular causes.11
Whether a low T3 concentration in ESRD is causally implicated in the high cardiovascular disease 
risk of  CKD is still unknown, but an accelerated rate of  atherosclerosis represents a potential 
mechanism. In support of  this, free T3 (fT3) levels were negatively associated with carotid artery 
intima–media thickness, arterial stiffness and pulse wave velocity in 137 non-diabetic HD patients.9 
In patients undergoing PD, an inverse association was described between fT3 levels and arterial 
stiffness.14 In addition, non-thyroidal illness has been implicated in uraemic endothelial dysfunc-
tion,15,16 and dyslipidaemia.17 This is further supported by the demonstration of  overt and subclini-
cal hypothyroidism as true cardiovascular disease risk factors in the community.18,19
Thus, the aim of  this study was to test the hypothesis that vascular calcifi cation mediates the effect 
of  non-thyroidal illness on mortality. To assess vascular calcifi cation, we performed non-contrast 
cardiac computed tomography (CT) and pulse wave-form analyses in a cohort of  prevalent patients 
undergoing maintenance PD. 
Methods and materials
Study population
We conducted a longitudinal follow-up study in a cohort of  prevalent PD patients from the Stock-
holm region. This cohort was originally designed to investigate infl ammatory marker variability 
over time. Subjects were recruited between March 2008 and April 2011. All patients who were 




Of  these, 55 patients did not provide informed consent, six underwent transplantation, two died, 
eight switched to haemodialysis and nine were excluded because of  medical conditions (including 
mental disorders) that precluded their entry into the study. Measurements were performed weekly 
during a period of  3 months in the remaining 84 patients. The causes of  ESRD in these patients 
were diabetes mellitus (n=10), renovascular disease (n=10), glomerulonephritis (n=5), immuno-
globulin A nephropathy (n=6) and other (n=20), or unknown (n=33). From inclusion onwards, 
events of  death and censoring due to the end of  follow-up or renal transplantation were recorded. 
Comorbidity was scored based on the 7-point scale of  Davies et al.20 simplifi ed into a three-cate-
gory comorbidity risk scale (low, medium and high). Nutritional status was evaluated using subjec-
tive global assessment (SGA) according to the method of  Detsky et al..21 Among all patients, 60 
(71%) used beta-blockers and 27 (32%) calcium antagonists. In addition, 47 subjects (56%) used 
angiotensin-converting enzyme inhibitors or angiotensin antagonists and 65 (77%) and 19 (23%) 
were receiving alfacalcidiol and calcitriol, respectively. The study protocol was approved by the 
Ethics Committee of  Karolinska Institutet at Huddinge University Hospital (Stockholm, Sweden) 
and informed consent was obtained from all patients.
Arterial stiffness
In 74 patients, central aortic pressure waveforms were recorded by applanation tonometry at the 
radial site using a SphygmoCor device (AtCor Medical, Sidney, Australia). The methodology utilizes 
a validated transfer function that creates aortic pressure wave shapes on the basis of  20 sequential 
peripheral arterial waveforms.22,23 In this way, aortic systolic and diastolic pressures were derived. 
Aortic pulse pressure was calculated by subtracting the central diastolic from the systolic blood 
pressure (BP). The difference between the fi rst and second systolic peaks of  the aortic waveform 
defi ned the aortic augmentation pressure. Patients with a negative aortic augmentation pressure 
were considered to have a value of  0 mmHg in the analysis. Buckberg’s subendocardial viability 
ratio (SEVR) was calculated by dividing the diastolic by the systolic pressure time index. An experi-
enced nurse performed the pulse waveform measurements in a temperature-controlled room, with 
patients in a supine position after resting for 5 min to acclimatize.
Cardiac CT protocol and coronary artery calcium score measurements
In 66 patients, cardiac CT scans were performed using an electrocardiogram (ECG)-gated tech-
nique on a 64-channel detector scanner [LightSpeed VCT, General Electric (GE) Healthcare, Mil-
waukee, WI, USA] in cine mode. A standard non-contrast protocol was used with the following 
parameters: tube voltage 100 kV, tube current 200 mA, rotation time 350 ms, slice thickness 2.5 
mm and displayed fi eld of  view 25 cm.
The data were transferred to a dedicated workstation (Advantage Workstation 4.4, GE Healthcare) 
for further processing and analysis using coronary artery calcium (CAC)-scoring software (Smart-
score 4.0, GE Healthcare). A standard threshold of  130 Hounsfi eld units for identifying calcifi ed 
plaque was adopted. CAC scores were expressed in Agatston units (AU) as previously described in 
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detail.24 Total CAC score was calculated as the sum of  the CAC scores in the left main artery, the 
left anterior descending artery, the left circumfl ex artery and the right coronary artery. CAC scores 
were expressed in percentiles with respect to the distribution for an age- and sex-matched reference 
population.25 
Biochemical measurements
Venous blood was collected after an overnight fast; all blood samples were centrifuged immediately 
and stored at −70 °C until required for analysis. Serum high-sensitivity C-reactive protein (CRP), 
calcium, phosphate, creatinine, urea and albumin levels (bromocresol purple) were determined us-
ing routine methods at the Department of  Laboratory Medicine, Karolinska University Hospital. 
Serum levels of  IL-6 were quantifi ed using an Immulite system (Siemens Healthcare Diagnostics, 
Los Angeles, CA, USA). Plasma analyses of  thyroid hormones were performed using a Roche 
Modular E/Cobas E analyser and commercially available electrochemiluminescence immunoassays 
for fT3 [analytical sensitivity (AS), 0.4 pmol/L; total coeffi cients of  variation (CVs), 6.27% and 
3.36% at 3.16 and 10.03 pmol/L, respectively], fT4 (AS, 0.3 pmol/L; total CVs, 2.05% and  3.03% 
at 12.01 and 34.70 pmol/L, respectively) and TSH (AS, 0.014 mU/L; total CVs, 2.16% and 2.42% 
at 0.995 and 5.530 mU/L, respectively).  Results are expressed as the average of  two measurements. 
Residual glomerular fi ltration rate (rGFR) was calculated as previously reported and expressed in 
mL/min/1.73m2.26
Statistical analysis
Patient characteristics are presented across two fT3 strata (based on the median value) as means 
(SD or SEM), medians [interquartile range (IQR)] or percentages, and compared appropriately. 
Linear regression analyses were performed to study associations between thyroid hormones and 
measures of  arterial stiffness. Due to non-normality, CAC scores were categorized and a linear 
trend of  thyroid hormones across these categories was investigated using a polynomial linear term 
in one-way ANOVA. Additionally, logistic regression models were applied to quantify the effect of  
thyroid hormone levels on CAC scores, dichotomized at the median value (920 AU). Univariate and 
multivariate regression models were used for analyses. In the multivariate models, age, sex, dialysis 
vintage and Davies scores were considered as confounders. For this purpose, dialysis vintage was 
logarithmically transformed due to non-normality. For the models including thyroid hormones as 
exposure, SGA, which showed the strongest association with non-thyroidal illness and mortality, 
was added. Because thyroid hormone status could also infl uence cytokine production,27 and we 
were restricted in the number of  covariates due to our small sample size, infl ammation was not 
included in the primary analyses. In a sensitivity analysis, however, we examined the results after ad-
justment for log(IL-6). Assumptions underlying linear and logistic regression analyses were tested 




Survival was analysed using Kaplan–Meier methodology. Only in the plot, mortality follow-up was 
restricted to the point at which 20% of  patients were still at risk (44 months).28 Cox proportional 
hazards models were fi tted on the whole follow-up period and used to calculate hazard ratios 
(HR). To anticipate the possibility of  monotone likelihood due to small numbers of  events, Cox 
models were re-run after applying a shrinkage factor according to a modifi ed version of  the Firth 
method.29 The same confounders described above were included in multivariate Cox models. 
Primary analyses were performed using SPSS 20 (IBM Inc., New York, NY, USA). SAS version 9.3 
(SAS Campus Drive, Cary, NC, USA) was used for Cox models with inclusion of  a shrinkage fac-
tor. In linear regression analyses, beta values with 95% confi dence intervals (CIs) not including 0 
and odds ratios with 95% CIs not including 1 were considered statistically signifi cant. For all other 
tests, a P-value lower than 0.05 was considered to indicate statistical signifi cance. Figures were cre-
ated with Prism 5.02 (Graphpad, 1992).
Results
The study population consisted of  84 PD patients; 68% were men, 24% had diabetes and 19% 
were smokers. The mean (SD) age of  participants was 63.7 (14.1) years. Subjects with serum fT3 
levels below the median value (3.95 pmol/L) had a higher prevalence of  diabetes and protein–en-
ergy wasting (Table 1), whereas those with relatively low fT3 levels tended to have lower haemo-
globin and albumin levels, lower rGFR but higher infl ammatory biomarker levels (IL-6 and CRP). 
Mean serum calcium and- phosphate levels and median dialysis vintage did not differ signifi cantly 
between the fT3 groups. 
Measures of  arterial stiffness, including aortic systolic BP, pulse pressure and augmentation pres-
sure were signifi cantly higher in the group with low fT3 values (Table 2). Results from linear regres-
sion analyses (Figure 1 and Table 3) showed statistically signifi cant univariate associations between 
fT3 and aortic systolic BP, pulse pressure, augmentation pressure and SEVR. After adjustment 
for confounders, beta values remained statistically signifi cant for aortic systolic BP, pulse pressure 
and augmentation pressure. A trend remained for the association between fT3 and SEVR, which 
was not different when heart rate and systolic BP were excluded from the analyses. Log(TSH) was 
strongly associated with aortic pulse pressure (β 17.7, 95% CI 5.2 to 30.2), aortic augmentation 
pressure (β 7.1, 95% CI 1.2 to 13.0) and SEVR (β -20.1, 95% CI -38.5 to -1.7). Adjustment for 
log(IL-6) levels did not signifi cantly alter the results.
The majority of  the patients had CAC scores above 1000 AU. Calcifi cation affected all three coro-
nary vessels in almost all patients. Compared to age- and sex-specifi c distributions among the gen-
eral population 25, 73% of  study subjects had CAC scores above the 90th percentile. As presented 
in Table 2, median total CAC scores were signifi cantly higher in subjects with low versus high fT3 
levels [1527, interquartile range (IQR) 594–2507 vs. 438, IQR 56–1824; P = 0.01]; this relationship 
was also true for the different coronary arteries separately. Conversely, fT3 levels showed a gradual 
decline across CAC categories (P for trend = 0.001). In logistic regression analyses (Table 3), the 
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risk of  having a CAC score >920 AU was higher in those with low versus high fT3 levels [odds 
ratio (OR) 3.4, 95% CI 1.2 to 9.4], an association that persisted after adjustment for confound-
ers. After adjustment for log(IL-6), point estimates remained approximately the same while the 
confi dence interval broadened substantially (OR 3.4, 95% CI 0.7 to 15.7). During a median (IQR) 
follow-up of  32 (22–42) months, a total of  24 (29%) patients died. Of  these deaths, 17 (41%) and 
seven (17%) occurred in the low and high fT3 groups, respectively (Fig. 2). In crude analyses, in-
dividuals in the low fT3 group had a higher mortality risk (HR 4.1, 95% CI 1.4 to 12.6) than those 
with high fT3 levels (Table 4). The point estimate was reduced after adjustment for confounders 
and even further after adjustment for CAC categories. Regarding to the association between CAC 
scores and mortality, 15 (46%) subjects died in the group with CAC scores >920 AU as compared 










Men, %1 60 76 0.10
Age, years2 65 (13) 62 (15) 0.33
Patients with medium/high Davies score, %1 55/21 60/7 0.15
Diabetes mellitus, %1 31 17 0.08
Protein–energy wasting, %1,4 50 30 0.09
Dialysis vintage, monthsc 15 (7 to 32) 11 (6 to 21) 0.44
CAPD, %1,5 78.6 76.2 0.794
Laboratory measurements
Creatinine, mmol/L2 738 (168) 710 (181) 0.46
Residual eGFR, mL/min/1.73m3,3 2.3 (1.0 to 3.2) 3.2 (2.1 to 5.8) 0.008
Albumin, g/L2 29.5 (4.6) 33.2 (3.9) <0.0001
Haemoglobin, mmol/L2 116 (12) 121 (10) 0.04
IL-6, pg/L3 8.2 (4.9 to 17.2) 5.1 (2.8 to 7.6) 0.001
C-reactive protein, mg/L3 5.2 (1.7 to 19.9) 3.3 (0.9 to 7.1) 0.05
TSH, mIU/L3 2.1 (1.3 to 3.2) 2.2 (1.4 to 3.1) 0.72
fT3 , pmol/L2 3.4 (0.3) 4.5 (0.4) -
fT4, pmol/L2 12.8 (2.5) 13.8 (3.5) 0.12
Calcium, mmol/L2 2.3 (0.2) 2.3 (0.2) 0.31
Phosphate, mmol/L2 1.7 (0.6) 1.7 (0.4) 0.54
1. Differences between groups for categorical data were tested by chi-squared test.
2. Data are expressed as mean (SD); differences between groups were tested using an independent sample t-test.
3. Data are expressed as median (interquartile range); differences between groups were tested by the Mann–
Whitney U test.
4. Protein–energy wasting defi ned as subjective global assessment score >1.
5. The remaining patients underwent automated peritoneal dialysis.
TSH, thyroid-stimulating hormone; fT4, free thyroxine; CAPD, continuous ambulatory peritoneal dialysis; eGFR, 




Table 2. Coronary artery calcium (CAC) scores and measures of  arterial stiffness according to median free triio-






Pulse waveform analyses n = 38 n = 38
Aortic systolic BP, mmHg1 134 (4) 120 (3) 0.005
Aortic diastolic BP, mmHg1 82 (2) 81 (2) 0.57
Aortic PP, mmHg1 52 (3) 40 (2) 0.006
Aortic AP, mmHg1 15 (1) 10 (1) 0.15
SEVR, %1 132 (5) 138 (4) 0.001
Coronary CT scans n = 33  n = 33
Total CAC score2 1527 (594–2507) 438 (56–1824) 0.01
LM CAC score2 70 (0–166) 22 (0–99) 0.41
LAD CAC score2 655 (203–1109) 194 (46–594) 0.002
LCx CAC score2 197 (74–617) 45 (0–269) 0.02
RCA CAC score2 339 (86–900) 33 (0–734) 0.04
1. Data are expressed as mean (SEM); differences between groups were tested with one-way ANOVA.
2. Data are expressed as median (IQR); differences between groups were tested using the Kruskal–Wallis test.
BP, blood pressure; PP, pulse pressure; AP, augmentation pressure; SEVR, subendocardial viability ratio; CT, com-
puted tomography; CAC, coronary artery calcium; LM, left main stem; LAD, left anterior descending; LCx left 
circumfl ex; RCA, right coronary artery.
to three (9%) patients with CAC scores ≤920 AU. The high CAC group had higher risks of  death 
in both crude (HR5.8, 95% CI 1.7 to 20.1) and adjusted (HR 5.6, 95% CI 1.4 to 22.9) Cox models. 
After applying a shrinkage factor to the Cox models, the associations between low fT3 and mortal-
ity (crude HR 2.6, 95% CI 1.2 to 6.6; adjusted HR 1.9, 95% CI 0.8 to 5.1) and between high CAC 
scores and mortality (crude HR 5.2, 95% CI 1.8 to 19.8; adjusted HR 4.5, 95% CI 1.3 to 20.0) re-
mained. Measures of  arterial stiffness were not associated with mortality (data not shown). 
Thyroid hormone levels did not differ between those who used or did not use beta-blockers (data 
not shown). Patients undergoing continuous ambulatory PD were not signifi cantly different from 
those undergoing automated PD with respect to demographic characteristics, thyroid hormone 
levels, total CAC scores and mortality (data not shown). Finally, demographic characteristics, thy-
roid status and survival were not signifi cantly different in patients who did and did not undergo 
cardiac CT scanning (data not shown). 
  Nonthyroidal Illness and Arterial Calcifi cation
111
7
 Table 3. Regression analyses of  associations between serum free triiodothyronine (fT3) levels and coronary ar-
tery calcium (CAC) scores and measures of  arterial stiffness
Crude Adjusted 2
Logistic regression Low fT3 - CAC score1 OR  (95%CI) 3.4 (1.2 to 9.4) 4.5 (1.1 to 19.1)
Linear regression fT3- Aortic systolic BP β  (95% CI) -11.3 (-18.2 to -4.3) -11.8 (-19.1 to -4.4)
fT3- Aortic diastolic BP β  (95% CI) -1.2 (-5.5 to 3.2) -2.3 (-6.8 to 2.2)
fT3- Aortic PP β  (95% CI) -10.1 (-15.1 to -5.1) -9.4 (-14.6 to -4.3)
fT3- Aortic AP β  (95% CI) -4.4 (-7.0 to -1.8) -3.1 (-5.7 to -0.5)
fT3- SEVR β  (95% CI) 10.1 (0.6 to 19.6) 7.5 (-0.7 to 15.8)
1. FT3 levels and CAC scores were dichotomized according to the median values (3.95 pmol L1 and 920 
Agatston units,respectively); for fT3, the highest group served as the reference.
2. Adjusted for age, gender, Davies comorbidity score, log (dialysis vintage) and SGA. The association be-
tween fT3 and SEVR was additionally adjusted for heart rate and systolic blood pressure.
BP, blood pressure; SEVR, subendocardial viability ratio; PP, pulse pressure; AP, augmentation pressure; SGA, 
subjective global assessment; OR, odds ratio; CI, confi dence interval.
Figure 1. Association between free triiodothyronine (T3) and aortic systolic blood pressure (BP) (A), pulse pressure 
(PP) (B), augmentation pressure (AP) (C) and subendocardial viability ratio (SEVR) (D)








































































In the present study, we found that serum fT3 levels were associated with measures of  coronary 
calcifi cation and arterial stiffness. Both fT3 and CAC, but not arterial stiffness, were associated with 
mortality. As 73% of  our patients had CAC scores above the 90th percentile of  age- and sex-specif-
ic distributions from the general population,25 our data confi rm previous fi ndings that this patient 
population is subject to accelerated vascular calcifi cation. CAC scores above 400 AU in the general 
population are considered to increase the short-term risk of  cardiovascular events and death.30
Compared to other PD31,32 and HD33 populations, the CAC scores in our cohort were considerably 
higher. This may be due to the fact that CAC scores increase with age34,35, and our group of  preva-
lent patients were on average 10 years older than in the previous studies.31–33
 Table 4. Cox regression analyses of  the association between free triiodothyronine (fT3) and coronary artery cal-
cium (CAC) scores and mortality
Exposure1 Crude
HR  (95% CI)
Adjusted2
HR  (95% CI)
Adjusted3
HR  (95% CI)
Low fT3 4.1 (1.4–12.6) 3.1 (0.9–10.1) 2.4 (0.7–8.6)
High CAC 5.8 (1.7–20.1) 5.6 (1.4–22.9) -
1. Exposures were dichotomized according to the median value. The complementary group served as the refer-
ence group.
2. Adjusted for age, sex, log(dialysis vintage) and Davies comorbidity score. The association between fT3 and 
mortality was additionally adjusted for SGA (see Methods).
3. Additionally adjusted for CAC score categories.
SGA, subjective global assessment; HR, hazard ratio; CI, confi dence interval.
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Figure 2. Kaplan–Meier survival curves according to free triiodothyronine (fT3) (A) and coronary artery calcium (CAC) 
score (B) categories
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The chief  fi nding of  the present study is an inverse association between serum fT3 levels and CAC 
scores. Notably, this association remained in multivariate models including SGA and IL-6 levels, 
suggesting an association independent of  the protein–energy wasting syndrome. Our results par-
tially agree with the observation in HD patients of  an inverse association between fT3 and CAC 
scores; however, this correlation did not remain after multivariate adjustment.9 The approach of  
covariate selection may, however, have resulted in adjustment within the causal pathway in the 
previous study and could explain this divergence in results. Our fi nding of  an inverse association 
between fT3 and measures of  arterial stiffness agrees with the results of  other studies in PD14 and 
HD patients9 also supporting a role of  adverse effects of  non-thyroidal illness on the systemic 
vasculature. Findings of  studies in the general population suggest that overt and subclinical hypo-
thyroidism are both true cardiovascular disease risk factors.18,19 Four possible mechanisms might 
explain how a low T3 milieu could augment atherosclerosis and vascular calcifi cation. First, a low 
T3 state in ESRD has been linked to dyslipidaemia, which is reversible after thyroid hormone 
replacement.17 Secondly, non-thyroidal illness is associated with endothelial dysfunction,15,16 and 
promotes vasoconstriction by a direct effect on vascular smooth muscle cells.36 Thirdly, in agree-
ment with previous studies in non-renal patient,37 our data show that non-thyroidal illness is associ-
ated with infl ammation, which may be indirectly related to low T3 levels, vascular calcifi cation and 
cardiovascular death via low fetuin-A levels.38 Finally, ex vivo studies have demonstrated that the 
expression of  Klotho39 and MGP40 are T3 dependent. The fi nding of  Mizuno et al.39 that T3 sig-
nifi cantly increased the expression levels of  the membrane form of  the klotho gene is of  interest 
as premature ageing and vascular calcifi cation are prominent features of  the uraemic phenotype.41 
Moreover, the observation by Sato et al.40 that physiological concentrations of  T3 facilitate MGP 
gene expression in smooth muscle indicates that thyroid hormone replacement may be a future 
option to treat vascular calcifi cation. Indeed, 45 years ago it was already known that cretinism was 
associated with vascular calcifi cation, especially in patients who did not receive suffi cient thyroid 
hormone replacement.42 The fact that thyroid hormones regulate skeletal development and syn-
thesis and secretion of  vitamin K-dependent proteins43 may support an indirect link between non-
thyroidal illness and vascular calcifi cation. 
The positive association between fT3 levels and mortality in our study is in agreement with an ear-
lier report that mortality hazards were 3.2 times higher per 1 pg/L decrease in serum fT3 levels in 
41 patients undergoing continuous ambulatory PD.13 Further, our results are consistent with fi nd-
ings in HD patients.10-12 We previously showed that this association was predominantly accounted 
for by cardiovascular-specifi c deaths.11 In agreement with previous data,3,4 our current analyses also 
illustrate that higher CAC scores were very strongly associated with consequent death. Although 
adjustment in a causal pathway may not be easy to interpret,44 the effect estimate of  the associa-
tion between fT3 and mortality was reduced considerably after adjustment for CAC categories, 
suggesting a mediating role for coronary calcifi cation. No association between measures of  arterial 
stiffness and mortality was apparent. It is conceivable however that patients with high as well as 




That is, low aortic augmentation and pulse pressures could refl ect poor systolic left ventricular 
function. As pulse waveform analysis is less infl uenced by this phenomenon, Blacher et al.45 were 
indeed able to show an association between this measure of  arterial stiffness and subsequent mor-
tality.
Some limitations should be acknowledged when interpreting our fi ndings. Although our sample 
size and the number of  events during follow-up were limited, associations remained strong and 
independent of  confounders considered. Nevertheless, larger studies are indicated to verify our 
fi ndings and to test whether non-thyroidal illness is linked to low levels of  circulating inhibitors of  
vascular calcifi cation, such as fetuin-A and MGP. Furthermore, the lack of  CT data in 18 out of  
84 patients could have resulted in a selection bias. However this is unlikely as demographic char-
acteristics, thyroid status and survival were not different between responders and non-responders. 
It should also be acknowledged that, as we only assessed calcifi cation in coronary arteries, we do 
not know whether non-thyroidal illness is also associated with increased calcifi cation at other arte-
rial sites. However, by inclusion of  mortality follow-up data and the description of  a biologically 
plausible causal chain, we do provide important evidence for this possibility. This may support the 
design of  studies aimed at testing whether restoration of  the low T3 syndrome may reduce the high 
risk of  atherosclerotic complications in the CKD population. 
In conclusion, serum fT3 levels were inversely associated with CAC scores and measures of  arterial 
stiffness in prevalent PD patients. Both fT3 and CAC scores were also associated with mortality. 
Specifi c mechanistic and intervention studies are warranted to clarify the nature of  the intriguing 
link between non-thyroidal illness and vascular calcifi cation.
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Background: Prevalence estimates of  thyroid dysfunction and chronic kidney disease both increase 
with age. The aim of  this study was to investigate the cross-sectional association between low 
thyroid function and renal function in subjects aged 85 years and to assess whether a low thyroid 
function at age 85 years is associated with an accelerated decline in renal function during follow up.
Methods: We included 558 participants from the Leiden 85-plus Study. At baseline (age 85), thyroid 
stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyroinine (fT3) levels were 
measured. Thyroid function groups were created using clinical cut-off  values of  TSH and fT4. 
Serum creatinine concentrations were determined at baseline and annually during a 5 year follow-
up period. Estimated glomerular fi ltration rates (eGFR) were calculated by means of  the MDRD 
equation. 
Results: At baseline, subjects with higher levels of  TSH and lower levels of  fT4 and fT3 had lower 
renal function. Participants with hypothyroidism (mean 53.7 (2.0) mL/min/1.73m2) and subclinical 
hypothyroidism (55.7 (2.1) mL/min/1.73m2) had lower mean eGFR (SE) than participants 
with normal thyroid function (59.5 (0.7) mL/min/1.73m2); the highest eGFR was observed in 
participants with hyperthyroidism (eGFR (61.5 (3.1) mL/min/1.73m2) (p-for trend=0.004). There 
was no association between thyroid hormone levels at baseline and the change in renal function 
during follow-up.
Conclusions: Although low thyroid function was associated with lower renal function at age 85 years, 
an association between a low thyroid function and change in renal function over time was absent. 
Our fi ndings question the causal relevance of  the thyroid status for the deterioration of  renal 
function in the oldest old. 




Renal function declines with increasing age.1 Up to 47 percent of  individuals aged 70 years and 
over are estimated to suffer from some stage of  Chronic Kidney Disease (CKD).2 Throughout 
all age strata, CKD is associated with an increased risk of  adverse cardiovascular outcomes, such 
as myocardial infarctions, heart failure and death.3,4 In the general population, CKD is commonly 
caused by diabetes mellitus, and hypertension,5 but treatment of  these risk factors does not fully 
prevent the decline in renal function with advancing age. Therefore, identifi cation of  other risk 
factors for a decline in renal function, that are potentially amenable for treatment, is needed.
Alike CKD, overt and subclinical hypothyroidism are common disease entities in the general 
population, especially in older persons.6,7 Up till 14 % of  individuals aged ≥80 years are reported to 
have elevated serum thyroid stimulating hormone (TSH) levels.6 In the general population, overt 
hypothyroidism and subclinical hypothyroidism are both associated with an increased cardiovascular 
risk,8,9 which could be attributed to various cardiovascular effects of  thyroid hormones.9 A low 
thyroid hormone state has been associated with adverse blood lipid alterations,10 endothelial 
dysfunction,11 and accelerated atherosclerosis.12 
Several small observational studies indicated a decline in renal function in patients with overt 
hypothyroidism as estimated by serum creatinine measurements13-15 and labeled edetic acid.16 These 
alterations attenuated or even reversed after thyroid hormone supplementation.13-15 Two very recent 
reports additionally showed a negative effect of  subclinical hypothyroidism on renal function over 
time in patients with pre-existing CKD.17,18 Potential pathophysiological mechanisms connecting a 
low thyroid function to a decrease in renal function could pertain to a decrease in cardiac output, 
direct vasoactive effects, a reduction in the size of  glomeruli, and promotion of  arteriosclerosis as 
induced by low serum thyroid hormone concentrations.19 
Although prevalence estimates of  a low thyroid function and CKD both increase with age, it is 
unknown whether subclinical and overt hypothyroidism are also associated with a deterioration 
of  renal function over time specifi cally in older persons. Therefore, the aim of  this study was to 
investigate the association between low thyroid function and renal function specifi cally in an elderly 
population. For this purpose, we investigated the cross-sectional association between thyroid status 
and renal function in subjects 85 years and assessed whether a low thyroid hormone state at age 85 
years associated with an accelerated decline in renal function over time. This is of  special interest as 
negative effects of  commonly appreciated risk factors in the general population,20,21 including the 







The Leiden 85-plus Study is a population-based prospective follow-up study of  85-year-old 
inhabitants of  Leiden, the Netherlands. The study protocol has been described in detail previously.21 
In short, between 1997 and 1999, all residents of  Leiden, the Netherlands, celebrating their 85th 
birthday (belonging to the 1912-1914 birth cohort) were contacted and asked to participate. Out 
of  the 705 individuals who were found eligible, 14 died before the recruitment phase and 92 
refused participation leaving a total of  599 individuals to be enrolled in the study (response rate 
87%).21 Within one month after their 85th birthday, participants were visited at home. During 
these visits, participants underwent face-to-face interviews, performance tests were done and a 
venous blood sample was drawn. 37 participants refused blood sampling. In the present analyses, 
558 participants were included with complete information on thyroid hormone status and renal 
function. Participants were visited annually until reaching the age of  90 years or death. At age 
88, 376 individuals underwent a second blood withdrawal. The medical ethical committee of  the 
Leiden University Medical Centre approved the study protocol, and informed consent was obtained 
from all participants. 
Laboratory measurements
Blood was withdrawn in a supine position and analyzed immediately. Plasma levels of  TSH and 
free thyroxine (fT4) were measured in a fully automatic fashion using an Elecsys 2010 system 
(Hitachi, Tokyo, Japan). For TSH, the coeffi cients of  variation (CV) ranged between 5% and 11%. 
For fT4, CVs varied between 5% and 8%. An electrochemiluminescence technique was applied 
(Boehringer, Mannheim, Germany). Plasma levels of  free triiodothyronine (fT3) were determined 
by a microparticle enzyme immunoassay (Abbott Diagnostics, Abbott Park, Ill) for which CVs 
were between 3% and 8%. 
The following thyroid hormone groups were created based on serum TSH and fT4 levels as widely 
accepted;25 1) Euthyroidism; TSH levels between 0.5 and 4.5 mIU/L. 2) overt hypothyroidism; 
TSH >4.5 mIU/L and fT4 <13 pmol/L, 3) subclinical hypothyroidism; TSH >4.5 mIU/L and fT4 
between 13 and 23 pmol/L, 4) overt hyperthyroidism; TSH <0.5 mIU/L and fT4 >23 pmol/L and 
5) subclinical hyperthyroidism; TSH levels <0.5 mIU/L and fT4 concentrations between 13 and 
23 pmol/L. Since only two subjects had overt hyperthyroidism, groups 4 and 5 were merged into 
one category named “hyperthyroidism”. Three patients, two of  whom with low TSH and low T4 
levels and one with high TSH and high T4 levels, fell out of  our classifi cation. When new thyroid 
dysfunction was discovered (n=39) subjects were referred to their general practitioner for further 
work-up.22
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Serum creatinine concentrations were measured according to the Jaffé method (Hitachi 747; Hitachi, 
Tokyo, Japan). For the primary analyses, glomerular fi ltrations rates were estimated using the four 
variable version of  the Modifi cation of  Diet in Renal Disease Study (MDRD) formula26 which has 
been validated in older adults.27 Subjects were divided into three eGFR groups (<30, 30-60, >60 
mL/min/1.73m2). For the purpose of  sensitivity analyses, creatinine clearances were calculated 
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)28 and Cockroft-Gault 
formulas.29 Plasma C-reactive protein (CRP) levels were assessed by utilization of  a Hitachi 747 
automated analyzer at the day the sample was drawn.
Information on the presence of  disease was obtained from general practitioners and nursing home 
physicians. The presence of  cardiovascular disease was defi ned as a history of  a cerebrovascular 
accident or transient ischemic attack, angina pectoris, myocardial infarction, peripheral vascular 
disease (including a history of  arterial grafting, endarterectomy, and/or angioplasty), an 
electrocardiogram suggesting myocardial ischemia or past infarction, and a history of  heart 
failure.30 Diabetes mellitus (DM) was considered present when diagnosed by a primary care 
physician, when routine non-fasting glucose levels exceeded 11.0 mmol/L, or when an individual 
was being prescribed anti-diabetic medication. Past and/or currently active malignancies were 
grouped into one category. Also, a simple physical examination was performed which included an 
assessment of  weight, height, and blood pressure. With an intervening period of  two weeks, blood 
pressure was measured twice by using a mercury sphygmomanometer.31 For every measurement, 
patients had rested for at least 5 minutes and performed no vigorous exercise in the preceding 30 
minutes. Information on the use of  thyroid medication (antithyroid medication and/or thyroxine 
supplementation) was obtained from pharmacy records. 
Statistical analyses
Baseline characteristics were presented as means with standard deviation (SD), medians plus 
interquartile ranges (IQR) or numbers with percentages (%) across thyroid hormone groups. 
Differences between thyroid hormone groups were tested by means of  one-way ANOVA, Kruskal 
Wallis and Chi square tests, as appropriate.
Mean (standard error of  the mean (SE) or 95% confi dence interval (95%CI)) eGFR values within 
tertiles of  thyroid hormone distributions or thyroid hormone groups at baseline were calculated 
using univariate and multivariate linear regression models. Univariate models (Model 1) comprised 
tertiles of  the specifi c thyroid hormone distribution or the different thyroid hormone groups as 
independent variables. In multivariate models, sex, DM, smoking, the presence of  cardiovascular 
disease (composite score ≥1), malignancies, and amiodarone usage were added as possible 




To examine the effects of  the different thyroid hormone groups and thyroid hormone concentrations 
at baseline on change of  renal function over time, linear mixed models were fi tted. A model with 
fi xed intercept and slope and unstructured covariance matrix was adopted because of  its best fi t as 
judged upon by the maximum likelihood estimate method and Akaikes information criterium. Mean 
annual changes per group were estimated by means of  multivariate models including the baseline 
variables sex, DM, smoking, cardiovascular disease, malignancies, and amiodarone treatment as 
possible confounders. The effect of  thyroid hormone status on the change in renal function over 
time was evaluated by implementation of  an interaction term between thyroid hormone state and 
time. 
As an alternative approach, regression lines were fi tted on the repeated measurements for each 
individual separately. Then these betas were pooled within the different thyroid hormone strata 
(tertiles for each hormone) and groups (as earlier specifi ed) and compared by means of  a one-
way ANOVA test. In addition, we compared the percentage of  individuals developing stage 4 or 
5 CKD (<30 mL/min/1.73m2) during follow-up between the different thyroid function groups.
As sensitivity analyses, models were rerun 1) in three different baseline strata of  renal function, 2) 
only in the 535 individuals not on drugs interfering with thyroid hormone measurements (thyroxine 
and/or antithyroid drugs), 3) specifi cally in those who lived to celebrate their 90th birthday (n=299), 
and in order to exclude those with possible non-thyroidal illness 4) only in subjects having CRP 
levels < 5 mg/L (n=317). Also, creatinine clearances as estimated with the Cockcroft Gault and 
CKD-EPI formulas were used as outcome variables. Further, multivariable models were further 
adjusted for systolic blood pressure, C-reactive protein levels, BMI, and total cholesterol levels. 
Finally, we investigated the association between different thyroid hormone change patterns over 
a 3 year period (85-88 years of  age) and progression of  renal function in the years thereafter. 
For this purpose, we categorized patients into four categories: 1) Those having elevated TSH 
levels (>4.5 mIU/L) at age 85 and 88 (Persistent hypothyroid group, n=31), 2) those having TSH 
levels between 0.5 and 4.5 mIU/L at both time points (Persistent euthyroid group, n=276), 3) 
those persistently having levels < 0.5 mIU/L (Persistent hyperthyroid group, n=12) and 4) patients 
changing categories (Change group, n=53).
In linear regression analyses and linear mixed models, betas with 95 percent confi dence intervals 
(95%CI) not including 0 were considered statistically signifi cant. For all other tests, a p-value smaller 
than 0.05 indicated statistical signifi cance. All analyses were performed using SPSS 20 (IBM Inc., 
New York, USA). Figures were created using Prism 5.02 (Graphpad, 1992).




Of  the total study population, 33.6 percent was male and 18.3 percent was institutionalized in 
a care home or a nursing home. 82 (14.8%) participants had diabetes mellitus, 52.2% (n=291) 
suffered from a history of  cardiovascular disease, and 98 (17.6%) participants had a past or current 
malignancy. The mean (SD) eGFR, as calculated with the MDRD formula, was 59.0 (14.4) mL/
min/17.3m2 (CKD-EPI: 49.0 (13.4), Cockroft-Gault: 45.4 (11.5) mL/min). In Table 1, baseline 
characteristics are compared between the different thyroid hormone groups. As compared to 
euthyroid subjects, those with overt and subclinical hypothyroidism were more frequently women 
and had more comorbidities. Also, they had higher BMI and CRP levels and were prescribed more 
frequently thyroxine as well as anti-thyroid medication.














Men, n, %1 9 (22.5) 7 (20.0) 161 (35.7) 10 (34.5) 0.104
BMI, kg/m2 28.5 (4.8) 28.2 (4.1) 26.7 (4.5) 25.1 (4.3) 0.040
Smoker, n, %1 5 (12.5) 5 (14.3) 74 (16.4) 4 (13.8) 0.888
Malignancy, n, %1 6 (15.0) 11 (31.4) 76 (16.9) 5 (17.2) 0.178
Institutionalized, n, %1 13 (32.5) 2 (5.7) 81 (18.0) 5 (17.2) 0.027
Cardiovascular profi le
Previous CVD, n, % 1,2 21 (52.5) 23 (65.7) 205 (45.5) 16 (55.2) 0.090
DM, n, %1 7 (17.5) 7 (20.0) 65 (14.4) 2 (6.9) 0.483
CRP, mg/L3 4.0 (2.0-8.0) 8.0 (3.0-11.0) 3.0 (1.0-7.0) 5.0 (1.0-10.0) 0.007
Thyroid profi le
TSH, mIU/L 3 6.45 (5.57-8.27) 5.57 (5.05-6.66) 1.67 (1.18-2.34) 0.19 (0.01-0.37) -
fT4, pmol/L 10.16 (1.24) 15.10 (1.41) 14.58 (2.31) 17.70 (3.92) -
fT3, pmol/L 3.20 (0.59) 3.32 (0.64) 3.39 (0.52) 3.65 (0.72) -
Medication usage
Thyroid hormone, n(%)1 2 (5.0) 6 (17.1) 6 (1.3) 2 (6.9) <0.001
Antithyroid med, n, %1 1 (2.5) 2 (5.7) 0 (0.0) 1 (3.4) <0.001
1. Categorical data are presented as numbers plus percentages and differences between groups were tested by 
means of  a X2 -square test.
2. CV disease comprised a composite score of  a history of  a myocardial infarction, angina pectoris, heart failure, 
peripheral arterial disease and/or cerebrovascular accident/transient ischemic attack. A score ≥ 1 indicated 
presence of  CV disease.
3. Nonnormally distributed data are presented as Medians plus interquartile ranges, differences were tested by 
means of  a Kruskal-Wallis test.
O: Overt. SC: Subclinical, CV: cardiovascular, DM: Diabetes Mellitus, CRP: C-reactive protein, TSH: thyroid stimu-




Table 2. Baseline levels of  renal function within tertiles of  distributions of  TSH and thyroid hormones 
Tertiles of  distribution of  thyroid hormones
Lower Middle Higher p-for trend1
TSH, mIU/L
0.01 – 1.38 1.39 – 2.35 2.35 – 33.0 
n 186 188 184
Crude eGFR, mean (SE)2 60.1 (1.1) 60.3 (1.0) 56.6 (1.1) 0.021
Adjusted  eGFR, mean (SE)3   61.5 (2.8) 61.9 (2.8) 58.2 (2.7) 0.037
fT3, pmol/L
0.77 – 3.19 3.20 – 3.63 3.63 – 6.60  
n 201 199 144
Crude eGFR, mean (SE)2    57.8 (1.0) 58.8 (1.0) 61.1 (1.2) <0.0001
Adjusted eGFR, mean (SE)3     59.3 (2.8) 59.5 (2.7) 62.1 (2.8) 0.074
fT4, pmol/L
8.4 – 13.4 13.5 – 15.3 15.3 – 30.9
n 189 190 174
Crude eGFR, mean (SE)2    57.4 (1.0) 59.4 (1.0) 60.0 (1.1) 0.083
Adjusted eGFR, mean (SE)3   57.4 (2.8) 60.2 (2.8) 61.5 (2.7) 0.005
1. The p-for trend was calculated by means of  regression analysis.
2. Crude means and SDs were calculated by means of  regression analyses.
3. Adjusted means and SDs were calculated by means of  multivariate regression analyses including sex, diabetes 
mellitus, smoking, cardiovascular disease, malignancies, and amiodarone usage as possible confounders. 
* In these analyses, a maximum of  14 individuals did not provide data.
The median (IQR) TSH level was 1.82 (1.16-2.90) mIU/L. 451 (81.2%) participants were cassifi ed 
in the euthyroid group, and 40 (7.2%) and 35 (6.3%) of  participants were classifi ed as having 
hypothyroidism and subclinical hypothyroidism, respectively. 4.9 percent (n=27) had subclinical 
hyperthyroidism and 0.4 percent (n=2) suffered from overt hyperthyroidism (5.3 percent in total). 
Median creatinine (IQR) levels were 92 (81-107) µmol/L translating into a mean (SD) eGFR 
(MDRD) of  59.0 (14.4) mL/min/1.73m2. 305 participants had an eGFR <60 mL/min/1.73m2 
(CKD ≥3) of  whom 7 and 2 values fi tting CKD stage 4 (15-30 mL/min/1.73m2) and 5 (<15 mL/
min/1.73m2), respectively.
As apparent from Figure 1A, 85-year old participants with overt hypothyroidism (53.7 (2.0) mL/
min/1.73m2) and participants with subclinical hypothyroidism (55.7 (2.1) mL/min/1.73m2) had a 
lower mean baseline eGFR (SE) than participants with normal thyroid function (59.5 (0.7) mL/
min/1.73m2). The highest eGFR was observed in participants with hyperthyroidism (61.5 (3.1) 
mL/min/1.73m2). After adjustment for confounders (Figure 1B), a trend remained. In Table 2, 
mean (95% CI) eGFR values are presented across tertiles of  distribution of  the different thyroid 
hormones. The eGFR was lower in participants with higher TSH levels (p=0.021). eGFR values 
were lower within the lower fT3 tertiles (<0.0001) and, although not statistically signifi cant, 
also lower in lower fT4 tertiles (p=0.083). After adjustment for possible confounding variables, 
associations were statistically signifi cant for TSH (p=0.0037) and for fT4 (p=0.005).
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Throughout a median follow-up of  5 years, during which 259 individuals died, the eGFR declined 
on average (SE) with -0.25 (SE 0.13, p=0.052) mL/min/1.73m2 per year. Figure 2 shows the 
estimated adjusted mean (95%CI) annual changes in eGFR across thyroid function groups as 
obtained from linear mixed models. No signifi cant differences were observed in the change in 
eGFR between thyroid function groups. In a second approach in which individual specifi c betas 
(slopes) were pooled within the different thyroid hormone groups (Appendix 3), similar results 
were found (p=0.149). No association between baseline thyroid hormone concentrations as 
continuous variables and the change in eGFR over time was present. Also, the percentage of  
individuals developing new CKD stage 4 or 5 did not differ between the thyroid function groups 





















































































































Mean (95% CI) eGFR at baseline within the different thyroid hormone groups. The value for P for trend was calcu-
lated by means of  polynomial trend analysis in a one-way ANOVA test. B, Mean adjusted eGFR (mL/min/1.73 m2) 
across different thyroid hormone groups at baseline. Mean (95% CI) eGFR at baseline within the different thyroid 
hormone groups was adjusted for sex, DM, smoking, the presence of  cardiovascular disease (composite score  1), 
malignancies, and amiodarone usage. The value for P trend was calculated by means of  linear regression analysis. O, 
overt; SC, subclinical.
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In sensitivity analyses, subgroup analyses in three different baseline strata of  renal function, solely in 
survivors reaching age 90 (n=299), and in those with CRP levels below 5 mg/L yielded no different 
results. Results did not materially change with respect to the effects of  basal thyroid hormone status 
on change in eGFR over time when renal function was estimated with CKD-EPI and Cockcroft 
Gault formulas (results not presented). Further adjustment for systolic blood pressure, C-reactive 
protein levels, BMI, and total cholesterol levels in multivariable models neither changed fi ndings. 
In the 535 individuals not on drugs interfering with thyroid hormone measurements, results were 
not different as in total the population (Appendix 4). Finally, we did not observe an association 
between different thyroid hormone groups as defi ned upon two thyroid hormone measurements 
in time (85 and 88 years of  age, see methods) and renal function at 88 years of  age and change in 
renal function from that point on forward (results shown in Figure 1 and 2 of  Appendix 5).




    
     
Figure 2. Mean annual change in eGFR (milliliters per minute per 1.73 m2) across different thyroid function groups. 
Mean (95% CI) annual change in eGFR per group was calculated by means of  multivariate linear mixed models includ-
ing sex, DM, smoking, cardiovascular disease, malignancies, and amiodarone usage as possible confounders. Negative 
values indicate a decline, whereas a positive value indicates an improvement in renal function over time. The mean 
annual changes in eGFR within the different thyroid function groups did not differ signifi cantly from the euthyroid 
group (reference, dotted line). O, overt; SC, subclinical. 




In this community based sample of  the oldest old, positive cross-sectional associations between 
thyroid function and renal function were observed. Over time, thyroid function was not associated 
with change of  renal function. 
In our cross sectional analyses, a low thyroid status associated with lower eGFR values at baseline 
in univariate as well as multivariate models when compared to participants with euthyroidism and 
overt- and subclinical- hyperthyroidism. These fi ndings align with cross-sectional observations 
from other large scaled community-based surveys.32,33 To our knowledge, this is the fi rst study to 
investigate the longitudinal association between thyroid hormone status and the change in renal 
function over time in the oldest old. We observed no longitudinal association as such. Although 
statistically non-signifi cant, one may interpret the fi ndings in Figure 2 as a slight trend in which 
overt hypothyroidism conveys a protective and hyperthyroidism a harmful effect on the change 
in renal function over time. However, this explanation seems unlikely. Not only had those with 
overt hypothyroidism a lower, and those with overt/subclinical hyperthyroidism a higher eGFR at 
baseline, it is biologically less plausible that hypothyroidism is protective against a decline in renal 
function. We therefore interpret this trend through the concept of  “regression to the mean”. In 
addition, analyses including the thyroid hormone measurements at 88 years of  age further support 
the absence of  an association between thyroid hormone status and (change of) renal function. Thus, 
our observations contrast with fi ndings in younger individuals having overt hypothyroidism13,14 and 
subclinical hypothyroidism17,18 who experienced a faster decline in renal function which in turn 
seemed to be attenuated or reversed by thyroid hormone replacement therapy.13,18 
It is of  interest to speculate why the association between thyroid status and change of  renal 
function over time is absent in the oldest old. As a result of  selection due to survival, the oldest old 
may be least susceptible to the detrimental effects of  common risk factors including a low thyroid 
status. Consequently, other pathophysiological mechanisms may be at play in this age category. This 
reasoning fi nds support in earlier studies in the oldest old indicating a reversal or disappearance of  
negative effects of  traditional risk factors like hypertension and hypercholesterolemia20,34 but also 
overt and subclinical hypothyroidism.22,23,35 The association between subclinical hypothyroidism 
and risk for cardiovascular events seems to diminish specifi cally in the elderly22,23,25,35 It has been 
suggested that a low thyroid function in the elderly represents a physiological downregulation of  the 
HPT-axis, possibly benefi tting life expectancy.36 A possible explanation lies in a slower metabolic 
rate which related to an increased survival in several species.37 In a recent study in families of  
nonagenarian siblings, a lower family mortality score was found to be associated with lower thyroid 
function in the offspring, leading the authors to speculate that low thyroid function may be an 
inheritable trait.38 This would imply that a low thyroid function could already be of  protective effect 
in specifi c subgroup of  younger individuals. Throughout all of  these explanations however, our 
fi ndings question the causal relation between low thyroid function and decline in renal function in 




Notably, the positive cross-sectional association in our study between thyroid function and renal 
function could also be explained through the concept of  reverse causality. Severe CKD commonly 
induces a hypothyroid state which exists in the absence of  primary HPT-axis dysfunction.39 
Presence of  this low thyroid state in states of  disease, commonly referred to as non-thyroidal 
illness or low-T3 syndrome, associates with substantially increased mortality rates.40,41 Consistently, 
a previous analysis in the Leiden 85 plus Study showed that low fT3 levels were associated with an 
increased mortality risk.22 This fi nding did however not withstand multivariate adjustment and was 
contradicted by another study in which this association appeared absent.23 
As TSH levels in non-thyroidal illness typically descend or remain within range, the fi nding of  
an increased prevalence of  elevated TSH levels in the oldest old 6 does not fi t this hypothesis. 
When we excluded those with CRP levels below 5 mg/L, cross-sectional associations between 
thyroid function and renal function remained present, pleading against non-thyroidal illness as an 
explanation for our results. 
A strength of  the present study is its population-based design with inclusion of  the oldest old. As 
there were no exclusion criteria, the Leiden 85-plus Study is a representation of  the very oldest 
in the general population. For the interpretation of  our results, some general limitations have to 
be discussed. First, as thyroid status could possibly infl uence plasma creatinine levels via muscle 
metabolism and volume status, the eGFR may not be a good approximation of  renal function 
in this association.42 Nevertheless, overt hypothyroidism was also linked to a reduced eGFR as 
measured by labeled edetic acid.16 In addition, sensitivity analyses using CKD-EPI and Cockcroft 
Gault formulas yielded similar results. Secondly, as subjects in whom new thyroid dysfunction was 
discovered were referred to their general practitioner, the possible initiation of  treatment could 
have masked a possible effect. As our results did not change when analyses were repeated solely in 
those not on thyroid hormone therapy, this effect is unlikely of  great importance. Lastly, bias due 
to competing events (death), and selection on basis of  survival at age 85 could theoretically both 
have masked a true association. 
In conclusion, in older persons in the general population, overt and subclinical hypothyroidism 
are associated with lower renal function at baseline but not with an additional decline in renal 
function over time. Ultimately, our fi ndings suggest an absence of  a causal relation between low 
thyroid function and decline in renal function in the oldest old. Further studies are warranted to 
disentangle the association between thyroid status and renal function throughout different age 
groups and whether thyroid hormone replacement therapy impacts positively on renal function in 
those with low thyroid function.
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I. Summary of  fi ndings
Introduction
Patients with end-stage renal disease have a very poor prognosis.1 Although mortality due to both 
cardiovascular causes and noncardiovscular causes are both an eight fold higher than in age and sex 
matched controls without end-stage renal disease, cardiovascular diseases remain the biggest cause 
of  death.2  The excess in cardiovascular morbidity and mortality cannot be explained by an increased 
prevalence of  traditional risk factors (smoking, hypertension, dyslipidemia and obesity etc.). Rather, 
so called “non-traditional risk factors” may be more important in the context of  reduced renal 
function and take over. In this thesis, two non-traditional risk factors plausibly involved in the 
increased cardiovascular risk of  end-stage renal disease were studied: 1) An increased infl ammatory 
state, and 2) thyroid hormone alterations fi tting the spectrum of  nonthyroidal illnesses. Because 
both risk factors, as a function of  other triggers and disease severity, fl uctuate over time, associations 
were studied in context of  risk factors’ temporal oscillations.
1. Infl ammation
In Chapter 2, the reasons and implications of  elevated serum infl ammatory markers in patients 
undergoing dialysis are reviewed. In the discussion, specifi c focus was placed on C-reactive protein 
(CRP). Also, an overview of  studies on this issue is presented. Further, we discuss the value of  
repeated versus single measurements of  infl ammatory markers in the clinical setting and provide 
solutions to reduce both sample size and intraindividual variability in hypothetical, randomized 
controlled trials aimed at reducing CRP levels in patients undergoing hemodialysis. In Chapter 
3, the impact of  trimestral variability patterns of  CRP, interleukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α) on mortality was studied in 218 maintenance hemodialysis patients. Individuals 
were categorized on basis trimestral variability patterns identifying a stable high, stable low, increase 
and decrease group. As compared with those having persistently low levels of  infl ammatory markers 
during the three months observational period (reference), patients with variable levels over time 
and persistently elevated levels had increasingly higher mortality hazards, respectively. Adjustment 
for confounding factors did not alter fi ndings much leading us to speculate on a possible dose 
response relationship in which a longer and more severe presence of  the risk factor translates into 
increased mortality hazards. Chapter 4 investigates the impact of  a pro-infl ammatory response 
versus a lower infl ammatory activation on the stimulus of  a single hemodialysis session on mortality. 
In 190 Swedish, and 94 Dutch hemodialysis patients, no difference in survival was noted between 
both groups. In addition, a low agreement between CRP changes in a fi rst hemodialysis and second 
hemodialysis session was found in the Dutch cohort. Therefore, we conclude on the absence of  
an association between a change in serum CRP levels during dialysis and mortality rates in two 
independent cohorts. This reasoning is supported by a low biological likelihood of  CRP to rise in 
such short timeframe.




In Chapter 5, we introduce the concept of  nonthyroidal illness and describe its genesis in renal 
and cardiac diseases. Both disease unspecifi c factors (like infl ammation, protein-energy wasting, 
and comorbidities) and renal disease specifi c factors (iodide retention, metabolic acidosis, selenium 
defi ciency, and certain medicaments) may be involved in its development. The potential impact 
of  nonthyroidal illness on cardiac and renal functioning is further discussed. Because of  its high 
prevalence in both settings, and its deleterious effects on both organ systems, we hypothesize 
on a possible role of  nonthyroidal illness in the induction and maintenance of  the cardio-renal 
syndrome. Finally, we provide results from a literature search focusing on the supplementation of  
thyroid hormone in the context of  end-stage renal disease induced nonthyroidal illness. Chapter 
6 reports a study on the association between trimestral variation patterns of  total triiodothyroinine 
and thyroxine over a three months period and mortality. In 218 patients on maintenance 
hemodialysis, we found that those having persistently low triiodothyronine levels had the highest 
cardiovascular mortality rates, followed by those having fl uctuating levels over time, and those 
having persistently high (normal) levels. For trimestral variation patterns of  serum thyroxine levels, a 
comparable association was seen. Interestingly, an association remained after adjustment for serum 
triiodothyronine levels, suggesting an independent effect of  thyroxine on cardiovascular mortality. 
On basis of  these fi ndings, we conclude that in patients with end-stage renal disease, trimestral 
variation patterns of  thyroid hormone concentrations are strongly associated with mortality. 
In Chapter 7, a study in 84 patients on maintenance peritoneal dialysis is presented investigating 
coronary artery calcifi cation scores and arterial stiffness as possible mediators in the association 
between nonthyroidal illness and mortality. Despite the low numbers of  patients and events, a 
low triiodothyronine state associated strongly with mortality, arterial stiffness and coronary artery 
calcifi cation (CAC) scores. A relatively high CAC score was strongly associated with higher mortality 
rates during follow-up. When the association between a low triiodothyronine state and mortality 
was adjusted for CAC scores, the magnitude of  the effect attenuated. These fi ndings support 
the hypothesis that vascular calcifi cation could be involved as an intermediate in the association 
between nonthyroidal illness and mortality. Chapter 8 describes a study in 558 elderly, home-
dwelling individuals in which we investigated the association between thyroid status and progression 
of  renal dysfunction over a 5-year observational period. Individuals were included during the year 
they turned 85 years of  age and at inclusion, baseline characteristics were collected and thyroid 
hormone function was measured. During subsequent follow-up, serum creatinine concentrations 
were measured annually and events of  death were recorded. At age 85, a low thyroid function was 
associated with lower renal function. During follow-up however, an association between a low 
thyroid function and change in renal function over time was absent. Our fi ndings question the 





In our studies, several methodological diffi culties were encountered and must be brought upfront. 
Whereas most of  these limitations have already been addressed in the discussions of  the different 
chapters, this sections aims at providing more general considerations. The discussion will be assisted 
by means of  “Directed Acyclic Graphs” (DAGs) which give graphical insight into the associations 
between different variables (vertices). The term “acyclic” refers to the fact that there are no loops 
in the graph, so a specifi c factor cannot cause itself. 
Selection bias
A common problem in scientifi c studies is selection bias, which concerns a systematic error 
that arises when the selection of  a population occurs on the basis of  both the exposure and the 
outcome.3 Consequently, the association between exposure and outcome is different in participants 
versus the cohort which would have participated if  all individuals would have been included. In our 
studies, two important sources of  selection bias must be discussed; 
1. Collider-stratifi cation bias: As illustrated Figure 1, collider-stratifi cation bias results when 
conditioning occurs on a collider (C), by defi nition being a consequence of  both the exposure (E) 
and other risk factors (U) 4. C often concerns an inclusion criterion. By conditioning on C, E is 
artifi cially associated with the outcome (O) via U. U can specify confounding factors or factors that 
exist independently of  the exposure (illustrated by the dotted line). Adjustment for U, if  known, 




Figure 1. A Directed Acyclic Graph (DAG) illustrating collider-stratifi cation bias. E: exposure, C: collider, U: other 
(un)known factors, O: outcome of  interest.
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2. Informative censoring: This type of  bias arises when individuals can no longer develop the outcome 
of  interest due to another reason which is associated with the exposure and outcome. Among the 
causes of  this latter form of  bias are loss to follow-up and competing risks. When competing risks 
occur, conventional Kaplan-Meier methodology can yield misleading results.5
1. Collider-stratifi cation bias 
In our studies ESRD (Chapter 3,4,6 and 7), individuals were eligible only when they were 
treated with dialysis and were thus required to have survived up to this point in time (C). Before 
this, infl ammation and a low thyroid function (E) likely caused death in a number of  patients. 
Accordingly, those with a higher grade of  both risk factors but who survived to reach the eligibility 
criteria are of  an unusual kind, typically having less other risk factors (U). By selectively including 
these patients, an artifi cial association can arise between infl ammation/low thyroid hormone state 
(E) and mortality (O) via other (un)known factors (U). As a result, the association between a 
high infl ammatory state/low thyroid hormone state and mortality artifi cially changes. This seems 
however unlikely because an increased mortality risk in those with higher grades of  infl ammation6;7 
and a low thyroid hormone status was also found in the general population.8 Therefore no paradox 
need be explained. Also, adjustment for known factors (U) did not result in differential fi ndings.
In Chapter 8, collider-stratifi cation bias could have masked the presence of  an association between 
thyroid hormone status (E) and the progression of  renal dysfunction over time (O) in elderly 
subjects. While a low thyroid status is a risk factor for mortality (C), it is possible that those 
with a low thyroid function who have lived to celebrate their 85th birthday, have less other risk 
factors (U). This could have resulted in an artifi cial association between E and O, via U. Indeed, 
associations between a low thyroid function and faster progression of  CKD were apparent in 
younger individuals (Chapter 8)9;10 but proved absent in the elderly (this thesis). Two arguments 
could plead against collider-stratifi cation bias explaining an absence of  fi ndings: 1) Adjustment for 
conventional risk factors (e.g. comorbidities, BMI, infl ammation and blood pressure) did not alter 
fi ndings suggesting a true absence of  an association. 2) It is not unlikely that physiology is different 
at old age as compared with younger age.
In the evaluation of  collider-stratifi cation bias, it must be noted that the situation is likely more 
complex than assumed in Figure 1. The presence of  a high infl ammatory/low thyroid hormone 
state is, in contrast to other exposures (e.g. genes or medication usage), subject to a certain 
temporal variability over time (this thesis). As many patients gain and lose the exposure over time, 
the exposed group is not a fi xed population. This phenomenon would require another vertex in the 
DAG indicating exposure status at time point 2 (E2). The same would hold for all the other factors 
implicating the differentiation of  U into U1 and U2. On top of  this, various factors can be thought 
of  which infl uence E, U and O in turn, further complicating the DAG. Ultimately, DAGs in end-
stage renal disease seem extremely complex due to the systemic nature of  disease and alterations in 




2. Informative censoring 
During the study period, loss to follow-up was low in all cohorts. This may be explained by two 
reasons; 1) mortality was the endpoint of  interest in most of  our studies being a characteristic 
which can be obtained through various sources. 2) dialysis patients depend on medical care and 
generally have a good liaison with their physicians whereby loss of  patients is limited. In the Leiden 
85 plus study, house visits contributed to a reduction in loss to follow-up. 
As another cause of  informative censoring, competing risks are important to discuss.11 In dialysis, 
the occurrence of  renal transplantation after which individuals are censored is a common competing 
risk. As we primarily used prevalent dialysis cohorts in which transplantation rate is lower, this 
cause of  competing risks is of  less relevance. Otherwise, when patients would die because of  
non-cardiovascular causes, they are not anymore at risk to die from a cardiovascular cause, yielding 
informative right censoring with the potential of  bias. In a sensitivity analysis in Chapter 6, we 
calculated cumulative mortality probabilities.11 Because our conclusions did not change and the 
conventional approach is more widely accepted, the latter form was adopted in the presentation of  
results. No Fine and Gray Cox regression models were applied.
Confounding
Observational studies are hindered by confounding, that is, when another factor, being associated 
with the exposure and outcome while not lying in the causal pathway, affects the association of  
interest.12 The selection of  confounders for specifi c associations in this thesis occurred on basis of  
biological knowledge and DAGs. Confounding was then corrected for by means of  stratifi cation or 
adjustment in multivariable regression models. Because of  low numbers of  events in the MIMICK 






Figure 2. A directed acyclic graph (DAG) illustrating the complexity of  collider stratifi cation bias in end-stage renal 
disease. E1: exposure at timepoint 1, E2: exposure at timepoint 2, C: collider, U1: other (un)known factors at timepoint 
1, U2: other (un)known factors at timepoint 2, O: outcome of  interest.
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an approach by correcting for propensity scores rather than all confounders separately. The small 
patient population (n=84) however limited the construction of  proper prediction models leading 
us to prefer the conventional way of  adjustment for the fi nal presentation of  results. Findings were 
however not substantially different between both approaches. Although associations were quite 
extensively adjusted, residual confounding from unknown factors cannot be excluded.
Mediation analyses 
In causal inference, mediation analyses are meant to clarify to what extent the association between 
exposure and outcome is mediated by a certain factor. A standard approach for mediation analyses 
is to regress the exposure on the outcome with and without the mediator included in the model. 
In mediation analyses, two limitations can be encountered. 1) The model is not robust when in 
fact effect measure modifi cation exists. 2) Possible outcome-mediator confounding can arise when 
the mediator behaves as a collider (C). Adjustment for C would then result in a false association 
between the exposure and outcome via other factors.13 Consequently, correction for these other 
factors (U) could remove this type of  confounding.
In Chapter 6, we adjusted the association between T4 and mortality for serum T3 levels. Interestingly, 
an independent effect remained suggesting that T4 also acts via direct pathways on mortality. In 
Chapter 7, we observed an attenuation in the association between T3 levels and mortality after 
correction for coronary artery calcifi cation scores, supporting the hypothesis of  an intermediate 
role for coronary calcifi cation. In both analyses, we tested the presence of  interaction between 
exposure and mediator in multivariable Cox models which appeared to be absent. Also here, we 
considered the possibility of  mediation-outcome confounding. A limitation in both mediation 
analyses was the fact that exposure and mediator were both measured at the same moment. Ideally, 
one would have measured the development of  coronary artery calcifi cation or occurrence of  
cardiac events during follow-up.
III. Infl ammation and non-thyroidal illness as cardiovascular risk factors 
Causal associations or merely epi-phenomena?
Several contextual arguments, as originally proposed by Hill,14 strengthen the belief  in a causal 
role for both an increased infl ammatory state and nonthyroidal illness in cardiovascular risk 
augmentation. Firstly, a biological gradient is seen in several of  the associations tested in this 
thesis, worse levels of  the exposure (over time) coexisting with higher occurrences of  the outcome. 
Secondly, as adjustment for confounders did not reduce effect estimates greatly, it can be speculated 
that adjustment for other, unknown, confounders will unlikely result in a disappearance of  the 
found associations. Third, the concept of  temporality was satisfi ed, meaning the exposure was 
there before the outcome occurred. Finally, associations were consistent within different cohorts 




Findings from the current thesis confi rm and expand prior reports in other patient populations, 
animals and ex-vivo experiments (reviewed in Chapters 2 and 5). Many of  these studies were, 
however, observational in nature and possibly hindered by confounding. In this respect, studies 
applying a Mendelian Randomization approach are of  special interest. By utilizing the random 
distribution of  genes in a certain population this approach can, under certain assumptions, provide 
estimates free of  confounding for an association of  interest.15 As such, a signifi cantly lower risk for 
developing coronary heart disease events and mortality was observed in patients with the functional 
interleukin-6 receptor (IL-6R) rs7529229 polymorphism versus those having the wild type allele, 
supporting a causal role for IL-6 signaling.16;17 Interestingly, CRP polymorphisms were not associated 
with mortality,17;18 implying that CRP is a marker of  infl ammation rather than a causative factor. 
Causal pathways linking a higher grade of  infl ammation to an increased cardiovascular risk pertain 
to the promotion of  plaque formation, destabilization and eventually rupture.19
Also for nonthyroidal illness, several pathways have been suggested that connect this risk factor to 
an increased cardiovascular risk in end-stage renal disease (extensively reviewed in Chapter 5). To 
our knowledge, no studies have applied the Mendelian randomization concept to the association 
between thyroid hormone alterations and cardiovascular risk in end-stage renal disease. 
Fluctuations of  serum infl ammatory markers and thyroid hormones over time
When evaluating the consequences of  a high infl ammatory state and nonthyroidal illness on 
cardiovascular risk, it is important to bear in mind their variable presence over time (this thesis). 
This may be valuable from both an etiological and predictive perspective. From an etiological 
perspective, the observation of  a dose response association between both exposures and outcome 
strengthens the belief  in causality (Chapters 3 and 6). Further, they could help in the identifi cation 
of  intermediate pathways. It is interesting to note that such intermediates are likely to show 
temporal variability as well. For example, the severity of  atherosclerotic plaques likely varies over 
time, certain plaques regressing while others showing progression.20 Finally, variability patterns 
provide information concerning the underlying stimulus (Chapter 2).
From a predictive point of  view, a second measurement of  a blood marker could add information 
by reducing measurement error and intra-patient variability (Chapter 2). It could thereby help 
in the discrimination between individuals with a true nonthyroidal illness syndrome and those 
with a random aberrant value in illness. Thereby it could also hold therapeutic consequences. For 
instance, thyroid hormone supplementation would theoretically only be of  value in chronic- but 
not in a temporary state of  defi ciency. Also, multiple measurements add prognostic value (this 
thesis). Finally, a second measurement adds information, improving risk stratifi cation in prediction 
models. 
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Clinical and scientifi c implications
Infl ammation
As reviewed in Chapter 2, the monitoring of  infl ammatory levels could serve for retrieving the 
cause of  infl ammation in a single patient which could again guide therapeutic interventions to 
treat its underlying cause. Efforts to identify anti-infl ammatory therapies of  benefi t for patients 
with end-stage renal disease have unfortunately been few and somewhat unsuccessful.21 Although 
several substances were shown to result in a reduction of  infl ammatory marker levels, no clear 
benefi t on primary endpoints has so far been reported. Recently, bardoxolone methyl generated 
much expectation on basis of  its anti-oxidant effects via the NR2f  pathway. Yet, a large scaled 
placebo randomized controlled trial investigating bardoxolone methyl in patients with end-stage 
renal disease and type 2 diabetes mellitus was terminated prematurely because of  an increased 
cardiovascular event rate in the treatment arm.22 A general fear for immune suppressive strategies 
concerns that of  potential infectious side effect. As such, no specifi c therapy is currently registered 
for anti-infl ammatory effects in patients with end-stage renal disease. 
Further observational and interventional studies are needed to gain more insight in specifi c 
infl ammatory pathways and potential interventions. It would be interesting to investigate whether 
the cardiovascular impact of  the infl ammatory response to different types of  stimuli would be 
different. Also, a more thorough understanding in the genesis of  the increased infl ammatory levels 
is necessary.
Nonthyroidal illness
As is the case for an increased grade of  infl ammation, also studies on correction of  thyroid hormone 
alterations in nonthyroidal illness due to end-stage renal disease have been largely negative. It must 
however be stated that the majority of  studies were insuffi cient in sample size, design and had other 
major shortcomings (further exemplifi ed in Chapter 5). In addition to that, our current knowledge 
on nonthyroidal illness seems insuffi cient to identify subjects who could benefi t from thyroid 
hormone supplementation. Presumably, the aspect of  temporal variability plays an important 
role in this. All in all, currently no evidence exists for thyroid hormone supplementation for this 
indication.
For the association between nonthyroidal illness and a possible increased cardiovascular risk, studies 
utilizing the Mendelian randomization approach could be of  aid to further address the question of  
causality. Also, a universal defi nition should be introduced on nonthyroidal illness, possibly with 
different grades of  severeness. Without any doubt, the temporal variability of  thyroid hormone 
derangements in chronic end-stage renal disease must be implemented in such defi nition. The 




of  thyroid hormone supplementation. As a next step, interventional studies should be designed 
with an adequate sample size and follow-up duration. In the design, special attention should also 
be given to the type of  compound used. As deiodinase defects are a cornerstone aberration in 
nonthyroidal illness, the supplementation of  thyroxine seems not legitimized. In the fi eld of  
cardiology, new trials have been initiated in patients with heart failure and myocardial infarctions. 
This could form an incentive for studies in the fi eld of  nephrology.
IV. Conclusions
1. Infl ammatory marker levels are elevated in the majority of  patients with end-stage renal disease 
and associate strongly with (cardiovascular) mortality. Also variability patterns of  infl ammatory 
markers over a three months observational period strongly associate with (cardiovascular) 
mortality while changes of  CRP during a single dialysis session do not. 
2. Alterations in thyroid hormone levels fi tting the spectrum of  nonthyroidal illness are observed 
in the majority of  patients with end-stage renal disease. The persistent and variable presence of  
these derangements strongly associate with (cardiovascular) mortality. This association may be 
intermediated by a higher coronary artery calcifi cation and arterial stiffness.  
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In het menselijk lichaam zijn de nieren betrokken bij een aantal belangrijke processen. Hiertoe 
behoren de vocht- en zoutbalans, het uitscheiden van afvalstoffen en de aanmaak van rode bloed-
cellen. Wanneer de nieren niet optimaal functioneren is behandeling met medicijnen noodzakelijk 
om deze processen alsnog goed te laten verlopen. In eindstadium nierfalen, wanneer de nieren bi-
jna niet meer werken, is medicamenteuze therapie niet afdoende en moet de functie van de nieren 
worden vervangen. Dit kan op twee manieren: middels een niertransplantatie of  dialyse. Transplan-
tatie is echter alleen voor een selecte groep patiënten mogelijk. Bij dialyse kan het bloed op twee 
manieren kunstmatig gereinigd worden van afvalstoffen: 1) hemodialyse en 2) peritoneale dialyse 
(ook wel buikspoelingen genoemd). Bij hemodialyse wordt bloed vanuit de patiënt door slangen 
naar een dialysemachine geleid alwaar het wordt gereinigd. Vervolgens wordt ‘schoon’ bloed het 
lichaam van de patiënt weer ingevoerd. Bij peritoneale dialyse wordt gebruikgemaakt van het eigen 
buikvlies om afvalstoffen en overtollig vocht af  te laten lopen. De patiënt laat hiertoe schoon vocht 
de buik inlopen om enkele uren later de buik te laten leeglopen. De keuze voor één van beide vor-
men van dialyse wordt door vele factoren bepaald waaronder de leeftijd, het aantal en de aard van 
andere ziekten van de patiënt, het sociale vangnet en de voorkeuren van de patiënt zelf.
Ondanks dialysebehandeling (zowel hemodialyse als peritoneale dialyse) hebben patiënten met eind
stadium nierfalen tot op heden een slechte prognose. Vijf  jaar na aanvang van dialysebehandeling 
is ongeveer 50 procent van alle patiënten overleden. Na tien jaar betreft dit zelfs 90 procent. Deze 
oversterfte bij dialyse patiënten wordt verklaard door het vaker voorkomen van hart- en vaatziekten 
(hartinfarcten, hartfalen, hartritmestoornissen, enzovoort), infecties, kanker en ondervoeding. 
Het feit dat sterfte door hart- en vaatziekten ongeveer achtmaal vaker voorkomt in de dialysepopu-
latie kan tot op heden niet verklaard worden door risicofactoren die bij patiënten zonder nierziek-
ten sterfte door hart- en vaatziekten veroorzaken (zoals roken, een te hoog cholesterolgehalte, hoge 
bloeddruk en obesitas). Deze risicofactoren worden beschouwd als de ‘traditionele risicofactoren’ 
voor hart- en vaatziekten. Gedurende de laatste jaren is gebleken dat in de dialysepopulatie ‘niet-
traditionele risicofactoren’ belangrijk zijn voor het ontstaan van hart- en vaatziekten. Deze risico-
factoren, waaronder infl ammatie, zijn het gevolg van de nierziekte zelf  en verminderen de functie 
van het hart en de bloedvaten. Onderzoek naar deze niet-traditionele risicofactoren is van belang 
voor het ontwikkelen van toekomstige therapieën voor dialysepatiënten.
In dit proefschrift werden twee niet-traditionele risicofactoren bestudeerd die mogelijk betrok-
ken zijn bij het verhoogde sterfterisico door hart- en vaatziekten bij patiënten met eindstadium 
nierfalen: een verhoogde staat van ontsteking (infl ammatie) en een verlaging van de concentratie 




1. Een verhoogde infl ammatoire staat 
In de meerderheid van de dialysepatiënten bestaat een chronisch verhoogde infl ammatoire staat. 
Hieraan lijken vele factoren bij te dragen waaronder een verminderde eliminatie van ontstekings-
factoren door de nieren, het vaker voorkomen van infecties, en prikkeling van het afweersysteem 
door dialyse. Deze gegeneraliseerde staat van infl ammatie zou door verscheidene effecten op de 
vaatwand bij kunnen dragen aan het vaker voorkomen van hart- en vaat-ziekten en de daardoor 
veroorzaakte sterfte. De exacte invloed en werkingsmechanisme zijn echter niet compleet duidelijk.
2. Nonthyroidal illness 
Bij ongeveer 70 procent van alle dialysepatiënten lijken schildklierhormoonconcentraties in het 
bloed te zijn verlaagd. Omdat deze afwijkingen niet veroorzaakt worden door ziekte in de schil-
dklier zelf, wordt dit beeld ook wel “nonthyroidal illness” genoemd waarbij 'thyroid' schildklier 
betekent en 'illness' ziekte. Het nierfalen zelf  lijkt via allerlei mechanismen de oorzaak van deze 
verlaging van de schildklierhormoonconcentraties. Lage spiegels van schildklierhormonen veroor-
zaken een lager metabolisme. Vroeger werd gedacht dat de lage schildklierhormoonconcentraties 
bij dialysepatiënten een aanpassing van het lichaam betekende waarin het lichaam ten tijde van 
ziekte langer kon volstaan met minder energie. Er bestaan echter aanwijzingen dat deze verander-
ingen nadelige consequenties zouden kunnen hebben op andere systemen. Schildklierhormonen 
zijn namelijk van invloed op de functie van hart en bloedvaten waarbij te lage schildklierhormoon-
waarden het ontstaan van hart- en vaatziekten zouden kunnen bevorderen.
In de voorgaande studies bestudeerden we twee mogelijke niet-traditionele risicofactoren voor 
sterfte door hart en vaatziekten bij patiënten met eindstadium nierfalen. Omdat zowel een ver-
hoogde staat van infl ammatie als ontregelde schildklierhormoonconcentraties niet altijd aanwezig 
zijn, verrichten we meerdere metingen per patiënt in de tijd. Het proefschrift is opgedeeld in twee 
stukken: 1) dat deel dat de implicaties van infl ammatie onderzocht en 2) het gedeelte dat studies 
naar de effecten van nonthyroidal illness omvat.
1. Infl ammatie
In hoofdstuk 2 beschrijven we in een review de oorzaak van verhoogde concentraties ontstekings
waarden in het bloed van dialysepatiënten. Hiertoe behoren onder andere ziekten die dialyse-
patiënten vaak naast hun nierfalen hebben (bijvoorbeeld diabetes mellitus en hart- en vaatziekten), 
het vaker optreden van infecties en de prikkeling van het afweersysteem door dialyse. Vervolgens 
geven we de resultaten weer van een literatuurstudie naar onderzoeken die de associatie tussen ver-
hoogde ontstekingswaarden en sterfte gedurende follow-up nagingen. Omdat de ernst van de in-
fl ammatoire staat wisselt over tijd wijden we ook een gedeelte aan de bespreking van studies die de 
waarde van herhaalde versus afzonderlijke metingen van ontsteking onderzochten. Aan het einde 
van dit hoofdstuk geven we een advies over hoe het aantal patiënten dat nodig is voor een studie 




In hoofdstuk 3 onderzochten we de invloed van veranderingen van infl ammatiemarkers over drie 
maanden tijd op sterfte bij patiënten met eindstadium nierfalen. Tot de infl ammatiemarkers die we 
onderzochten, behoorden C-reactief  proteïne (CRP), interleukine-6 (IL-6) en tumornecrosefactor-α 
(TNF-α). Patiënten werden verdeeld in vier groepen op basis van de veranderingen in infl ammatie
markerwaarden die bij hen werden gemeten. De vier groepen werden als volgt gedefi nieerd: 1) 
patiënten met stabiel lage concentraties, 2) degenen die een stijging lieten zien in serumwaarden, 
3) degenen die een daling toonden, en 4) degenen met stabiel hoge waarden (de hoogste graad van 
infl ammatie). Gedurende verdere follow-up in de tijd scoorden we welke patiënten van de initiële 
populatie overleden of  de studie verlieten om andere redenen. We vonden dat, in vergelijking met 
patiënten die aanhoudend lage CRP-, IL-6- en TNF-α-waarden hadden gedurende drie maanden 
observatie, patiënten met wisselende waarden in de tijd (stijging of  daling), en stabiel verhoogde 
waarden een sterk verhoogd sterfterisico hadden. De oorzaak van deze verhoogde risico’s zou een 
langere blootstelling aan de risicofactor kunnen zijn geweest. 
In hoofdstuk 4 stelden we de vraag of  patiënten die een hogere infl ammatoire activatie zouden 
ontwikkelen op de stimulus van een hemodialysesessie een hoger sterfterisico zouden hebben dan 
patiënten die weinig infl ammatie zouden ontwikkelen na een dialysesessie. Hiertoe maten we in 
190 Zweedse en 94 Nederlandse hemodialysepatiënten bloedwaarden van CRP vóór en na een he-
modialysesessie. De veranderingen in concentraties corrigeerden we voor de hoeveelheden vocht 
die tijdens dialyse aan de bloedbaan werden onttrokken omdat deze een (valse) stijging in CRP-
concentraties zouden kunnen veroorzaken die niet toe te bedelen is aan een infl ammatoire activatie. 
Tijdens de follow-up telden we telkens degenen die overleden en degenen die in leven bleven. In 
onze studie bevonden we geen verschil in overleving tussen patiënten in wie serum CRP concen-
traties stegen en degenen in wie de waarden ongeveer gelijk bleven of  daalden. Ook vonden we bij 
dezelfde patiënten die gedurende twee hemodialysesessies metingen ondergingen geen overeen-
komst in CRP-veranderingen. Op basis van deze gegevens concludeerden we dat veranderingen in 
bloed-CRP-waarden tijdens een dialysesessie (als maat voor de infl ammatoire activatie) niet geas-
socieerd zijn met sterfte. Deze redenering werd ondersteund door een bevinding in de literatuur dat 
CRP-waarden vaak meer tijd nodig hebben om te stijgen dan de duur van een hemodialysesessie 
(mediane duur vier uur).
2. Nonthyroidal illness
In hoofdstuk 5 introduceren we het concept 'nonthyroidal illness' en beschrijven we het ontstaan 
daarvan bij patiënten met eindstadium nierfalen. Hierbij treffen we een vergelijking met de ontstaan-
swijze van nonthyroidal illness bij patiënten met hartziekten. Op basis van een uitgebreide literatuur
studie lijken zowel nierfalen-gerelateerde factoren (jodiumretentie, verzuring van het bloed, sele-
niumtekorten en gebruik van bepaalde geneesmiddelen) als niet-nierfalen-gerelateerde factoren 
(ontsteking, vermagering) een rol te spelen bij het ontstaan van nonthyroidal illness. Aansluitend 




aannemelijk dat lage schildklierhormoonwaarden, veroorzaakt door nonthyroidal illness, een ver-
hoogd risico geven op sterfte door het bevorderen van vaatverkalking en verdikking van de hart-
spier. Tot slot tonen we een literatuuroverzicht van studies die de effecten van schildklierhormoon
toediening op hart-en vaat-functie en sterfte bij patiënten met nonthyroidal illness, veroorzaakt 
door eindstadium nierfalen, onderzochten. Er wordt gespeculeerd dat een compensatie van het 
schildklierhormoontekort een gunstig effect zou kunnen hebben op deze eindpunten. Onze lit-
eratuurstudie toont dat er weinig grote studies bestaan over het effect van schildklierhormoonbe-
handeling met deze indicatie bij patiënten met eindstadium nierfalen. We komen tot het advies om 
verdere studies hiernaar te verrichten. 
Hoofdstuk 6 rapporteert een studie waarin de associatie tussen veranderingen van schildklier-
hormoonconcentraties over drie maanden tijd en sterfte (door hart- en vaatziekten) werd onder-
zocht. Bij 224 hemodialysepatiënten werden T3-, T4- en TSH-concentraties bij inclusie en na drie 
maanden follow-up gemeten. Groepen werden gecreëerd op basis van veranderingspatronen zoals 
besproken in de samenvatting van hoofdstuk 3. Hier vertegenwoordigde echter de groep met sta-
biel lage concentraties de slechtste categorie. Gedurende verdere follow-up in de tijd scoorden we 
welke patiënten overleden of  de studie verlieten. Overeenkomstig onze hypothese bevonden we 
dat bij patiënten met verlaagde schildklierhormoonwaarden (zowel lage T3- als T4-concentraties 
die passen bij de hoogste graad van nonthyroidal illness) de meeste sterfte optrad, gevolgd door 
de patiëntencategorie met wisselende waarden over de tijd en patiënten met aanhoudend hoge (bij 
benadering normale) waarden. 
In hoofdstuk 7 tonen we een studie naar de effecten van lage schildklierhormoonconcentraties op 
kransslagaderverkalking, vaatstijfheid en sterfte bij 84 patiënten die peritoneale dialyse ondergin-
gen. Bij inclusie in de studie ondergingen de patiënten metingen van vaatstijfheid en CT-scans van 
het hart om de kransslagaderverkalking te scoren. Gedurende follow-up werd bijgehouden welke 
patiënten overleden of  de studie verlieten. De opzet van de studie was gekozen met de gedachte 
dat het effect van lage schildklierhormoonconcentraties op sterfte geïntermedieerd zou kunnen 
worden door een verhoogde kransslagaderverkalking en vaatstijfheid. De resultaten tonen dat lage 
T3-waarden sterk geassocieerd waren met een verhoogd sterfterisico en een verhoogde krans-
slagaderverkalking en vaatstijfheid. Ook een verhoogde kransslagaderverkalking was, zoals tevens 
bevonden in andere studies, sterk geassocieerd met een verhoogd sterfterisico. Op basis van deze 
resultaten speculeren we dat een verhoogd sterfterisico bij patiënten met lage schildkierhormoon-
waarden (met name T3) veroorzaakt wordt door verhoogde kransslagaderverkalking en vaatstijf-
heid. 
In hoofdstuk 8 presenteren we een onderzoek in een populatie van 85-jarigen zonder primaire 
nierziekten waarin we de effecten van lage schildklierhormoonwaarden op veranderingen in nier-
functie over tijd onderzochten. Tussen 1997 en 1999 werden alle inwoners van Leiden die hun 85e 
verjaardag vierden benaderd voor deelname aan de zogenaamde Leiden 85 plus studie. Bij de 558 
deelnemers werden bij inclusie in de studie schildklierhormoonconcentraties in het bloed gemeten. 




nierfunctie gemeten (ook door middel van een bloedafname). Uit onze analyses bleek dat schildkli-
erhormoonstatus op 85 jaar niet geassocieerd was met het nierfunctiebeloop in de jaren daarna. In 
de analyse van de gegevens vormt de hoge sterfte echter een probleem waarbij een mogelijke bias 
de interpretatie van de data bemoeilijkt. Verdere studies naar de effecten van schild klierfunctie op 
het beloop van nierfunctie zullen moeten uitwijzen of  schildklierhormoonstatus een risicofactor is 
voor achteruitgang in nierfunctie over de tijd bij ouderen.
Conclusies
1. Bij een meerderheid van alle patiënten met eindstadium nierfalen worden verhoogde waarden 
van infl ammatiemarkers (CRP, IL-6 en TNF-α) gevonden waarvan de aanwezigheid geasso-
cieerd is met een sterk verhoogde sterfte. Ook veranderpatronen van infl ammatiemarkers over 
drie maanden tijd zijn geassocieerd met sterfte gedurende follow-up. Hierin hadden patiënten 
met stabiel verhoogde waarden het hoogste sterfterisico, gevolgd door degenen met wisselende 
waarden (stijging en daling) en patiënten met stabiel lage waarden. 
2. Bij een meerderheid van alle patiënten met eindstadium nierfalen worden verlaagde schildklier 
waarden gevonden welke veroorzaakt worden door het nierfalen zelf  en passen binnen het 
spectrum van nonthyroidal illness. De aanwezigheid van verlaagde schildklierhormoonconcen-
traties bij patiënten met eindstadium nierfalen is geassocieerd met verhoogde kransslagader-








The following Pubmed searching queries were used to identify relevant publications on the topic 
of  discussion. When relevant publications were retrieved, articles citing that publication afterwards 
were also tracked at ISI web of  Knowledge.
(“Kidney Failure, Chronic”[Mesh] OR “Chronic kidney failure”[All Fields] OR “End stage kidney disease”[All Fields] 
OR “End-stage kidney disease”[All Fields] OR “End stage renal disease”[All Fields] OR “End-stage renal disease”[All 
Fields] OR “End stage kidney failure”[All Fields] OR “End-stage kidney failure”[All Fields] OR “End stage renal 
failure”[All Fields] OR “End-stage renal failure”[All Fields] OR “chronic renal failure”[All Fields] OR “ESRD”[All Fields] 
OR “Renal Dialysis”[Mesh] OR “Renal Dialysis”[All Fields] OR “hemodialysis”[All Fields] OR “haemodialysis”[All 
Fields] OR “Extracorporeal dialysis”[All Fields] OR “peritoneal dialysis”[All Fields] OR “CAPD”[All Fields] OR 
“Hemodiafi ltration”[All Fields] OR “Uremia”[Mesh] OR “uraemia”[All Fields] OR “uremia”[All Fields]) 
AND
(“C-Reactive Protein”[Mesh] OR “c reactive protein”[All Fields] OR “c-reactive protein”[All Fields] OR “C-reactive 
protein (192-201) “[Substance Name] OR “CRP”[All Fields] OR “C-reactive protein (164-173) “[Substance Name] 
OR “Interleukin-6”[Mesh] OR  “interleukin-6, 2-nitrophenylsulfenyl-Trp(36,160)- “[Substance Name] OR “Interleu-
kin-6”[All Fields] OR “Interleukin 6”[All Fields] OR “IL 6”[All Fields] OR “IL-6”[All Fields] OR “Tumor Necrosis 
Factor-alpha”[Mesh] OR “Tumor Necrosis Factor alpha”[All Fields] OR “Tumor Necrosis Factor-alpha”[All Fields] 
OR “TNFalpha”[All Fields] OR “TNF alpha”[All Fields] OR “Cachectin”[All Fields]) 
AND  
(“Mortality”[Mesh] OR “Mortality”[All Fields] OR “Death”[All Fields] OR “Survival”[Mesh] OR “Survival”[All 
Fields] OR  “Treatment Outcome”[Mesh] OR “outcome”[All Fields] OR  “Cardiovascular Diseases”[Mesh] OR 
“Cardiovascular Diseases”[All Fields] OR “Cardiovascular Disease”[All Fields] OR “hypertrophy”[All Fields] OR 
“cardiomyopathy”[All Fields] OR “atherosclerosis”[All Fields]  OR “arteriosclerosis”[All Fields]) 
AND 
(“Time Factors”[Mesh] OR “time factors”[All Fields] OR “Variation”[All Fields] OR “Variation”[All Fields] 
OR “Repeated”[All Fields] OR “Repeatedly”[All Fields] OR “Serial”[All Fields] OR “Multiple”[All Fields] OR 
“Consecutive”[All Fields] OR “Consecutively”[All Fields] OR “values”[All Fields] OR “Measurements”[All 
Fields] OR “monthly”[All Fields] OR “Daily”[All Fields] OR “Weekly”[All Fields] OR “Yearly”[All Fields] OR 
“Monitoring”[All Fields] OR “persistent”[All Fields] OR “Persistent”[All Fields] OR “Time-course”[All Fields] OR 
“Time course”[All Fields] OR “in Time”[All Fields] OR “twice”[All Fields] OR “thrice”[All Fields] OR “more”[All 
Fields] OR “regular”[All Fields] OR “regularly”[All Fields] OR “Interval”[All Fields] OR “Succeeding”[All Fields] OR 
“Successive”[All Fields] OR “Fluctuating”[All Fields] OR “fl uctuation” OR “fl uctuations”[All Fields] OR “course”[All 





Pubmed (from 1940 till August 2012) was searched with terms as enlisted below. Scripts were 
modifi ed to fi t an inquiry for Embase (from 1974) and Web-of  Science (from 1945). 
(“Kidney Failure, Chronic”[Mesh] OR “Chronic kidney failure”[All Fields] OR “End stage kidney disease”[All 
Fields] OR “End-stage kidney disease”[All Fields] OR “Endstage kidney disease”[All Fields] OR “End stage renal 
disease”[All Fields] OR “End-stage renal disease”[All Fields] OR “Endstage renal disease”[All Fields] OR “End stage 
kidney failure”[All Fields] OR “End-stage kidney failure”[All Fields] OR “Endstage kidney failure”[All Fields] OR 
“End stage renal failure”[All Fields] OR “End-stage renal failure”[All Fields] OR “Endstage renal failure”[All Fields] 
OR “chronic renal failure”[All Fields] OR “ESRD”[All Fields] OR “Renal Dialysis”[Mesh] OR “Renal Dialysis”[All 
Fields] OR “hemodialysis”[All Fields] OR “haemodialysis”[All Fields] OR “Extracorporeal dialysis”[All Fields] OR 
“peritoneal dialysis”[All Fields] OR “CAPD”[All Fields] OR “Hemodiafi ltration”[All Fields] OR “Uremia”[Mesh] 
OR “uraemia”[All Fields] OR “uremia”[All Fields] OR “Kidney Tubular Necrosis, Acute”[Mesh] OR “Acute tu-
bular necrosis”[All Fields] OR “Acute renal insuffi ciency”[All Fields] OR “Acute tubular necrosis”[All Fields] OR 
“Acute tubulus necrosis”[All Fields] OR “Acute Kidney Injury”[Mesh] OR “Renal Insuffi ciency”[Mesh] OR “Renal 
insuffi ciency”[All Fields] OR “Nephritis, Interstitial”[Mesh] OR “Interstitial Nephritis”[All Fields]) 
AND 
(“Euthyroid Sick Syndromes”[Mesh] OR “Euthyroid Sick Syndromes”[All Fields] OR “Euthyroid Sick Syndrome”[All 
Fields] OR “Non-thyroidal Illness”[All Fields] OR “Nonthyroidal Illness”[All Fields] OR “Non thyroidal Illness”[All 
Fields] OR “Low-T3 Syndrome”[All Fields] OR “Low T3 Syndrome”[All Fields]  OR “Low-T3 Syndromes”[All 
Fields]  OR “Low T3 Syndromes”[All Fields] OR “Low-Triiodothyronine Syndrome”[All Fields] OR “Thyroid 
Hormones”[Mesh] OR “Thyroid hormone”[All Fields] OR “Thyroid hormones”[All Fields]  OR “Thyroxine”[Mesh] 
OR “Thyroxine”[All Fields]  OR “T4”[All Fields]  OR “Tetraiodothyronine”[All Fields]  OR “T3”[All Fields] 
OR “rT3”[All Fields] OR “Triiodothyronine”[Mesh] OR “Triiodothyronine”[All Fields] OR “Triiodothyronine, 
Reverse”[Mesh] OR “Thyrotropin”[Mesh] OR “TSH”[All Fields]  OR “Thyroid Stimulating hormone”[All Fields] 
OR “Thyroid Stimulating hormones”[All Fields]  OR “Thyroid-Stimulating hormones”[All Fields] OR “Thyroid-stim-
ulating hormone”[All Fields] OR “Thyreotropin”[all fi elds] OR “Thyrotrophin”[all fi elds] OR “Thyrotropin-Releas-
ing Hormone”[Mesh] OR “Thyrotropin-Releasing hormone”[All Fields] OR “Thyrotropin Releasing hormone”[All 
Fields] OR “Thyrotropin-Releasing hormones”[All Fields]  OR “Thyrotropin Releasing hormones”[All Fields] OR 
“Thyroxine-Binding Proteins”[Mesh] OR “TBG”[All Fields] OR “Thyroxin-Binding Proteins”[All Fields] OR “Thy-
roxin-Binding Protein “[All Fields] OR “Thyroxin Binding Proteins”[All Fields] OR “Thyroxin Binding Protein”[All 
Fields]) 
AND 
(“Thyroxine”[Mesh] OR “Levo-thyroxine”[All Fields] OR “Levo thyroxine”[All Fields] OR “L-thyroxine”[All 
Fields] OR “L thyroxine”[All Fields] OR “Thyroxine”[All Fields] OR “T4”[All Fields] OR “Levothyroxine “[All 
Fields] OR “Levoxine”[All Fields] OR “Synthrox”[All Fields] OR “Thyrax”[All Fields] OR “Thyrox”[All Fields] OR 
“Levo-Thyrox”[All Fields] OR “Levo thyrox”[All Fields] OR “L Thyrox”[All Fields] OR “L-Thyrox”[All Fields] OR 
“Levo-T”[All Fields] OR “3,5-diiodothyropropionic acid”[All Fields] OR “DITPA”[All Fields] OR “3,5 DITPA”[All 
Fields] OR “Triiodothyronine”[Mesh] OR “Levo-triiodothyronine”[All Fields] OR “Levo-T3”[All Fields] OR “L-
triiodothyronine”[All Fields] OR “L-T3”[All Fields] OR “L triiodothyronine”[All Fields] OR “L T3”[All Fields] OR 









    
     
1. Regression lines were fi tted on the repeated measurements for each individual separately. Then these betas were 
pooled within the different thyroid hormone groups (as specifi ed in the methods section) and compared by means 
of  a one-way ANOVA test. Mean annual changes were not different between groups (p=0.149). Adjusted for sex, 
DM, smoking, cardiovascular disease, malignancies, and amiodarone treatment.
Figure 1. Mean (95%CI) annual change in eGFR (mL/min/1.73m2) across different thyroid function groups as calcu-































































Figure 1. Crude (A) and adjusted (B)2 mean (95%CI) eGFR (mL/min/1.73m2) in those not using thyroid medication 
at age 85 across different thyroid hormone groups*




    
     





























































1. The association between thyroid hormone groups and renal function was studied in those without medication 
infl uencing thyroid function (thyroid hormone supplementation or antithyroid medication).








































































Figure 1. Crude (A) and adjusted (B)2 mean (95%CI) eGFR (mL/min/1.73m2) at age 88 across different thyroid 
hormone change groups1
     
     
  






     




































































1. Change groups were based on categorization at 85 and 88 years (see above). Pers. = Persistent. eGFR in mL/
min/1.73m2.








Bij de totstandkoming van dit proefschrift gaat mijn erkenning uit naar vele mensen die mij aldoor 
de onuitputtelijke steun gaven om deze taak te volbrengen. In het speciaal noem ik een aantal 
mensen.
Prof. dr. F.W. Dekker, Beste Friedo, je ontfermde je over me als tweedejaars geneeskundestudent 
en gaf  me een wetenschappelijk basis. Ik dank je hier zeer voor en hoop dat mijn lessen bij jou hier 
niet ophouden. Prof. dr. P. Stenvinkel, Dear Peter, the time I spent in Stockholm was very inspiring. 
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afdelingen, de tijd met jullie was erg leerzaam en waardevol, ik ben jullie zeer erkentelijk. Raymond 
Krediet, Els Boeschoten, Nynke Halbesma, Ton de Craen, en Jacobijn Gussekloo als co-auteuren 
op mijn stukken dank ik jullie voor jullie opbouwende kritiek. 
During my time in Stockholm, several people were very important for me and my research. First of  
all, Bengt, I thank you for the great support I received from you. I’m not aware of  any other person 
with your skills to bring people together. Every visit in Stockholm felt like home. Tony, Olof, Peter 
and Elvia, I thank you for the warm atmosphere and the critical appraisal and questions on my 
studies. Xiaoyan, our long nightly discussions and conversations were very valuable to me, thank 
you. Also, I would like to pay gratitude to Anna, Evianne, Jonas, Thiane, Marie, Ulrika, Paul, Hadi, 
Iván, Jia, Hong, Tao, Ting, Tetsu, Ayumu, Naohito, Hannes, and Jonaz, for the scientifi c lessons 
and nice times in Stockholm. 
Wetenschap is nietszeggend zonder kliniek besef  ik mij. Mijn bijbaan gedurende mijn studietijd 
als Joshua op de Thorax Intensive Care van het Leids Universitair Medisch Centrum stuurde mij 
richting het hart. Tot op de dag van vandaag ben ik de verpleegkundigen, intensivisten, thoraxchi-
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afdeling Cardiologie in het UMC Utrecht voelde ik mij tot in het hoogste uitgedaagd. Ik dank al 
mijn collega’s en stafartsen voor het warme onthaal en de prachtige tijd. Beste Hans in het speciaal, 
dank voor jouw voorbeeld en het vertrouwen wat je me geeft. In mijn huidige werk op de afdeling 
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fartsen erkentelijk voor de geweldige tijd die we mogen ervaren. 
Lieve Ouders, mijn dank voor jullie is niet in woorden uit te drukken. Jullie hebben me de absolute 
basis gegeven om alles te bereiken wat ik de van dag vandaag mag meemaken. Ik draag dit werk aan 
jullie op. Bart, Michel, en Arthur, mn vroegste herinneringen zijn met jullie, een oneindig krachtig 
fundament! You are extraordinary gentlemen! Lieve Judith, het leven met jou is vol met geur, kleur 
en vuurwerk. Je maakt me gelukkig! Lieve familie, waaronder Jolanda, Jan Willem, Dirk, Willem, 
oma en Marjolein, en uiteraard familie Meuwese, dank voor jullie onvoorwaardelijke support. Lieve 
Marjolijn, dank voor je warmte en altijd bemoedigende woorden. Letsch, partner in crime, dank 
voor alle genegenheid en die heerlijke tijd in Leiden en overzeese contreien. Meester Hermans, wat 
de overhang je al niet brengt, het is me een eer je te kennen! Karel, ik dank je voor je wijsheid, al 
onze mooie discussies en vriendschap. Jaap, Jeannette en Vincent, dank voor de warme vriendsc-
hap en fi jne momenten.
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laughs. They shaped me physically and mentally to a great portion of  what I am today. Franck, Ed-
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